heat-	C	C	NN
and	CC	CC	CC
cadmium-	C	C	*
pretreated	O	O	JJ
cells	O	O	NNS
O	O	O	
proliferating	C	C	VBG
and	CC	CC	CC
nonproliferating	C	C	JJ
hematopoietic	O	O	JJ
cells	O	O	NNS
O	O	O	
52	C	C	CD
and	CC	CC	CC
45	C	C	CD
kilodaltons	O	O	NNS
(	O	O	(
kD	O	O	NN
)	O	O	)
O	O	O	
c-Jun	C	C	NN
and	CC	CC	CC
ATF-2	C	C	NN
proteins	O	O	NNS
O	O	O	
lymphoid	C	C	JJ
and	CC	CC	CC
pancreatic	C	C	JJ
tissues	O	O	NNS
O	O	O	
basal	C	C	JJ
,	CC	CC	,
PMA-	C	C	NN
,	CC	CC	,
and	CC	CC	CC
RA-	C	C	*
inducible	O	O	JJ
CD23	O	O	NN
expression	O	O	NN
O	O	O	
alpha	C	C	NN
and	CC	CC	CC
beta	C	C	NN
subunits	O	O	NNS
O	O	O	
IL-6	C	C	NN
chloramphenicol	C	C	NN
acetyl	C	C	NN
transferase	C	C	NN
(	C	C	(
CAT	C	C	NN
)	C	C	)
or	CC	CC	CC
IL-6	C	C	NN
luciferase	C	C	NN
constructs	O	O	NNS
O	O	O	
CD11c	C	C	NN
and	CC	CC	CC
CD11b	C	C	NN
promoters	O	O	NNS
O	O	O	
tetanus	O	C	NN
toxoid	O	C	NN
specific	C	C	JJ
and	CC	CC	CC
HLA-DR-restricted	C	C	JJ
T	O	O	NN
lymphocytes	O	O	NNS
O	O	O	
human	C	C	JJ
,	CC	CC	,
squirrel	C	C	NN
monkey	C	C	NN
,	CC	CC	,
owl	C	C	NN
monkey	C	C	NN
,	CC	CC	,
and	CC	CC	CC
cotton-top	C	C	JJ
tamarin	C	C	NN
receptors	O	O	NNS
O	O	O	
young	C	C	JJ
and	CC	CC	CC
aged	C	C	JJ
subjects	O	O	NNS
O	O	O	
extracellular	C	C	JJ
and	CC	CC	CC
transmembrane	C	C	NN
regions	O	O	NNS
O	O	O	
Murine	C	C	JJ
and	CC	CC	CC
human	C	C	JJ
MZF-2	O	O	NN
proteins	O	O	NNS
O	O	O	
IL-3	C	C	NN
,	CC	CC	,
GM-CSF	C	C	NN
,	CC	CC	,
FMS	C	C	NN
and	CC	CC	CC
EGR-1	C	C	NN
genes	O	O	NNS
O	O	O	
myelomonocytic	C	C	JJ
and	CC	CC	CC
glia	C	C	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
erythroid	O	O	JJ
differentiation	C	C	NN
and	CC	CC	CC
maturation	C	C	NN
O	O	O	
basal	C	C	JJ
and	CC	CC	CC
PMA	C	C	NN
induced	C	C	JJ
activity	O	O	NN
O	O	O	
normal	C	C	JJ
and	CC	CC	CC
hypopigmented	C	C	JJ
skin	O	O	NN
samples	O	O	NNS
O	O	O	
Egr-1	C	C	NN
and	CC	CC	CC
c-fos	C	C	NN
mRNA	O	O	NN
expression	O	O	NN
sIgM-	C	C	NN
and	CC	CC	CC
sIgD-	C	C	*
crosslinking	O	O	NN
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
megakaryocyte	C	C	NN
lineages	O	O	NNS
O	O	O	
normal	C	C	JJ
resting	C	C	VBG
or	CC	CC	CC
activated	C	C	VBN
O	O	O	
antitumor	C	C	JJ
,	CC	CC	,
antiinflammatory	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
antiinfectious	C	C	JJ
activities	O	O	NNS
O	O	O	
TCR	O	C	NN
beta	C	C	NN
and	CC	CC	CC
TCR	C	C	NN
delta	C	C	NN
enhancers	O	O	NNS
O	O	O	
basic	C	O	JJ
leucine	C	O	NN
zipper	C	O	NN
(	C	O	(
bZIP	O	O	NN
)	O	O	)
DNA-binding	C	C	NN
and	CC	CC	CC
protein	C	C	NN
dimerization	C	C	NN
domain	O	O	NN
O	O	O	
endogenous	O	O	JJ
glucocorticoid	O	O	NN
peripheral	C	C	JJ
and	CC	CC	CC
central	C	C	JJ
function	O	O	NN
O	O	O	
I	C	C	NN
kappa	C	C	NN
B	C	C	NN
alpha	C	C	NN
and	CC	CC	CC
IL-2	C	C	NN
gene	O	O	NN
expression	O	O	NN
O	O	O	
jun	C	C	NN
and	CC	CC	CC
fos	C	C	NN
gene	O	O	NN
expression	O	O	NN
O	O	O	
antigen-	C	C	JJ
or	CC	CC	CC
cAMP-	C	C	*
stimulated	O	O	JJ
IL-5	O	O	NN
promoter	O	O	NN
activation	O	O	NN
O	O	O	
primitive	C	C	JJ
and	CC	CC	CC
definitive	C	C	JJ
erythroid	O	O	JJ
cells	O	O	NNS
O	O	O	
human	O	O	JJ
peripheral	O	C	JJ
blood	C	C	NN
T	C	C	NN
and	CC	CC	CC
NK	C	C	NN
cell	O	O	NN
activation	O	O	NN
O	O	O	
phosphatases	O	O	NNS
1	C	C	CD
and	CC	CC	CC
2A	C	C	NN
O	O	O	
myelomonocytic	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
glial	C	C	JJ
cell	O	O	NN
lines	O	O	NNS
O	O	O	
IL-2	C	C	NN
and	CC	CC	CC
IL-12	C	C	NN
stimulation	O	O	NN
O	O	O	
TRAFs	O	O	NNS
1	C	C	CD
,	CC	CC	,
2	C	C	CD
,	CC	CC	,
3	C	O	CD
,	CC	CC	,
and	CC	CC	CC
5	C	C	CD
O	O	O	
interleukin	C	C	NN
2	C	C	CD
(	C	C	(
IL-2	C	C	NN
)	C	C	)
,	CC	CC	,
gamma	C	C	NN
interferon	C	C	NN
,	CC	CC	,
and	CC	CC	CC
granulocyte-macrophage	C	C	JJ
colony-stimulating	C	C	JJ
factor	C	C	NN
mRNA	O	O	NN
levels	O	O	NNS
O	O	O	
IL-2	C	C	NN
,	CC	CC	,
IL-1beta	C	C	NN
,	CC	CC	,
and	CC	CC	CC
IL-6	C	C	NN
mRNA	O	O	NN
O	O	O	
cytoskeletal	C	C	JJ
and	CC	CC	CC
cell-surface	C	C	JJ
proteins	O	O	NNS
signaling	C	C	NN
,	CC	CC	,
chemokine	C	C	NN
,	CC	CC	,
and	CC	CC	CC
IFN-gamma-inducible	C	C	JJ
genes	O	O	NNS
O	O	O	
lymphoid	C	C	JJ
and	CC	CC	CC
nonlymphoid	C	C	JJ
components	O	O	NNS
O	O	O	
NF-kappaB	C	C	NN
and	CC	CC	CC
Sp1	C	C	NN
binding	O	O	NN
site	O	O	NN
mutants	O	O	NNS
O	O	O	
NF-ATc	C	O	*
/	CC	CC	*
B	C	C	NN
and	CC	CC	CC
-	C	CC	*
C	O	C	NN
NF-ATc	C	O	*
/	CC	CC	*
B	C	C	NN
and	CC	CC	*
-	CC	C	CC
C	C	C	NN
O	O	O	
c-jun	C	C	NN
but	CC	CC	CC
not	CC	CC	RB
c-fos	C	C	NN
mRNA	O	O	NN
O	O	O	
pre-B	C	C	JJ
and	CC	CC	CC
B	C	C	NN
lymphocyte-specific	C	O	JJ
mb-1	C	O	NN
gene	O	O	NN
O	O	O	
interleukin-2	C	C	NN
(	C	C	(
IL-2	C	C	NN
)	C	C	)
and	CC	CC	CC
IL-4	C	C	NN
gene	O	O	NN
transcription	O	O	NN
O	O	O	
STAT1	C	C	NN
and	CC	CC	CC
STAT5	C	C	NN
genes	O	O	NNS
O	O	O	
delta-	C	C	NN
and	CC	CC	CC
kappa-	C	C	*
opioid	O	O	JJ
receptors	O	O	NNS
thymic	C	C	JJ
and	CC	CC	CC
peripheral	C	C	JJ
T	O	O	NN
lymphocytes	O	O	NNS
O	O	O	
DNA	C	C	NN
sequence-	C	C	NN
and	CC	CC	CC
pituitary-	C	C	*
specific	O	O	JJ
manner	O	O	NN
O	O	O	
p50-	C	C	NN
,	CC	CC	,
p65-	C	C	NN
,	CC	CC	,
and	CC	CC	CC
c-Rel-	C	C	*
mediated	O	O	JJ
transactivation	O	O	NN
O	O	O	
adenovirus	C	C	NN
E1A	C	CC	NN
and	CC	CC	CC
hexon	C	C	NN
genes	O	O	NNS
O	O	O	
c-fos	C	C	NN
and	CC	CC	CC
c-jun	C	C	NN
mRNA	O	O	NN
O	O	O	
Sp1	C	C	NN
,	CC	CC	,
Sp1/AP-2	C	C	NN
,	CC	CC	,
and	CC	CC	CC
cAMP	C	C	NN
response	C	C	NN
element	C	C	NN
(	C	C	(
CRE	C	C	NN
)	C	C	)
binding	O	O	NN
sites	O	O	NNS
Sp1	C	C	NN
,	CC	CC	,
NRE-2a	C	C	NN
,	CC	CC	,
TCF-1/LEF-1	C	C	NN
,	CC	CC	,
and	CC	CC	CC
Sp1/NF-AT	C	C	NN
binding	O	O	NN
sites	O	O	NNS
O	O	O	
CD4(+)	C	C	JJ
and	CC	CC	CC
CD8(+)	C	C	JJ
T	O	O	NN
lymphocytes	O	O	NNS
O	O	O	
type	C	C	NN
I	C	C	CD
and	CC	CC	CC
type	C	C	NN
II	C	C	CD
IL-1R	O	O	NN
gene	O	O	NN
expression	O	O	NN
O	O	O	
deletional	C	C	JJ
and	CC	CC	CC
alanine	C	C	NN
mutagenesis	O	O	NN
O	O	O	
cis-	C	C	JJ
and	CC	CC	CC
trans-	C	C	*
rotamers	O	O	NNS
O	O	O	
lymphoid	C	C	JJ
and	CC	CC	CC
myeloid	C	C	JJ
cells	O	O	NNS
O	O	O	
Sp1	C	C	NN
and	CC	CC	CC
Ap2	C	C	NN
binding	O	O	NN
site/s	O	O	NNS
TATA	C	C	NN
or	CC	CC	CC
CAAT	C	C	NN
motifs	O	O	NNS
O	O	O	
NF-kappaB	C	C	NN
and	CC	CC	CC
Sp1	C	C	NN
binding	O	O	NN
elements	O	O	NNS
O	O	O	
human	O	O	JJ
interleukin	O	C	*
-12	C	C	NN
and	CC	CC	CC
interleukin	C	C	*
-10	O	C	NN
production	O	O	NN
O	O	O	
CD45-	C	C	NN
or	CC	CC	CC
Lck-	C	C	*
deficient	O	O	JJ
cell	O	O	NN
lines	O	O	NNS
O	O	O	
erythroid	C	C	JJ
,	CC	CC	,
megakaryocytic	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
basosophilic	C	C	JJ
lineages	O	O	NNS
O	O	O	
megakaryocytic	C	C	JJ
and	CC	CC	CC
erythroid	C	C	JJ
cell	O	O	NN
lines	O	O	NNS
O	O	O	
nontransformed	O	O	JJ
human	C	C	JJ
and	CC	CC	CC
mouse	C	C	NN
T	O	O	NN
cells	O	O	NNS
O	O	O	
FOS	C	C	NN
and	CC	CC	CC
JUN	C	C	NN
proteins	O	O	NNS
O	O	O	
mitogen-	C	C	NN
or	CC	CC	CC
CD3-	C	C	*
activated	O	O	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
alpha	C	C	NN
and	CC	CC	CC
beta	C	C	NN
subunits	O	O	NNS
O	O	O	
cytogenetic	C	C	JJ
or	CC	CC	CC
molecular	C	C	JJ
abnormalities	O	O	NNS
O	O	O	
E4	C	C	NN
and	CC	CC	CC
the	CC	CC	DT
octamerlike	C	C	JJ
motifs	O	O	NNS
O	O	O	
c-jun	C	C	NN
and	CC	CC	CC
c-fos	C	C	NN
early	O	O	JJ
response	O	O	NN
genes	O	O	NNS
O	O	O	
IL-4-	C	C	NN
and	CC	CC	CC
IL-13-	C	C	*
induced	O	O	JJ
gene	O	O	NN
expression	O	O	NN
O	O	O	
red	O	C	JJ
cell	C	C	NN
,	CC	CC	,
platelet	C	C	NN
and	CC	CC	CC
granulocyte	C	C	NN
antibodies	O	O	NNS
O	O	O	
serines	C	O	NNS
32	C	C	CD
and	CC	CC	CC
36	C	C	CD
O	O	O	
viral	C	C	JJ
and	CC	CC	CC
immune	C	C	JJ
stimuli	O	O	NNS
O	O	O	
neuroglial	C	C	JJ
and	CC	CC	CC
lymphocytic	C	C	JJ
origin	O	O	NN
O	O	O	
human	O	O	JJ
B	O	O	NN
cell	O	O	NN
proliferation	C	C	NN
and	CC	CC	CC
differentiation	C	C	NN
O	O	O	
synovial	C	C	JJ
and	CC	CC	CC
peripheral	C	C	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
tumor	C	C	NN
necrosis	C	C	NN
factor	C	C	NN
alpha	C	C	NN
(	C	C	(
TNF-alpha	C	C	NN
)	C	C	)
-	CC	C	CC
and	CC	CC	CC
phorbol	C	C	NN
12-myristate	C	C	NN
13-acetate	C	C	NN
(	C	C	(
PMA	C	C	NN
)	C	C	)
-	C	C	*
induced	O	O	JJ
HIV-1	O	O	NN
replication	O	O	NN
O	O	O	
serine/threonine	O	O	NN
protein	O	O	NN
phosphatases	O	O	NNS
1	C	C	CD
and	CC	CC	CC
2A	C	C	NN
O	O	O	
nervous	C	C	JJ
and	CC	CC	CC
immune	C	C	JJ
systems	O	O	NNS
O	O	O	
jun	C	C	NN
and	CC	CC	CC
fos	C	C	NN
gene	O	O	NN
family	O	O	NN
members	O	O	NNS
O	O	O	
virally	O	C	RB
encoded	C	C	VBN
and	CC	CC	CC
cellular	C	C	JJ
proteins	O	O	NNS
O	O	O	
c-fos	C	C	NN
,	CC	CC	,
c-jun	C	C	NN
,	CC	CC	,
c-myc	C	C	NN
,	CC	CC	,
junB	C	C	NN
,	CC	CC	,
and	CC	CC	CC
fra-1	C	C	NN
mRNAs	O	O	NNS
O	O	O	
SH2	C	C	NN
and	CC	CC	CC
SH3	C	C	NN
domains	O	O	NNS
O	O	O	
NH2-	C	C	NN
and	CC	CC	CC
COOH-	C	C	*
terminal	O	O	JJ
domains	O	O	NNS
O	O	O	
immune	C	C	JJ
and	CC	CC	CC
inflammatory	C	C	JJ
responses	O	O	NNS
O	O	O	
naive	C	C	JJ
and	CC	CC	CC
memory	C	C	NN
T	O	O	NN
lymphocytes	O	O	NNS
O	O	O	
NF-kappaB	C	C	NN
and	CC	CC	CC
four	C	C	CD
Spl	C	C	NN
binding	O	O	NN
elements	O	O	NNS
O	O	O	
hypercortisolemic	C	C	JJ
and	CC	CC	CC
cortisol-resistant	C	C	JJ
patients	O	O	NNS
O	O	O	
sialylated	O	C	VBN
tetra-	C	C	JJ
and	CC	CC	CC
hexasaccharide	C	C	NN
chains	O	O	NNS
O	O	O	
CRE	C	C	NN
and	CC	CC	CC
POS	C	C	NN
sites	O	O	NNS
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
cell	O	O	NN
antigen	O	O	NN
receptors	O	O	NNS
O	O	O	
HIV	C	C	*
-	CC	CC	NN
but	CC	CC	CC
not	CC	CC	RB
phorbol	C	C	NN
myristate	C	C	NN
acetate-	C	C	NN
or	CC	CC	CC
lipopolysaccharide-	C	C	*
mediated	O	O	JJ
activation	O	O	NN
O	O	O	
cellular	C	C	JJ
and	CC	CC	CC
viral	C	C	JJ
genes	O	O	NNS
O	O	O	
muA	C	C	NN
and	CC	CC	CC
muB	C	C	NN
sites	O	O	NNS
O	O	O	
GH/PRL-	C	C	NN
and	CC	CC	CC
insulin-	O	C	*
producing	C	O	JJ
,	CC	CC	,
B-	C	C	NN
and	CC	CC	CC
T-	C	C	*
lymphocyte	O	O	NN
cells	O	O	NNS
O	O	O	
TRAF2	C	C	NN
and	CC	CC	CC
TRAF6	C	C	NN
adaptors	O	O	NNS
O	O	O	
jun	C	C	NN
and	CC	CC	CC
fos	C	C	NN
family	O	O	NN
O	O	O	
AP-2-	C	C	NN
and	CC	CC	CC
AP-1-	C	C	*
like	O	O	JJ
consensus	O	O	NN
sequences	O	O	NNS
O	O	O	
LAM-	C	C	NN
,	CC	CC	,
LPS-	C	C	NN
,	CC	CC	,
or	CC	CC	CC
TNF-alpha-	C	C	*
stimulated	O	O	JJ
THP-1	O	O	NN
cells	O	O	NNS
O	O	O	
human	C	C	JJ
and	CC	CC	CC
mouse	C	C	NN
gene	O	O	NN
O	O	O	
CD45RO+	C	C	JJ
and	CC	CC	CC
CD45RA+	C	C	JJ
T	O	O	NN
cell	O	O	NN
subsets	O	O	NNS
O	O	O	
immature	C	C	JJ
and	CC	CC	CC
mature	C	C	JJ
lymphoid	O	O	JJ
T-cell	O	O	NN
proliferations	O	O	NNS
O	O	O	
NFAT-	C	C	NN
and	CC	CC	CC
interleukin-2-	C	C	*
dependent	O	O	JJ
transcription	O	O	NN
O	O	O	
tumor	C	C	NN
and	CC	CC	CC
constitutional	C	C	JJ
(	C	C	(
lymphocyte	C	C	NN
)	C	C	)
DNA	O	O	NN
O	O	O	
immunosuppressive	C	C	JJ
and	CC	CC	CC
antiviral	C	C	JJ
therapies	O	O	NNS
O	O	O	
type	C	C	NN
A	C	C	NN
and	CC	CC	CC
type	C	C	NN
B	C	C	NN
EBV	O	O	NN
carriers	O	O	NNS
O	O	O	
glucocorticoid	C	C	NN
and	CC	CC	CC
mineralocorticoid	C	C	NN
receptors	O	O	NNS
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
lymphocyte	O	O	NN
function	O	O	NN
O	O	O	
Recombinant	C	O	JJ
murine	C	C	JJ
and	CC	CC	CC
human	C	C	JJ
TCF-1	O	O	NN
O	O	O	
MRL-lpr/lpr	C	C	NN
and	CC	CC	CC
C3H-gld/gld	C	C	JJ
CD4(-)	C	C	JJ
CD8(-)	C	C	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
cytoskeletal	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
extracellular	C	C	JJ
matrix	O	C	NN
genes	O	O	NNS
O	O	O	
PML/RAR	O	C	NN
alpha	C	C	NN
or	CC	CC	CC
AML1/ETO	C	C	NN
mRNA	O	O	NN
possible	O	O	JJ
T	C	C	NN
and	CC	CC	CC
natural	C	C	JJ
killer	C	C	NN
cells	O	O	NNS
O	O	O	
Type	C	C	NN
I	C	C	CD
and	CC	CC	CC
Type	C	C	NN
II	C	C	CD
receptors	O	O	NNS
O	O	O	
human	C	O	JJ
chromosomal	O	O	JJ
bands	O	O	NNS
6q26-27	C	C	NN
,	CC	CC	,
1p21-22	C	C	NN
,	CC	CC	,
3q21-24	C	C	NN
,	CC	CC	,
8p12	C	C	NN
,	CC	CC	,
13q14	C	C	NN
,	CC	CC	,
19p13.3	C	C	NN
and	CC	CC	CC
11p14-15.1	C	C	NN
O	O	O	
Jak	O	O	NN
1	C	C	CD
and	CC	CC	CC
3	C	C	CD
O	O	O	
zinc	O	C	NN
finger	C	C	NN
and	CC	CC	CC
POU	C	C	NN
families	O	O	NNS
O	O	O	
CD11a	C	C	NN
,	CC	CC	,
CD11b	C	C	NN
,	CC	CC	,
and	CC	CC	CC
CD11c	C	C	NN
gene	O	O	NN
promoters	O	O	NNS
O	O	O	
stage	O	O	NN
I	C	C	CD
and	CC	CC	CC
II	C	C	CD
breast	O	O	NN
cancer	O	O	NN
patients	O	O	NNS
O	O	O	
acute	C	C	JJ
and	CC	CC	CC
chronic	C	C	JJ
HBV	O	O	NN
infection	O	O	NN
O	O	O	
normal	C	C	JJ
and	CC	CC	CC
leukemic	C	C	JJ
hematopoiesis	O	O	NN
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
megakaryocytic	C	C	JJ
differentiation	O	O	NN
pathways	O	O	NNS
O	O	O	
human	O	C	JJ
immunodeficiency	O	C	NN
virus	C	C	NN
and	CC	CC	CC
beta	C	C	NN
interferon	C	C	NN
promoters	O	O	NNS
O	O	O	
leukocyte	O	C	NN
alkaline	O	C	NN
phosphatase	C	C	NN
,	CC	CC	,
CD11b	C	C	NN
,	CC	CC	,
CD33	C	C	NN
,	CC	CC	,
and	CC	CC	CC
G-CSF	C	C	NN
receptor	O	C	NN
mRNA	O	O	NN
O	O	O	
CD44	O	O	NN
mRNA	O	O	NN
expression	C	C	NN
and	CC	CC	CC
transcription	C	C	NN
levels	O	O	NNS
EGR1	C	O	*
-expressing	C	C	JJ
but	CC	CC	CC
not	CC	CC	RB
in	CC	CC	IN
nonexpressing	C	C	JJ
subclones	O	O	NNS
O	O	O	
VP16	C	C	NN
and	CC	CC	CC
E1A	C	C	NN
viral	O	O	JJ
transactivation	O	O	NN
domains	O	O	NNS
O	O	O	
proapoptotic	C	C	JJ
and	CC	CC	CC
antiapoptotic	C	C	JJ
functions	O	O	NNS
O	O	O	
wild-type	C	C	JJ
or	CC	CC	CC
mutated	C	C	VBN
human	O	O	JJ
retinoic	O	O	JJ
acid	O	O	NN
receptor	O	O	NN
alpha	O	O	NN
O	O	O	
water	C	C	NN
and	CC	CC	CC
electrolyte	C	C	NN
balance	O	O	NN
O	O	O	
Erk	O	O	*
1	C	C	NN
and	CC	CC	CC
2	C	C	CD
O	O	O	
AML1	C	C	NN
and	CC	CC	CC
CBF	C	C	NN
beta	C	C	NN
genes	O	O	NNS
O	O	O	
CACCC	C	C	NN
and	CC	CC	CC
CCAAT	C	C	NN
motifs	O	O	NNS
O	O	O	
GATA	O	O	*
-1	C	C	NN
and	CC	CC	CC
-2	C	C	CD
or	CC	CC	CC
GATA	C	O	*
-1	C	C	NN
and	CC	CC	CC
-3	C	C	CD
gene	O	C	NN
products	O	C	NNS
GATA	O	O	*
-1	C	C	NN
and	CC	CC	CC
-2	C	C	CD
GATA	O	O	*
-1	C	C	NN
and	CC	CC	CC
-3	C	C	CD
O	O	O	
estrogen-	C	C	NN
or	CC	CC	CC
thyroid	C	C	NN
hormone-	C	C	*
response	O	O	NN
elements	O	O	NNS
O	O	O	
normal	C	C	JJ
and	CC	CC	CC
neoplastic	C	C	JJ
T-lineage	O	O	JJ
lymphocytes	O	O	NNS
O	O	O	
supershift	C	C	NN
and	CC	CC	CC
competition	C	C	NN
experiments	O	O	NNS
O	O	O	
NFAT	C	C	NN
and	CC	CC	CC
NF-kappaB	C	C	NN
targets	O	O	NNS
O	O	O	
inflammatory	C	C	JJ
and	CC	CC	CC
immune	C	C	JJ
processes	O	O	NNS
O	O	O	
I	C	C	NN
kappa	C	C	NN
B	C	C	NN
alpha	C	C	NN
and	CC	CC	CC
I	C	C	NN
kappa	C	C	NN
B	C	C	NN
beta	C	C	NN
stability	O	O	NN
O	O	O	
cytokeratins	O	O	NNS
8	C	C	CD
and	CC	CC	CC
18	C	C	CD
O	O	O	
N-hydroxy	C	C	NN
(	C	C	(
SMX-NHOH	C	C	NN
)	C	C	)
and	CC	CC	CC
nitroso	C	C	NN
(	C	C	(
SMX-NO	C	C	NN
)	C	C	)
metabolites	O	O	NNS
O	O	O	
RNA	O	O	NN
polymerases	O	O	NNS
II	C	C	CD
and	CC	CC	CC
III	C	C	CD
O	O	O	
lymphoid	C	C	JJ
and	CC	CC	CC
pancreatic	C	C	JJ
tissues	O	O	NNS
O	O	O	
cyclin	C	C	NN
E-Cdk2-	C	C	NN
and	CC	CC	CC
cyclin	C	C	NN
A-Cdk2-	C	C	*
dependent	O	O	JJ
phosphorylation	O	O	NN
homo	C	C	*
-	CC	CC	JJ
or	CC	CC	CC
hetero	C	C	*
dimer	O	O	NN
complex	O	O	NN
formation	O	O	NN
O	O	O	
type	C	C	NN
1	C	C	CD
or	CC	CC	CC
type	C	C	NN
2	C	C	CD
EBV	O	O	NN
O	O	O	
interleukin-1	C	C	NN
and	CC	CC	CC
MHC	C	C	NN
class	C	C	NN
II	C	C	CD
genes	O	O	NNS
immune	C	C	JJ
and	CC	CC	CC
nervous	C	C	JJ
systems	O	O	NNS
O	O	O	
overt	C	C	JJ
hypo	C	C	*
-	CC	CC	JJ
or	CC	CC	CC
hyper	C	C	*
thyroidism	O	O	NN
O	O	O	
Plasma	C	C	NN
cortisol	C	C	NN
and	CC	CC	CC
aldosterone	C	C	NN
levels	O	O	NNS
O	O	O	
GM-CSF	C	C	NN
and	CC	CC	CC
IL-2	C	C	NN
genes	O	O	NNS
O	O	O	
IL	O	O	*
-10	C	C	NN
and	CC	CC	CC
-11	C	C	CD
O	O	O	
cytoskeleton	C	C	NN
and	CC	CC	CC
intracellular	C	C	JJ
proteins	O	O	NNS
O	O	O	
NK	C	C	NN
and	CC	CC	CC
T	C	C	NN
cells	O	O	NNS
O	O	O	
T-cell	O	O	NN
receptor	O	O	NN
alpha-	C	C	NN
and	CC	CC	CC
delta-	C	C	*
chains	O	O	NNS
O	O	O	
TNF	O	O	NN
receptors	O	O	NNS
1	C	C	CD
and	CC	CC	CC
2	C	C	CD
PKC	O	O	NN
isoforms	O	O	NNS
alpha	C	C	NN
,	CC	CC	,
beta	C	C	NN
I	C	C	CD
,	CC	CC	,
beta	C	C	NN
II	C	C	CD
,	CC	CC	,
and	CC	CC	CC
mu	C	C	NN
O	O	O	
aberrant	O	C	JJ
double-negative	O	C	JJ
lpr	C	C	NN
and	CC	CC	CC
gld	C	C	NN
T	O	O	NN
cells	O	O	NNS
O	O	O	
IL-4	C	C	NN
and	CC	CC	CC
IL-13	C	C	NN
promoters	O	O	NNS
O	O	O	
CD45RA	C	C	NN
and	CC	CC	CC
CD45R0	C	C	NN
T	O	O	NN
helper	O	O	NN
subsets	O	O	NNS
O	O	O	
AES	O	O	NN
peptides	O	O	NNS
G75	C	C	NN
(	C	C	(
128-135	C	C	CD
)	C	C	)
and	CC	CC	CC
G76	C	C	NN
(	C	C	(
128-135	C	C	CD
)	C	C	)
(	C	C	(
L128G	C	O	NN
)	C	C	)
O	O	O	
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
type	C	C	NN
I	C	C	CD
and	CC	CC	CC
type	C	C	NN
II	C	C	CD
IL-1	O	O	NN
receptors	O	O	NNS
O	O	O	
IL-2	C	C	NN
or	CC	CC	CC
IL-4	C	C	NN
genes	O	O	NNS
O	O	O	
human	O	O	JJ
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
human	O	C	JJ
T-cell	O	C	NN
leukemia	O	C	NN
virus	O	C	NN
type	C	C	NN
I	C	C	CD
(	C	C	(
HTLV-I	C	C	NN
)	C	C	)
and	CC	CC	CC
HTLV-II	C	C	NN
Tax	O	O	NN
proteins	O	O	NNS
O	O	O	
type	C	C	NN
A	C	C	NN
and	CC	CC	CC
one	C	C	CD
with	C	C	IN
type	C	C	NN
B	C	C	NN
EBV	O	O	NN
O	O	O	
stimulated	O	O	VBD
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
IFN-alpha	C	C	NN
and	CC	CC	CC
IFN-gamma	C	C	NN
stimulation	O	O	NN
O	O	O	
transcription	C	C	NN
,	CC	CC	,
differentiation	C	C	NN
and	CC	CC	CC
proliferation	C	C	NN
factors	O	O	NNS
O	O	O	
L428	C	C	NN
and	CC	CC	CC
HDLM-1	C	C	NN
cells	O	O	NNS
O	O	O	
CD4+	C	C	JJ
and	CC	CC	CC
CD8+	C	C	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
human	O	O	JJ
GM-CSF	O	O	NN
promoter	C	C	NN
and	CC	CC	CC
enhancer	C	C	NN
O	O	O	
cross-prime	C	O	VB
E1A-	C	C	NN
and	CC	CC	CC
E1B-	C	C	*
specific	O	O	JJ
CTLs	O	O	NNS
O	O	O	
myeloid	C	C	JJ
and	CC	CC	CC
B	C	C	NN
cells	O	O	NNS
B	C	C	NN
cell	C	C	NN
and	CC	CC	CC
myeloid	C	C	JJ
genes	O	O	NNS
O	O	O	
Elf-1	C	C	NN
or	CC	CC	CC
the	CC	CC	DT
HMG-I(Y)	C	C	NN
binding	O	O	NN
site	O	O	NN
O	O	O	
hematopoietic	C	C	JJ
and	CC	CC	CC
trophoblast	C	C	NN
cells	O	O	NNS
O	O	O	
FY*A	C	C	NN
and	CC	CC	CC
FY*B	C	C	NN
alleles	O	O	NNS
O	O	O	
DQ2	O	O	NN
homo	C	C	*
-	CC	CC	JJ
and	CC	CC	CC
hetero	C	C	*
zygous	C	O	JJ
B-	C	O	*
LCLs	O	O	NNS
O	O	O	
Interleukin	O	O	*
-4	C	C	NN
and	CC	CC	CC
-13	C	C	CD
O	O	O	
FY*A	C	C	NN
and	CC	CC	CC
FY*B	C	C	NN
alleles	O	O	NNS
O	O	O	
type	C	C	NN
I	C	C	CD
and	CC	CC	CC
type	C	C	NN
II	C	C	CD
interferons	O	O	NNS
O	O	O	
autoimmune	C	C	JJ
,	CC	CC	,
allergic	C	C	JJ
,	CC	CC	,
infectious	C	C	JJ
,	CC	CC	,
or	CC	CC	CC
neoplastic	C	C	JJ
diseases	O	O	NNS
O	O	O	
fetal	C	C	JJ
or	CC	CC	CC
the	CC	CC	DT
adult	C	C	JJ
globin	O	O	NN
developmental	O	O	JJ
program	O	O	NN
O	O	O	
adhesion	C	C	NN
molecule	C	C	NN
and	CC	CC	CC
Hsp	C	C	NN
expression	O	O	NN
O	O	O	
myeloid	C	C	JJ
,	CC	CC	,
B-lymphoid	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
erythroid	C	C	JJ
lineages	O	O	NNS
O	O	O	
positive	C	C	JJ
and	CC	CC	CC
negative	C	C	JJ
regulatory	O	O	JJ
factors	O	O	NNS
O	O	O	
Fetal	C	C	JJ
and	CC	CC	CC
neonatal	C	C	JJ
lymphocytes	O	O	NNS
O	O	O	
C/EBP-	C	C	NN
and	CC	CC	CC
GATA-	C	C	*
binding	O	O	JJ
sites	O	O	NNS
O	O	O	
heparin-like	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
therefore	C	CC	RB
cytokine-binding	C	C	JJ
,	CC	CC	,
GAGs	C	O	NNS
O	O	O	
T-helper	C	O	NN
0	C	C	CD
(	C	C	(
Th0	C	C	NN
)	C	C	)
and	CC	CC	CC
2	C	C	CD
(	C	C	(
Th2	C	C	NN
)	C	C	)
subset	C	O	NN
IL-1	C	C	NN
alpha	C	C	NN
,	CC	CC	,
IL-1	C	C	NN
beta	C	C	NN
,	CC	CC	,
IL-6	C	C	NN
,	CC	CC	,
IL-8	C	C	NN
,	CC	CC	,
and	CC	CC	CC
TNF-alpha	C	C	NN
gene	O	O	NN
expression	O	O	NN
O	O	O	
protein	C	C	NN
and	CC	CC	CC
RNA	C	C	NN
synthesis	O	O	NN
O	O	O	
AP-1	O	C	*
-TRE	C	C	NN
,	CC	CC	,
NF-AT	C	C	NN
,	CC	CC	,
and	CC	CC	CC
IL-2	C	C	NN
promoter	O	O	NN
regions	O	O	NNS
O	O	O	
genes	O	O	NNS
UL49	C	C	NN
and	CC	CC	CC
UL50	C	C	NN
O	O	O	
viral	O	O	JJ
gene	O	O	NN
expression	C	C	NN
and	CC	CC	CC
replication	C	C	NN
viral	O	O	JJ
transcription	O	O	NN
initiation	C	C	NN
and	CC	CC	CC
elongation	C	C	NN
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
megakaryocytic	C	C	JJ
cells	O	O	NNS
O	O	O	
atopic	C	C	JJ
and	CC	CC	CC
nonatopic	C	C	JJ
asthma	O	O	NN
O	O	O	
IL-2	C	C	NN
and	CC	CC	CC
IL-4	C	C	NN
genes	O	O	NNS
O	O	O	
immune	C	C	JJ
and	CC	CC	CC
inflammatory	C	C	JJ
responses	O	O	NNS
O	O	O	
Oct	C	C	NN
and	CC	CC	CC
NFAT	C	C	NN
elements	O	O	NNS
O	O	O	
cytoplasmic	O	O	JJ
mRNA	C	C	NN
and	CC	CC	CC
protein	C	C	NN
expression	O	O	NN
O	O	O	
antiviral	C	C	JJ
and	CC	CC	CC
antiproliferative	C	C	JJ
effects	O	O	NNS
O	O	O	
NF-kappaB	C	C	NN
or	CC	CC	CC
CREB/ATF	C	C	NN
pathway	O	O	NN
O	O	O	
protein	O	O	NN
phosphatases	O	O	NNS
1	C	C	CD
and	CC	CC	CC
2A	C	C	NN
O	O	O	
immunoglobulin	O	O	NN
heavy	C	C	JJ
and	CC	CC	CC
kappa	C	C	NN
light	C	C	JJ
chain	O	O	NN
gene	O	O	NN
enhancers	O	O	NNS
O	O	O	
Oct1	C	C	NN
and	CC	CC	CC
NF-AT	C	C	NN
DNA	O	O	NN
binding	O	O	NN
activity	O	O	NN
O	O	O	
B-	C	C	NN
and	CC	CC	CC
T-	C	C	*
lymphocyte	O	O	NN
development	O	O	NN
O	O	O	
Positive	C	C	JJ
and	CC	CC	CC
negative	C	C	JJ
regulation	O	O	NN
O	O	O	
tumor	C	C	NN
necrosis	C	C	NN
factor-alpha	C	C	NN
and	CC	CC	CC
interleukin-1	C	C	NN
beta	C	C	NN
genes	O	O	NNS
O	O	O	
multipotent	C	C	*
/	CC	CC	*
erythroid	C	C	*
/	CC	CC	*
monocytic	C	C	JJ
to	CC	O	TO
the	CC	O	DT
granulocytic-neutrophilic	C	O	JJ
differentiation	O	O	NN
program	O	O	NN
O	O	O	
c-fos	C	C	NN
or	CC	CC	CC
jun	C	C	NN
B	C	C	NN
mRNA	O	O	NN
expression	O	O	NN
O	O	O	
IL-4-	C	C	NN
,	CC	CC	,
IL-5-	C	C	NN
,	CC	CC	,
or	CC	CC	CC
ionomycin-	C	C	*
stimulated	O	O	JJ
eosinophils	O	O	NNS
O	O	O	
myeloid	C	C	JJ
and	CC	CC	CC
B	C	C	NN
cell	O	C	NN
extracts	O	O	VBZ
O	O	O	
immune	C	C	JJ
and	CC	CC	CC
inflammatory	C	C	JJ
responses	O	O	NNS
O	O	O	
erythrocytic	C	C	JJ
and	CC	CC	CC
the	CC	CC	DT
megakaryocytic	C	C	JJ
lineages	O	O	NNS
erythrocytic	C	C	JJ
and	CC	CC	CC
megakaryocytic	C	C	JJ
lineages	O	O	NNS
erythroblastic	C	C	JJ
and	CC	CC	CC
megakaryoblastic	C	C	JJ
permanent	O	O	JJ
cell	O	O	NN
lines	O	O	NNS
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
megakaryocytic	C	C	JJ
pathways	O	O	NNS
O	O	O	
upstream	C	C	JJ
and	CC	CC	CC
downstream	C	C	JJ
positive	O	O	JJ
regulatory	O	O	JJ
elements	O	O	NNS
O	O	O	
tumor	C	C	NN
necrosis	C	C	NN
factor	C	C	NN
(	C	C	(
TNF	C	C	NN
)	C	C	)
-	C	C	:
and	CC	CC	CC
Fas-	C	C	*
mediated	O	O	JJ
apoptosis	O	O	NN
O	O	O	
c-fos	C	C	NN
and	CC	CC	CC
c-myc	C	C	NN
proto-oncogenes	O	O	NNS
O	O	O	
activated	C	O	VBN
T	C	C	NN
lymphoid	C	C	JJ
and	CC	CC	CC
monocytic	C	C	JJ
cells	O	O	NNS
O	O	O	
mouse	C	C	NN
and	CC	CC	CC
human	C	C	JJ
BOB.1/OBF.1	O	O	NN
O	O	O	
ATF1-	C	C	NN
and	CC	CC	CC
CREB-	C	C	*
induced	O	O	JJ
trans-activation	O	O	NN
O	O	O	
type-	C	C	NN
and	CC	CC	CC
differentiation-	C	C	*
specific	O	O	JJ
expression	O	O	NN
O	O	O	
TAL1-	C	C	NN
and	CC	CC	CC
LMO-	C	C	*
dependent	O	O	JJ
transcriptional	O	O	JJ
activation	O	O	NN
O	O	O	
Resting	O	O	VBG
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
anti-	O	O	*
IgM	C	C	JJ
or	CC	CC	CC
IgD	C	C	NN
antibodies	O	O	NNS
O	O	O	
hematopoietic	C	C	JJ
and	CC	CC	CC
epithelial	C	C	JJ
cells	O	O	NNS
O	O	O	
unilineage	O	O	JJ
erythroid	C	C	JJ
or	CC	CC	CC
granulocytic	C	C	JJ
differentiation	O	O	NN
O	O	O	
transcriptional	C	C	JJ
and	CC	CC	CC
post-transcriptional	C	C	JJ
levels	O	O	NNS
O	O	O	
NF-kappa	C	C	NN
B	C	C	NN
and	CC	CC	CC
AP-1	C	C	NN
activation	O	O	NN
O	O	O	
HL-60	C	C	NN
,	CC	CC	,
U937	C	C	NN
,	CC	CC	,
HEL/S	C	C	NN
,	CC	CC	,
KU812F	C	C	NN
,	CC	CC	,
K562	C	C	NN
,	CC	CC	,
and	CC	CC	CC
HEL	C	C	NN
cells	O	O	NNS
O	O	O	
human	C	C	JJ
and	CC	CC	CC
murine	C	C	JJ
interleukin-2	O	O	NN
enhancers	O	O	NNS
O	O	O	
IL-1RI	C	C	NN
and	CC	CC	CC
IL-1RII	C	C	NN
mRNA	O	O	NN
levels	O	O	NNS
O	O	O	
antiestrogens	O	O	NNS
H1285	C	C	NN
and	CC	CC	CC
ICI	C	C	NN
182	C	C	CD
,	CC	C	,
780	C	C	CD
O	O	O	
MZF-1	C	C	NN
and	CC	CC	CC
MZF-2	C	C	NN
mRNAs	O	O	NNS
O	O	O	
T	C	C	NN
and	CC	CC	CC
NK	C	C	NN
cells	O	O	NNS
O	O	O	
proliferation	C	C	NN
and	CC	CC	CC
cytotoxicity	C	C	NN
assays	O	O	NNS
O	O	O	
NF-kappa	C	C	NN
B2	C	C	NN
(	C	C	(
p100	C	C	NN
)	C	C	)
and	CC	CC	CC
NF-kappa	C	C	NN
B1	C	C	NN
(	C	C	(
p105	C	C	NN
)	C	C	)
genes	O	O	NNS
O	O	O	
acetaminophen-	C	C	NN
and	CC	CC	CC
CCl4-	C	C	*
induced	O	O	JJ
hepatotoxicity	O	O	NN
O	O	O	
bronchial	C	C	JJ
and	CC	CC	CC
alveolar	C	C	JJ
cells	O	O	NNS
O	O	O	
AP-1	C	C	NN
,	CC	CC	,
NF	C	C	NN
kappa	C	C	NN
B	C	C	NN
,	CC	CC	,
and	CC	CC	CC
CREB	C	C	NN
DNA	O	O	NN
binding	O	O	NN
O	O	O	
-70	C	C	CD
to	C	C	TO
-65	C	C	CD
and	CC	CC	CC
-121	C	C	CD
to	C	C	TO
-103	C	C	CD
regions	O	O	NNS
O	O	O	
B-cell-restricted	C	C	JJ
and	CC	CC	CC
ubiquitous	C	C	JJ
transcription	O	O	NN
factors	O	O	NNS
O	O	O	
human	C	C	JJ
and	CC	CC	CC
murine	C	C	JJ
GM-CSF	C	O	NN
genes	O	O	NNS
O	O	O	
upstream	C	C	JJ
and	CC	CC	CC
a	C	CC	DT
downstream	O	C	JJ
regulatory	O	O	JJ
region	O	O	NN
O	O	O	
distal	C	C	JJ
and	CC	CC	CC
proximal	C	C	JJ
promoter	O	O	NN
elements	O	O	NNS
O	O	O	
HIV-1-	C	C	NN
and	CC	CC	CC
interleukin	C	C	NN
2-	C	C	*
directed	O	O	JJ
gene	O	O	NN
expression	O	O	NN
O	O	O	
LEF-1	C	C	NN
and	CC	CC	CC
Ets-1	C	C	NN
sites	O	O	NNS
O	O	O	
promoter	C	C	NN
and	CC	CC	CC
enhancer	C	C	NN
positions	O	O	NNS
O	O	O	
pro-	C	C	JJ
,	CC	CC	,
pre-	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
mature	C	C	JJ
B-cell	O	O	NN
lines	O	O	NNS
pro-B-cell	C	C	JJ
or	CC	CC	CC
T-cell	C	C	NN
lines	O	O	NNS
O	O	O	
Categories	O	O	NNS
Va	C	C	NN
,	CC	CC	,
VI	C	C	NN
and	CC	CC	CC
DFR	C	C	NN
but	CC	CC	CC
not	CC	CC	RB
Category	C	O	NN
III	C	O	CD
cells	O	C	NNS
O	O	O	
transcriptional	C	C	JJ
and	CC	CC	CC
post-transcription	C	C	JJ
regulation	O	O	NN
O	O	O	
RAR	C	C	NN
(	C	C	(
alpha	C	C	NN
)	C	C	)
and	CC	CC	CC
PML-RAR	C	C	NN
mRNAs	O	O	NNS
O	O	O	
cis-	C	C	JJ
and	CC	CC	CC
trans	C	C	*
acting	C	O	VBG
factors	O	O	NNS
O	O	O	
TGF	O	O	*
-alpha	C	C	NN
and	CC	CC	CC
-beta1	C	C	NN
O	O	O	
E-selectin	C	C	NN
or	CC	CC	CC
interleukin	C	C	NN
(	C	C	(
IL	C	C	NN
)	C	C	)
-8	C	C	CD
promoters	O	O	NNS
O	O	O	
proapoptotic	C	C	JJ
and	CC	CC	CC
antiapoptotic	C	C	JJ
regulatory	O	O	JJ
factor	O	O	NN
O	O	O	
CD68-	C	C	JJ
and	CC	CC	CC
CD1a-	C	C	*
cells	O	O	NNS
O	O	O	
BZLF1	C	C	NN
and	CC	CC	CC
BRLF1	C	C	NN
immediate-early	C	O	JJ
transcripts	O	O	NNS
CD4+	C	C	JJ
and	CC	CC	CC
CD8+	C	C	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
primary	O	O	JJ
CD45RA	C	C	NN
and	CC	CC	CC
CD45R0	C	C	NN
CD4+	C	O	JJ
T	O	O	NN
cell	O	O	NN
subsets	O	O	NNS
O	O	O	
human	O	O	JJ
B-	C	C	NN
or	CC	CC	CC
T-	C	C	*
cell	O	O	NN
lines	O	O	NNS
O	O	O	
naive	C	C	JJ
and	CC	CC	CC
memory	C	C	NN
T	O	O	NN
cells	O	O	NNS
O	O	O	
myeloid-cell-specific	C	C	JJ
c-mim	C	C	NN
and	CC	CC	CC
human	C	C	JJ
myeloperoxidase	O	C	JJ
promoters	O	O	NNS
O	O	O	
CD2	C	C	NN
but	CC	CC	CC
not	CC	CC	RB
CD3	C	C	NN
receptor	C	O	NN
cross-linking	O	O	NN
O	O	O	
purified	O	O	VBN
CD4+	C	C	JJ
or	CC	CC	CC
CD8+	C	C	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
cellular	C	C	JJ
and	CC	CC	CC
viral	C	C	JJ
genes	O	O	NNS
O	O	O	
Fos	C	C	NN
and	CC	CC	CC
Jun	C	C	NN
family	O	O	NN
proteins	O	O	NNS
O	O	O	
fetal	C	C	JJ
and	CC	CC	CC
erythroid	C	C	*
-specific	O	O	JJ
protein	O	O	NN
O	O	O	
CD2	C	C	NN
and	CC	CC	CC
CD25	C	C	NN
receptors	O	O	NNS
O	O	O	
AP-1-	C	C	NN
and	CC	CC	CC
NF-kappaB-	C	C	*
binding	O	O	JJ
sites	O	O	NNS
O	O	O	
IL-12R	C	O	NN
beta	C	C	NN
1	C	C	CD
and	CC	CC	CC
beta	C	C	NN
2	C	C	CD
subunits	O	O	NNS
O	O	O	
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
tyrosine	C	C	NN
,	CC	CC	,
and	CC	CC	CC
serine	C	C	NN
phosphorylation	O	O	NN
O	O	O	
interleukin	C	C	NN
(	C	C	(
IL	C	C	NN
)	C	C	)
-2-stimulated	C	C	JJ
or	CC	CC	CC
IL-2-deprived	C	C	JJ
cells	O	O	NNS
O	O	O	
monocytic	C	C	JJ
or	CC	CC	CC
epithelial	C	C	JJ
cells	O	O	NNS
O	O	O	
delta	C	C	NN
and	CC	CC	CC
beta	C	C	NN
5'	C	O	JJ
flanking	O	O	NN
regions	O	O	NNS
delta	C	C	NN
or	CC	CC	CC
beta	C	C	NN
fragment	C	O	NN
proximal	C	O	JJ
beta	C	C	NN
or	CC	CC	CC
delta	C	C	NN
sequence	O	O	NN
O	O	O	
calcineurin-	C	C	NN
and	CC	CC	CC
PKC-	C	C	*
dependent	O	O	JJ
signaling	O	O	NN
systems	O	O	NNS
O	O	O	
granulocytic	C	C	JJ
and	CC	CC	CC
monocytic	C	C	JJ
lineages	O	O	NNS
O	O	O	
HLA	O	O	*
-DR	C	C	NN
,	CC	CC	,
-DQ	C	C	NN
,	CC	CC	,
and	CC	CC	CC
-DP	C	C	NN
O	O	O	
M-TAT/EPO	C	C	NN
,	CC	CC	,
M-TAT/GM-CSF	C	C	NN
,	CC	CC	,
and	CC	CC	CC
M-TAT/SCF	C	C	NN
cells	O	O	NNS
O	O	O	
human	O	O	JJ
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
FOSB/G0S3	C	C	NN
and	CC	CC	CC
FOS/G0S7	C	C	NN
mRNAs	O	O	NNS
O	O	O	
positively	C	C	RB
and	CC	CC	CC
negatively	C	C	RB
acting	O	O	VBG
sequences	O	O	NNS
O	O	O	
virus-encoded	C	C	JJ
and	CC	CC	CC
cellular	C	C	JJ
proteins	O	O	NNS
O	O	O	
matrix	O	O	NN
metalloproteinases	O	O	NNS
1	C	C	CD
and	CC	CC	CC
3	C	C	CD
O	O	O	
human	C	O	JJ
papillomavirus-	C	C	NN
or	CC	CC	CC
adenovirus-	C	C	*
transformed	O	O	JJ
cells	O	O	NNS
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
cells	O	O	NNS
O	O	O	
2.7	C	C	CD
and	CC	CC	CC
4.5	C	C	CD
kilobase	O	O	NN
pairs	O	O	NNS
O	O	O	
Jun	C	C	NN
,	CC	CC	,
Fos	C	C	NN
,	CC	CC	,
NF-kappaB	C	C	NN
,	CC	CC	,
Oct	C	C	NN
or	CC	CC	CC
Ets	C	C	NN
family	O	O	NN
members	O	O	NNS
O	O	O	
immune	C	C	JJ
and	CC	CC	CC
inflammatory	C	C	JJ
responses	O	O	NNS
O	O	O	
lineage	C	C	NN
and	CC	CC	CC
stage	C	C	*
-specific	O	O	JJ
expression	O	O	NN
O	O	O	
specific	C	C	JJ
and	CC	CC	CC
non-specific	C	C	JJ
immunoreaction	O	O	NN
O	O	O	
B	C	O	NN
and	CC	CC	CC
T	C	O	NN
lymphocyte	O	C	NN
activation	C	C	NN
and	CC	CC	CC
mitogenesis	C	C	NN
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
lymphocyte	O	O	NN
O	O	O	
erythroid	C	C	JJ
,	CC	CC	,
myeloid	C	C	JJ
and	CC	CC	CC
lymphoid	C	C	JJ
cell	O	O	NN
types	O	O	NNS
O	O	O	
IFN-gamma	C	C	NN
and	CC	CC	CC
IL-2	C	C	NN
mRNA	O	O	NN
accumulation	O	O	NN
O	O	O	
all-trans	C	C	JJ
and	CC	CC	CC
9-cis	C	C	JJ
RA	O	O	NN
O	O	O	
eutopic	C	C	JJ
and	CC	CC	CC
ectopic	C	C	JJ
endometrium	O	O	NN
O	O	O	
nuclear	C	C	JJ
factor	C	C	NN
kappa	C	C	NN
B	C	C	NN
or	CC	CC	CC
signal	C	C	NN
transducer	C	C	NN
and	CC	C	CC
activator	C	C	NN
of	C	C	IN
transcription	C	C	NN
(	C	C	(
STAT	C	C	NN
)	C	C	)
activation	O	O	NN
pathways	O	O	NNS
O	O	O	
ectopic	C	C	JJ
and	CC	CC	CC
uterine	C	C	JJ
pregnancies	O	O	NNS
O	O	O	
cytoplasmic	O	O	JJ
p62c-fos	C	C	NN
and	CC	CC	CC
p39c-jun	C	C	NN
O	O	O	
dominant-negative	O	O	JJ
cdk4	C	C	NN
and	CC	CC	CC
cdk6	C	C	NN
constructs	O	O	NNS
O	O	O	
T-lymphoid	C	C	JJ
and	CC	CC	CC
monocytoid	C	C	JJ
cell	O	O	NN
lines	O	O	NNS
O	O	O	
human	C	C	JJ
and	CC	CC	CC
mouse	C	C	NN
cells	O	O	NNS
O	O	O	
65-75	C	C	CD
and	CC	CC	CC
120-125	C	C	CD
kDa	O	O	NN
O	O	O	
NF-kappa	C	C	NN
B	C	C	NN
and	CC	CC	CC
STAT-6	C	C	NN
binding	O	O	NN
sites	O	O	NNS
O	O	O	
CD3	C	C	NN
antigen-	C	C	NN
and	CC	CC	CC
CD2	C	C	NN
antigen-	C	C	*
derived	O	O	JJ
signals	O	O	NNS
O	O	O	
gC2-	C	C	NN
and	CC	CC	CC
gD2-	C	C	*
specific	O	O	JJ
CD4+	O	O	JJ
clones	O	O	NNS
O	O	O	
resident	C	C	JJ
and	CC	CC	CC
inflammatory	C	C	JJ
cells	O	O	NNS
O	O	O	
CD14-	C	C	NN
and	CC	CC	CC
protein	C	C	NN
tyrosine	C	C	NN
phosphorylation-	C	C	*
dependent	O	O	JJ
event	O	O	NN
O	O	O	
tissue-specific	C	C	JJ
and	CC	CC	CC
developmental	C	C	JJ
stage-specific	O	C	JJ
regulation	O	O	NN
O	O	O	
NF-E2	C	C	NN
and	CC	CC	CC
tandem	C	C	JJ
GATA	C	C	NN
binding	O	O	NN
sites	O	O	NNS
O	O	O	
IL-1	C	C	NN
beta	C	C	NN
,	CC	CC	,
IL-6	C	C	NN
or	CC	CC	CC
TNF	C	C	NN
alpha	C	C	NN
mRNA	O	O	NN
levels	O	O	NNS
O	O	O	
T	C	C	NN
and	CC	CC	CC
mast	C	C	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
c-Fos	C	C	NN
and	CC	CC	CC
Jun	C	C	NN
immunoreactivity	O	O	NN
O	O	O	
c-rel	C	C	NN
and	CC	CC	CC
p105/p50	C	C	NN
mRNA	O	O	NN
synthesis	O	O	NN
O	O	O	
CN	C	C	NN
A	C	C	NN
(	C	C	(
catalytic	C	C	JJ
)	C	C	)
and	CC	CC	CC
CN	C	C	NN
B	C	C	NN
(	C	C	(
regulatory	C	C	JJ
)	C	C	)
subunits	O	O	NNS
O	O	O	
tumor	C	C	NN
necrosis	C	C	NN
factor	C	C	NN
alpha	C	C	NN
(	C	C	(
TNF-alpha	C	C	NN
)	C	C	)
and	CC	CC	CC
IL-6	C	C	NN
mRNAs	O	O	NNS
O	O	O	
tarsal	C	C	JJ
and	CC	CC	CC
bulbar	C	C	JJ
conjunctival	C	O	JJ
biopsies	O	O	NNS
severe	C	C	JJ
and	CC	CC	CC
symptomatic	C	C	JJ
VKC	O	O	NN
O	O	O	
proIL-1	C	C	NN
beta	C	C	NN
and	CC	CC	CC
the	CC	CC	DT
simian	C	C	JJ
virus	C	C	NN
40	C	C	CD
enhancer	O	O	NN
elements	O	O	NNS
O	O	O	
TRAF	O	O	*
1	C	C	NN
,	CC	CC	,
-2	C	C	CD
,	CC	CC	,
or	CC	CC	CC
-3	C	C	CD
O	O	O	
hematopoietic	C	C	JJ
and	CC	CC	CC
nonhematopoietic	C	C	JJ
cell	O	O	NN
types	O	O	NNS
O	O	O	
IL-2	C	C	NN
and	CC	CC	CC
IL-2-R	C	C	NN
alpha	C	C	NN
promoters	O	O	NNS
O	O	O	
silencers	O	O	NNS
I	C	C	CD
and	CC	CC	CC
II	C	C	CD
O	O	O	
neonatal	C	C	JJ
and	CC	CC	CC
adult	C	C	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
NFAT	C	C	NN
or	CC	CC	CC
AP-1	C	C	NN
elements	O	O	NNS
O	O	O	
protein	C	C	NN
tyrosine	C	C	NN
kinase-	C	C	NN
and	CC	CC	CC
PKC-	C	C	*
dependent	O	O	JJ
O	O	O	
CREB	C	C	NN
,	CC	CC	,
CTF	C	C	NN
,	CC	CC	,
OTF-1	C	C	NN
,	CC	CC	,
OFT-2	C	C	NN
,	CC	CC	,
and	CC	CC	CC
NF-kappa	C	C	NN
B	C	C	NN
genes	O	O	NNS
O	O	O	
Oct-1	C	C	NN
and	CC	CC	CC
OCA-B	C	C	NN
function	O	O	NN
O	O	O	
X	C	C	NN
and	CC	CC	CC
Y	C	C	NN
boxes	O	O	NNS
O	O	O	
activating	C	C	VBG
and	CC	CC	CC
inhibitory	C	C	JJ
sequences	O	O	NNS
O	O	O	
NK	C	C	NN
and	CC	CC	CC
T	C	C	NN
cells	O	O	NNS
O	O	O	
FasL	O	O	NN
transcription	C	C	NN
and	CC	CC	CC
expression	C	C	NN
O	O	O	
p105	C	C	NN
and	CC	CC	CC
p100	C	C	NN
inhibitors	O	O	NNS
O	O	O	
Th2	C	C	NN
but	CC	CC	CC
not	CC	CC	RB
Th1	C	C	NN
cells	O	O	NNS
O	O	O	
p50/p50	C	C	NN
and	CC	CC	CC
p50/p65	C	C	NN
heterodimers	O	O	NNS
O	O	O	
monocyte	C	C	NN
and	CC	CC	CC
lymphocyte	C	C	NN
counts	O	O	NNS
O	O	O	
T	O	O	NN
cell	O	O	NN
activation	C	C	NN
and	CC	CC	CC
differentiation	C	C	NN
O	O	O	
anti-inflammatory	C	C	JJ
and	CC	CC	CC
immunosuppressive	C	C	JJ
agents	O	O	NNS
O	O	O	
IL-10	C	C	NN
and	CC	CC	CC
TGF-beta	C	C	NN
gene	O	O	NN
promoters	O	O	NNS
O	O	O	
HLA	O	O	*
-DR	C	C	NN
or	CC	CC	CC
-DP	C	C	NN
transcription	O	O	NN
O	O	O	
B	C	C	NN
,	CC	CC	,
but	CC	CC	CC
not	CC	CC	RB
T	C	C	NN
,	CC	CC	,
cell	C	O	NN
lines	O	O	NNS
O	O	O	
S2	C	C	NN
,	CC	CC	,
S1	C	C	NN
,	CC	CC	,
S1'	C	C	NN
,	CC	CC	,
and	CC	CC	CC
S2'	C	C	NN
subsites	O	O	NNS
cathepsin	O	O	NN
B	C	C	NN
and	CC	CC	CC
L	C	C	NN
O	O	O	
exons	O	O	NNS
2	C	C	CD
and	CC	CC	CC
7	C	C	CD
O	O	O	
interleukin-2	C	O	NN
receptor	C	O	NN
alpha	C	C	NN
and	CC	CC	CC
-beta	C	C	NN
subunit	C	O	NN
expression	O	O	NN
O	O	O	
positive	C	C	JJ
and	CC	CC	CC
negative	C	C	JJ
cis-acting	O	O	JJ
DNA	O	O	NN
elements	O	O	NNS
O	O	O	
octamer	C	C	NN
or	CC	CC	CC
kappa	C	C	NN
B	C	C	NN
consensus	O	O	NN
sequences	O	O	NNS
O	O	O	
Ig-silenced	C	C	JJ
(	C	C	(
common	C	C	JJ
)	C	C	)
and	CC	CC	CC
Ig-expressing	C	C	JJ
(	C	C	(
rare	C	C	JJ
)	C	C	)
hybrids	O	O	NNS
O	O	O	
murine	C	C	JJ
and	CC	CC	CC
human	C	C	JJ
GATA-3	O	O	NN
proteins	O	O	NNS
O	O	O	
c-fos	C	C	NN
and	CC	CC	CC
c-jun	C	C	NN
mRNA	O	O	NN
O	O	O	
young	C	C	JJ
and	CC	CC	CC
old	C	C	JJ
donors	O	O	NNS
O	O	O	
multiple	O	O	JJ
DNA	O	O	NN
binding	O	O	NN
homo-	C	C	JJ
and	CC	CC	CC
hetero	C	C	*
dimer	O	O	NN
complexes	O	O	NNS
O	O	O	
RA	C	C	NN
and	CC	CC	CC
VitD3	C	C	NN
receptor	O	O	NN
network	O	O	NN
O	O	O	
B-cell	O	O	NN
activation	C	C	NN
,	CC	CC	,
differentiation	C	C	NN
or	CC	CC	CC
function	C	C	NN
O	O	O	
water	C	C	NN
and	CC	CC	CC
electrolyte	C	C	NN
balances	O	O	NNS
O	O	O	
E1A	C	C	NN
and	CC	CC	CC
hexon	C	C	NN
primers	O	O	NNS
O	O	O	
viral	C	C	JJ
and	CC	CC	CC
cellular	C	C	JJ
genes	O	O	NNS
O	O	O	
neither	CC	CC	CC
LMP1	C	C	NN
nor	CC	CC	CC
LMP2B	C	C	NN
mRNA	O	O	NN
O	O	O	
p16	C	C	NN
,	CC	CC	,
p15	C	C	NN
or	CC	CC	CC
CDK4	C	C	NN
genes	O	O	NNS
O	O	O	
fetal	C	C	JJ
or	CC	CC	CC
the	CC	CC	DT
adult	C	C	JJ
globin	O	O	NN
program	O	O	NN
O	O	O	
hematopoietic	C	O	JJ
stem	C	C	NN
and	CC	CC	CC
progenitor	C	C	NN
cells	O	O	NNS
O	O	O	
non-transformed	O	O	JJ
murine	O	O	JJ
Th1	C	C	NN
and	CC	CC	CC
Th2	C	C	NN
clones	O	O	NNS
O	O	O	
IL-4-	C	C	NN
and	CC	CC	CC
IFN-gamma-	C	C	*
activated	O	O	JJ
factors	O	O	NNS
homodimeric	C	C	JJ
or	CC	CC	CC
heterodimeric	C	C	JJ
forms	O	O	NNS
O	O	O	
DP	O	O	*
1	C	C	NN
and	CC	CC	CC
-2	C	C	CD
O	O	O	
anti-inflammatory	C	C	JJ
and	CC	CC	CC
anti-allergic	C	C	*
/hypereosinophilic	O	O	JJ
agents	O	O	NNS
O	O	O	
kinase	C	C	NN
or	CC	CC	CC
protease	C	C	NN
pathways	O	O	NNS
O	O	O	
granulocytic	C	C	JJ
or	CC	CC	CC
monocytic	C	C	JJ
differentiation	O	O	NN
O	O	O	
homogeneous	O	O	JJ
CD4+	C	C	JJ
and	CC	CC	CC
CD8+	C	C	JJ
lymphocytes	O	O	NNS
O	O	O	
ERK1/2	C	C	NN
and	CC	CC	CC
JNK	C	C	NN
proteins	O	O	NNS
O	O	O	
c-	O	C	*
Rel	C	C	NN
and	CC	CC	CC
p65	C	C	NN
homodimers	O	O	NNS
O	O	O	
vascular	C	C	JJ
endothelial	C	C	JJ
and	CC	CC	CC
smooth	C	C	VB
muscle	O	C	NN
cells	O	O	NNS
O	O	O	
jun	C	C	NN
and	CC	CC	CC
fos	C	C	NN
gene	O	O	NN
family	O	O	NN
members	O	O	NNS
O	O	O	
HIV-1	O	O	NN
mRNA	C	C	NN
and	CC	CC	CC
virus	C	C	NN
production	O	O	NN
O	O	O	
erythroid	C	C	JJ
,	CC	CC	,
megakaryocyte	C	C	NN
and	CC	CC	CC
mast	C	C	NN
cell	O	O	NN
populations	O	O	NNS
O	O	O	
mouse	O	O	NN
macrophage	C	C	NN
and	CC	CC	CC
fibrosarcoma	C	C	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
c-jun	C	C	NN
,	CC	CC	,
jun	C	C	NN
B	C	C	NN
and	CC	CC	CC
jun	C	C	NN
D	C	C	NN
transcripts	O	O	NNS
O	O	O	
T	O	O	NN
cell	O	O	NN
development	C	C	NN
and	CC	CC	CC
activation	C	C	NN
O	O	O	
Mouse	C	C	NN
,	CC	CC	,
rat	C	C	NN
,	CC	CC	,
hamster	C	C	NN
,	CC	CC	,
and	CC	CC	CC
human	C	C	JJ
cells	O	O	NNS
CL-induced	C	C	JJ
and	CC	CC	CC
chemically	C	C	RB
induced	C	C	VBN
apoptosis	O	O	NN
O	O	O	
nervous	C	C	JJ
and	CC	CC	CC
immune	C	C	JJ
tissues	O	O	NNS
O	O	O	
tumour	C	C	NN
and	CC	CC	CC
non	C	C	JJ
tumour	C	C	NN
cells	O	O	NNS
O	O	O	
PTHrP	C	C	NN
and	CC	CC	CC
IL2R	C	C	NN
alpha	C	C	NN
promoters	O	O	NNS
O	O	O	
c-jun	C	C	NN
and	CC	CC	CC
c-fos	C	C	NN
mRNA	O	O	NN
levels	O	O	NNS
O	O	O	
TSG101	C	C	NN
and	CC	CC	CC
FHIT	C	C	NN
genes	O	O	NNS
O	O	O	
fetal	C	C	JJ
or	CC	CC	CC
the	CC	CC	DT
adult	C	C	JJ
globin	O	O	NN
gene	O	CC	NN
program	O	O	NN
O	O	O	
human	C	C	JJ
and	CC	CC	CC
mouse	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
P1	C	C	NN
,	CC	CC	,
P2	C	C	NN
,	CC	CC	,
and	CC	CC	CC
P4	C	C	NN
NFAT	O	O	NN
elements	O	O	NNS
O	O	O	
PML	C	C	NN
and	CC	CC	CC
Rb	C	C	NN
protein	O	O	NN
expression	O	O	NN
O	O	O	
erythroid	C	C	JJ
,	CC	CC	,
megakaryocytic	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
mastocytic/basophilic	C	C	JJ
lineages	O	O	NNS
O	O	O	
homo-	C	C	JJ
or	CC	CC	CC
hetero	C	C	*
dimer	O	O	NN
formation	O	O	NN
O	O	O	
wild-type	C	C	JJ
and	CC	CC	CC
dl337-infected	C	C	JJ
cells	O	O	NNS
O	O	O	
mammalian	O	O	JJ
MCM5	C	C	NN
and	CC	CC	CC
MCM6	C	C	NN
genes	O	O	NNS
O	O	O	
follicular	C	C	JJ
and	CC	CC	CC
luteal	C	C	JJ
phases	O	O	NNS
O	O	O	
HTLV-I	C	C	NN
and	CC	CC	CC
HTLV-II	C	C	NN
Tax	O	O	NN
O	O	O	
type	C	O	NN
1	C	C	CD
and	CC	CC	CC
2A	C	C	NN
phosphatases	O	O	NNS
O	O	O	
C/EBPbeta	C	C	NN
and	CC	CC	CC
GATA-1	C	C	NN
expression	O	O	NN
vectors	O	O	NNS
O	O	O	
steroid-sensitive	C	C	JJ
and	CC	CC	CC
steroid-resistant	C	C	JJ
asthma	O	O	NN
O	O	O	
positive	C	C	JJ
and	CC	CC	CC
negative	C	C	JJ
regulatory	O	O	JJ
elements	O	O	NNS
O	O	O	
TNF-alpha-	C	C	NN
or	CC	CC	CC
PMA-	C	C	*
induced	O	O	JJ
stimulation	O	O	NN
O	O	O	
B	C	C	NN
(	C	C	(
Raji	C	C	NN
)	C	C	)
,	CC	CC	,
but	CC	CC	CC
not	CC	CC	RB
a	CC	CC	DT
T	C	C	NN
(	C	C	(
HUT78	C	C	NN
)	C	C	)
cell	O	O	NN
line	O	O	NN
O	O	O	
granulocyte-macrophage	C	C	JJ
colony-stimulating	C	C	JJ
factor	C	C	NN
(	C	C	(
GM-CSF	C	C	NN
)	C	C	)
-	C	C	:
or	CC	CC	CC
interleukin-3	C	C	NN
(	C	C	(
IL-3	C	C	NN
)	C	C	)
-	C	C	*
induced	O	O	JJ
GM	O	O	NN
colony	O	O	NN
formation	O	O	NN
O	O	O	
human	C	C	JJ
and	CC	CC	CC
mouse	C	C	NN
genomic	O	O	JJ
sequences	O	O	NNS
O	O	O	
Ets	C	C	NN
and	CC	CC	CC
NF-kappaB/NFAT	C	C	NN
proteins	O	O	NNS
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
megakaryocytic	C	C	JJ
cells	O	O	NNS
O	O	O	
M7	C	C	NN
and	CC	CC	CC
TMD	C	C	NN
cases	O	O	NNS
erythroid	C	C	JJ
and	CC	CC	CC
megakaryocytic	C	C	JJ
phenotypes	O	O	NNS
O	O	O	
endocrine	C	C	JJ
and	CC	CC	CC
nonendocrine	C	C	JJ
cell	O	O	NN
lineages	O	O	NNS
O	O	O	
fetal	C	C	JJ
and	CC	CC	CC
adult	C	C	JJ
Hb	O	O	NN
synthesis	O	O	NN
embryonic	C	C	JJ
,	CC	CC	,
fetal	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
adult	C	C	JJ
Hb	O	O	NN
synthesis	O	O	NN
O	O	O	
W-X-Y	C	C	NN
or	CC	CC	CC
X-Y	C	C	NN
regulatory	O	O	JJ
elements	O	O	NNS
O	O	O	
protein-tyrosine	O	O	NN
kinase	O	CC	NN
inhibitors	O	O	NNS
genistein	C	C	NN
and	CC	CC	CC
herbimycin	C	C	NN
A	O	C	NN
O	O	O	
lpr/lpr	C	C	NN
and	CC	CC	CC
gld/gld	C	C	NN
mice	O	O	NNS
O	O	O	
c-Jun	C	C	NN
and	CC	CC	CC
JunD	C	C	NN
genes	O	O	NNS
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
megakaryocytic	C	C	JJ
phenotypes	O	O	NNS
O	O	O	
anti-CD28	C	C	JJ
mAb	C	C	NN
and	CC	CC	CC
CHO-CD80	C	C	NN
stimulation	O	O	NN
O	O	O	
NF-E2	C	C	NN
and	CC	CC	CC
tandem	C	C	JJ
GATA	C	C	NN
sites	O	O	NNS
O	O	O	
NF-kappaB	C	C	NN
and	CC	CC	CC
AP-1	C	C	NN
generation	O	O	NN
O	O	O	
HLA-DQ	C	C	NN
and	CC	CC	CC
DR	C	C	NN
haplotypes	O	O	NNS
O	O	O	
rheumatoid	C	O	JJ
synovial	O	O	JJ
fluid	O	O	NN
monocytes	O	C	*
/macrophages	C	C	NNS
,	CC	CC	,
but	CC	CC	CC
not	CC	CC	RB
in	CC	CC	IN
lymphocytes	C	C	NNS
or	CC	CC	CC
neutrophils	C	C	NNS
O	O	O	
Spi-1	C	C	NN
and/or	CC	CC	CC
Fli-1	C	C	NN
genes	O	O	NNS
O	O	O	
Th1	C	C	NN
and	CC	CC	CC
Th2	C	C	NN
cells	O	O	NNS
O	O	O	
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
IL-1	C	C	NN
and	CC	CC	CC
tumour	C	C	NN
necrosis	C	CC	NN
factor	C	CC	NN
alpha	C	CC	NN
(	C	C	(
TNF	C	C	NN
alpha	C	CC	NN
)	C	C	)
-induced	C	O	JJ
changes	O	O	NNS
O	O	O	
estrogen	C	O	NN
type	C	C	NN
I	C	C	CD
(	C	C	(
high	C	C	JJ
affinity	C	C	NN
,	CC	C	,
low	C	C	JJ
capacity	C	C	NN
)	C	C	)
and	CC	CC	CC
type	C	C	NN
II	C	C	CD
(	C	C	(
low	C	C	JJ
affinity	C	C	NN
,	CC	C	,
high	C	C	JJ
capacity	C	C	NN
)	C	C	)
binding	O	O	NN
sites	O	O	NNS
O	O	O	
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
cells	O	O	NNS
O	O	O	
plasma	C	C	NN
and	CC	CC	CC
urinary	C	C	JJ
cortisol	C	O	NN
concentrations	O	O	NNS
O	O	O	
human	C	C	JJ
fibroblastic	C	C	JJ
or	CC	CC	CC
keratinocyte-derived	C	C	JJ
human	C	C	JJ
cells	O	O	NNS
O	O	O	
interleukin-2	C	C	NN
,	CC	CC	,
CD44	C	C	NN
,	CC	CC	,
ICAM-1	C	C	NN
,	CC	CC	,
and	CC	CC	CC
tumor	C	C	NN
necrosis	C	C	NN
factor	C	C	NN
genes	O	O	NNS
O	O	O	
NK	C	C	NN
and	CC	CC	CC
T	C	C	NN
cells	O	O	NNS
O	O	O	
erythroid	C	C	JJ
,	CC	CC	,
megakaryocytic	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
mast	C	C	NN
cell	O	O	NN
lineages	O	O	NNS
O	O	O	
5'-	C	C	JJ
and	CC	CC	CC
3'-	C	C	*
ends	O	O	NNS
O	O	O	
erythroid	C	C	JJ
,	CC	CC	,
mast	C	C	NN
and	CC	CC	CC
megakaryocyte	C	C	NN
lineages	O	O	NNS
O	O	O	
haematopoietic	C	C	JJ
and	CC	CC	CC
solid	C	C	JJ
tumours	O	O	NNS
O	O	O	
c-jun	C	C	NN
and	CC	CC	CC
c-fos	C	C	NN
messenger	O	O	NN
RNA	O	O	NN
O	O	O	
MCP-1	C	C	NN
and	CC	CC	CC
ICAM-1	C	C	NN
promoter-dependent	O	O	JJ
transcription	O	O	NN
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
granulocytic	C	C	JJ
colonies	O	O	NNS
O	O	O	
DR	C	C	NN
alpha	C	C	NN
and	CC	CC	CC
DP	C	C	NN
alpha	C	C	NN
element	O	O	NN
O	O	O	
mitogen-	C	C	NN
and	CC	CC	CC
anti-CD3-	C	C	*
treated	O	O	JJ
peripheral	O	O	JJ
blood	O	O	NN
lymphocytes	O	O	NNS
O	O	O	
B-cell	O	O	NN
expansion	C	C	NN
and	CC	CC	CC
maturation	C	C	NN
O	O	O	
Tax-expressing	C	C	JJ
and	CC	CC	CC
type	C	C	NN
I	C	C	CD
human	O	C	JJ
T-cell	O	C	NN
leukemia	O	C	NN
virus-infected	O	C	JJ
human	O	C	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
growth-	C	C	NN
and	CC	CC	CC
cell	C	C	NN
cycle-	C	C	*
controlling	O	O	JJ
genes	O	O	NNS
O	O	O	
unstimulated	C	C	JJ
and	CC	CC	CC
12-O-tetradecanoylphorbol	C	C	NN
13-acetate/phytohemagglutinin-stimulated	C	C	JJ
human	C	O	JJ
Jurkat	O	O	NN
T	O	O	NN
cells	O	O	NNS
O	O	O	
control	C	C	JJ
and	CC	CC	CC
infected	C	C	JJ
cells	O	O	NNS
O	O	O	
SV40	O	O	NN
early	C	C	JJ
and	CC	CC	CC
late	C	C	JJ
promoters	O	O	NNS
O	O	O	
IFNalpha-	C	C	NN
and	CC	CC	CC
IFNgamma-	C	C	*
inducible	O	O	JJ
genes	O	O	NNS
O	O	O	
CD4+	C	C	JJ
and	CC	CC	CC
CD8+	C	C	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
ERK	C	C	NN
or	CC	CC	CC
p38	C	C	NN
pathway	O	O	NN
O	O	O	
anti-inflammatory	C	C	JJ
,	CC	CC	,
immunosuppressive	C	C	JJ
or	CC	CC	CC
anti-tumoral	C	C	JJ
agents	O	O	NNS
O	O	O	
monocytic	C	C	JJ
and	CC	CC	CC
erythroid	C	C	JJ
differentiation	O	O	NN
O	O	O	
RXR	O	O	NN
alpha	C	C	NN
,	CC	CC	,
beta	C	C	NN
,	CC	CC	,
gamma	C	C	NN
O	O	O	
immediate	O	C	JJ
early	C	C	JJ
and	CC	CC	CC
early	C	C	JJ
proteins	O	O	NNS
O	O	O	
corticosteroid	O	O	NN
Type	C	C	NN
I	C	C	CD
and	CC	CC	CC
Type	C	C	NN
II	C	C	CD
receptors	O	O	NNS
O	O	O	
paternal	C	C	JJ
or	CC	CC	CC
biallelic	C	C	JJ
expression	C	O	NN
maternal	C	C	JJ
or	CC	CC	CC
biallelic	C	C	JJ
expression	O	O	NN
O	O	O	
fetal	C	C	JJ
and	CC	CC	CC
adult	C	C	JJ
B-lymphopoiesis	O	O	NN
O	O	O	
bone	C	C	NN
morphogenetic	C	C	JJ
protein-	C	C	NN
and	CC	CC	CC
activin-	C	C	*
mediated	O	O	JJ
growth	O	O	NN
arrest	O	O	NN
O	O	O	
class	O	O	NN
I	C	C	CD
and	CC	CC	CC
II	C	C	CD
interferons	O	O	NNS
O	O	O	
Western	C	C	NN
and	CC	CC	CC
supershift	C	C	NN
analyses	O	O	NNS
functional	C	O	JJ
Jun	C	C	NN
and	CC	CC	CC
Fos	C	C	NN
proteins	O	O	NNS
O	O	O	
STAT1alpha	C	C	NN
and	CC	CC	CC
IP-10	C	C	NN
expression	O	O	NN
O	O	O	
GM-CSF	C	C	NN
and	CC	CC	CC
IL-2	C	C	NN
gene	O	O	NN
transcription	O	O	NN
O	O	O	
diploid	C	C	JJ
or	CC	CC	CC
tetraploid	C	C	JJ
B	O	O	NN
cells	O	O	NNS
O	O	O	
42-	C	C	CD
and	CC	CC	CC
44-	C	C	*
kDa	O	O	JJ
proteins	O	O	NNS
O	O	O	
interleukin-2	O	C	NN
receptor	O	C	NN
alpha-chain	C	C	NN
and	CC	CC	CC
interleukin-2	C	C	NN
genes	O	O	NNS
O	O	O	
MEL	C	C	NN
and	CC	CC	CC
NIH3T3	C	C	NN
cells	O	O	NNS
O	O	O	
NK-	C	C	NN
and	CC	CC	CC
T-cell	C	C	NN
subtypes	O	O	NNS
O	O	O	
IL-12	C	C	NN
and	CC	CC	CC
IL-10	C	C	NN
secretion	O	O	NN
O	O	O	
IgM	C	C	NN
,	CC	CC	,
IgD	C	C	NN
,	CC	CC	,
kappa	C	C	NN
L	C	C	NN
chain	C	C	NN
,	CC	CC	,
and	CC	CC	CC
lambda	C	C	NN
L	O	C	NN
chain	O	C	NN
expression	O	O	NN
O	O	O	
PRL-	C	C	NN
and	CC	CC	CC
IL-2-	C	C	*
induced	O	O	JJ
factors	O	O	NNS
O	O	O	
fetal	C	C	JJ
and	CC	CC	CC
term	C	C	JJ
neonatal	O	C	JJ
cord	O	O	NN
bloods	O	O	NNS
O	O	O	
RA	O	O	NN
receptors	O	O	NNS
alpha	C	C	NN
,	CC	CC	,
beta	C	C	NN
,	CC	CC	,
and	CC	CC	CC
gamma	C	C	NN
O	O	O	
time-	C	C	NN
and	CC	CC	CC
dose-	C	C	*
dependent	O	O	JJ
manner	O	O	NN
O	O	O	
TNF	C	C	*
-	CC	CC	NN
or	CC	CC	CC
PMA-	C	C	*
induced	O	O	JJ
HIV	O	O	NN
replication	O	O	NN
O	O	O	
mouse	C	C	NN
and	CC	CC	CC
human	C	C	JJ
lymphoma	O	O	NN
cells	O	O	NNS
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
non-erythroid	C	C	JJ
cells	O	O	NNS
O	O	O	
beta-	C	C	NN
and	CC	CC	CC
gamma-	C	C	*
globin	O	O	NN
genes	O	O	NNS
beta-	C	C	NN
and	CC	CC	CC
gamma-	C	C	*
specific	O	O	JJ
antibodies	O	O	NNS
O	O	O	
human	other_name	O	JJ
fetal	other_name	C	JJ
and	other_name	CC	CC
adult	other_name	C	JJ
erythroid	other_name	O	JJ
progenitors	other_name	O	NNS
O	O	O	
human	O	O	JJ
interleukin	O	O	*
-2	C	C	NN
,	CC	CC	,
-4	C	C	CD
,	CC	CC	,
-5	C	C	CD
and	CC	CC	CC
-13	C	C	CD
human	C	C	JJ
and	CC	CC	CC
mouse	C	C	NN
granulocyte/macrophage-colony	O	O	NN
stimulating	O	O	JJ
factor	O	O	NN
O	O	O	
TCR	O	O	NN
beta	C	C	NN
,	CC	CC	,
gamma	C	C	NN
,	CC	CC	,
delta	C	C	NN
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
NK	C	C	NN
and	CC	CC	CC
T	C	C	NN
cells	O	O	NNS
O	O	O	
anti-CD3	C	C	JJ
mAb/IL-2-	C	C	NN
or	CC	CC	CC
PHA-	C	C	*
mediated	O	O	JJ
IFN-gamma	O	O	NN
production	O	O	NN
O	O	O	
Y	C	C	NN
,	CC	CC	,
X1	C	C	NN
,	CC	CC	,
and	CC	CC	CC
X2	C	C	NN
boxes	O	O	NNS
O	O	O	
sites	O	O	NNS
1	C	C	CD
,	CC	CC	,
2	C	C	CD
,	CC	CC	,
and	CC	CC	CC
3	C	C	CD
O	O	O	
IL	O	O	*
-2	C	C	NN
,	CC	CC	,
-4	C	C	CD
,	CC	CC	,
-7	C	C	CD
,	CC	CC	,
-9	C	C	CD
,	CC	CC	,
and	CC	CC	CC
-15	C	C	CD
O	O	O	
genetic	C	C	JJ
and	CC	CC	CC
pharmacological	C	C	JJ
manipulation	O	O	NN
O	O	O	
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
protein	O	O	NN
kinase	O	O	NN
C	O	O	*
-alpha	C	C	NN
,	CC	CC	,
-epsilon	C	C	NN
,	CC	CC	,
and	CC	CC	CC
-zeta	C	C	NN
O	O	O	
CD40-	C	C	NN
or	CC	CC	CC
pervanadate-	C	C	*
mediated	O	O	JJ
I	C	O	NN
kappa	C	O	NN
B	C	O	NN
tyrosine	O	O	NN
phosphorylation	O	O	NN
O	O	O	
B-	C	C	NN
and	CC	CC	CC
myeloid	C	C	JJ
cell	O	O	NN
markers	O	O	NNS
O	O	O	
G1	C	C	NN
and	CC	CC	CC
S	C	C	NN
phase	O	O	NN
O	O	O	
heterologous	O	O	JJ
acidic	C	C	JJ
,	CC	CC	,
proline-rich	C	C	JJ
,	CC	CC	,
or	CC	CC	CC
glutamine-rich	C	C	JJ
activation	O	O	NN
domain	O	O	NN
O	O	O	
GATA-1	C	C	NN
and	CC	CC	CC
tal-1	C	C	NN
genes	O	O	NNS
O	O	O	
oxidant	C	C	JJ
and	CC	CC	CC
antioxidant	C	C	JJ
conditions	O	O	NNS
O	O	O	
Corticosteroid	O	O	NN
Type	C	C	NN
I	C	C	CD
and	CC	CC	CC
Type	C	C	NN
II	C	C	CD
receptors	O	O	NNS
O	O	O	
M-CSF	C	C	NN
and	CC	CC	CC
FMS	C	C	NN
genes	O	O	NNS
O	O	O	
Transcriptional	C	C	JJ
and	CC	CC	CC
posttranscriptional	C	C	JJ
regulation	O	O	NN
O	O	O	
c-fos	C	C	NN
and	CC	CC	CC
c-jun	C	C	NN
gene	O	O	NN
transcription	O	O	NN
O	O	O	
c-fos	C	C	NN
and	CC	CC	CC
c-jun	C	C	NN
mRNA	O	O	NN
levels	O	O	NNS
pre-B	C	C	JJ
(	C	C	(
Hyon	C	C	NN
)	C	C	)
and	CC	CC	CC
T	C	C	NN
(	C	C	(
DND-41	C	C	NN
)	C	C	)
cell	O	O	NN
lines	O	O	NNS
O	O	O	
extracellular	C	C	JJ
and	CC	CC	CC
transmembrane	C	C	JJ
domains	O	O	NNS
O	O	O	
supershift	C	C	NN
and	CC	CC	CC
immunoblot	C	C	NN
analysis	O	O	NN
O	O	O	
carcinoma	C	C	NN
and	CC	CC	CC
lymphoid	C	C	JJ
cells	O	O	NNS
O	O	O	
amino-	C	C	NN
or	CC	CC	CC
carboxy-	C	C	*
terminal	O	O	JJ
sequences	O	O	NNS
O	O	O	
homotypic	O	O	JJ
aggregation	C	C	NN
and	CC	CC	CC
proliferation	C	C	NN
O	O	O	
protein	O	O	NN
synthesis	O	O	*
-dependent	C	C	JJ
and	CC	CC	CC
-independent	C	C	JJ
pathways	O	O	NNS
O	O	O	
mitogenic	C	C	JJ
or	CC	CC	CC
alloantigenic	C	C	JJ
stimuli	O	O	NNS
O	O	O	
VitD3	C	C	*
-	CC	CC	NN
and	CC	CC	CC
the	CC	CC	DT
PMA	C	C	*
-induced	C	O	JJ
CD14	O	O	NN
expression	O	O	NN
O	O	O	
animal	C	C	NN
and	CC	CC	CC
human	C	C	JJ
populations	O	O	NNS
O	O	O	
muA	C	C	NN
,	CC	CC	,
muE3	C	C	NN
,	CC	CC	,
and	CC	CC	CC
muB	C	C	NN
sites	O	O	NNS
O	O	O	
tissue-	C	C	NN
,	CC	CC	,
promoter-	C	C	NN
,	CC	CC	,
and	CC	CC	CC
factor-	C	C	*
specific	O	O	JJ
coactivator	O	O	NN
O	O	O	
immunosuppressive	C	C	JJ
and/or	CC	CC	CC
anti-inflammatory	C	C	JJ
cytokine	O	O	NN
O	O	O	
PKC	O	O	*
-alpha	C	C	NN
,	CC	CC	,
-epsilon	C	C	NN
,	CC	CC	,
or	CC	CC	CC
-zeta	C	C	NN
O	O	O	
homo-	C	C	JJ
and	CC	CC	CC
hetero	C	C	*
dimers	O	O	NNS
O	O	O	
UV-	C	C	NN
and	CC	CC	CC
H2O2-	C	C	*
induced	O	O	JJ
T	O	O	NN
cell	O	O	NN
signal	O	O	NN
transduction	O	O	NN
O	O	O	
AP-1	C	C	NN
and	CC	CC	CC
NF-IL6	C	C	NN
binding	O	O	NN
activity	O	O	NN
O	O	O	
CD4+	C	C	JJ
or	CC	CC	CC
CD8+	C	C	JJ
cells	O	O	NNS
O	O	O	
IL-2-	C	C	NN
,	CC	CC	,
IL-3-	C	C	NN
,	CC	CC	,
or	CC	CC	CC
GM-CSF-	C	C	*
induced	O	O	JJ
proinflammatory	O	O	JJ
cytokine	O	O	NN
gene	O	O	NN
expression	O	O	NN
O	O	O	
HL-60	C	C	NN
and	CC	CC	CC
NB4	C	C	NN
cells	O	O	NNS
O	O	O	
human	C	C	JJ
fetal	C	C	JJ
(	C	C	(
A	C	C	NN
gamma-	C	C	NN
)	C	C	)
globin	C	C	NN
(	C	C	(
HBG1	C	C	NN
)	C	C	)
or	CC	CC	CC
simian	C	C	JJ
virus	C	C	NN
40	C	C	CD
(	C	C	(
SV40	C	C	NN
)	C	C	)
promoters	O	O	NNS
O	O	O	
IL-2R	O	O	NN
alpha-	C	C	NN
and	CC	CC	CC
gamma-	C	C	*
chains	O	O	NNS
O	O	O	
viral	C	C	JJ
and	CC	CC	CC
cellular	C	C	JJ
promoters	O	O	NNS
O	O	O	
Fas	C	C	NN
and	CC	CC	CC
CD23	C	C	NN
expression	O	O	NN
O	O	O	
Helices	O	O	NNS
I	C	C	CD
and	CC	CC	CC
II	C	C	CD
O	O	O	
erythroid	C	C	JJ
,	CC	CC	,
megakaryocyte	C	C	NN
,	CC	CC	,
and	CC	CC	CC
mast	C	C	NN
cell	O	O	NN
lineages	O	O	NNS
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
antiproliferative	C	C	JJ
and	CC	CC	CC
differentiating	C	C	VBG
agent	O	O	NN
O	O	O	
memory	C	C	NN
(	C	C	(
CD45RO+	C	C	JJ
)	C	C	)
and	CC	CC	CC
naive	C	C	JJ
(	C	C	(
CD45RA+	C	C	JJ
)	C	C	)
T	O	O	NN
cell	O	O	NN
subsets	O	O	NNS
O	O	O	
AP-1	C	C	NN
,	CC	CC	,
NF-AT	C	C	NN
,	CC	CC	,
and	CC	CC	CC
NF-kB	C	C	NN
motifs	O	O	NNS
O	O	O	
inflammatory	C	C	JJ
and	CC	CC	CC
immunoregulatory	C	C	JJ
responses	O	O	NNS
O	O	O	
CD3	C	C	NN
and	CC	CC	CC
CD25	C	C	NN
(	C	C	(
IL-2R	C	C	NN
)	C	C	)
receptors	O	O	NNS
O	O	O	
c-erbB2	C	C	NN
,	CC	CC	,
int-2	C	C	NN
,	CC	CC	,
and	CC	CC	CC
c-myc	C	C	NN
gene	O	O	NN
amplification	O	O	NN
O	O	O	
AP-1	C	C	NN
,	CC	CC	,
AP-2	C	C	NN
,	CC	CC	,
and	CC	CC	CC
NF	C	C	NN
kappa	C	C	NN
B	C	C	NN
sequence	O	O	NN
O	O	O	
Ca(2+)-	C	C	NN
and	CC	CC	CC
PKC-	C	C	NN
dependent	O	O	JJ
pathways	O	O	NNS
O	O	O	
human	C	C	JJ
and	CC	CC	CC
murine	C	C	JJ
B	O	O	NN
lymphocytes	O	O	NNS
O	O	O	
Th1	C	C	NN
and	CC	CC	CC
Th2	C	C	NN
type	O	O	NN
cytokines	O	O	NNS
O	O	O	
p65	C	C	NN
,	CC	CC	,
p50	C	C	NN
,	CC	CC	,
and	CC	CC	CC
c-Rel	C	C	NN
activities	O	O	NNS
CD4-	C	C	NN
and	CC	CC	CC
CD8-	C	C	*
positive	O	O	JJ
thymocytes	O	O	NNS
O	O	O	
LMP1+	C	C	JJ
and	CC	CC	CC
LMP1-	C	C	*
tumour	O	O	NN
cells	O	O	NNS
O	O	O	
memory	C	C	NN
and	CC	CC	CC
naive	C	C	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
neutrophilic	C	C	JJ
and	CC	CC	CC
eosinophilic	C	C	JJ
granulocytes	O	O	NNS
O	O	O	
IL-10-	C	C	NN
and	CC	CC	CC
IFN-gamma-	C	C	*
activated	O	O	JJ
STAT	O	O	NN
molecules	O	O	NNS
O	O	O	
T	O	O	NN
cell	O	O	NN
receptor	O	O	NN
alpha	C	C	NN
and	CC	CC	CC
-beta	C	C	NN
O	O	O	
C-terminal	C	O	JJ
activating	C	C	VBG
and	CC	CC	CC
inhibitory	C	C	JJ
domains	O	O	NNS
O	O	O	
Rel	C	C	NN
,	CC	CC	,
Fos	C	C	NN
,	CC	CC	,
and	CC	CC	CC
Jun	C	C	NN
proteins	O	O	NNS
O	O	O	
c-jun	C	C	NN
,	CC	CC	,
jun-B	C	C	NN
,	CC	CC	,
jun-D	C	C	NN
,	CC	CC	,
c-fos	C	C	NN
,	CC	CC	,
or	CC	CC	CC
Fos-B	C	C	NN
expression	O	O	NN
vectors	O	O	NNS
O	O	O	
Gender	C	C	NN
and	CC	CC	CC
vascular	C	C	JJ
reactivity	O	C	NN
O	O	O	
HNF	O	O	*
-3alpha	C	C	NN
,	CC	CC	,
-3beta	C	C	NN
,	CC	CC	,
-3gamma	C	C	NN
,	CC	CC	,
-4gamma	C	C	NN
,	CC	CC	,
and	CC	CC	CC
-6	C	C	CD
O	O	O	
wild-type	C	C	JJ
or	CC	CC	CC
the	CC	C	DT
truncated	C	C	VBN
ER	O	O	NN
O	O	O	
euthymic	C	C	JJ
,	CC	CC	,
depressed	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
manic	C	C	JJ
patients	O	O	NNS
O	O	O	
Extracellular	O	C	JJ
signal-regulated	O	C	JJ
protein	O	C	NN
kinase	O	C	NN
(	O	C	(
ERK	O	C	NN
)	O	C	)
-dependent	C	C	JJ
and	CC	CC	CC
ERK-independent	C	C	JJ
pathways	O	O	NNS
O	O	O	
major	O	O	JJ
histocompatibility	O	O	NN
complex	O	O	NN
class	O	O	NN
I	C	C	CD
or	CC	CC	CC
II	C	C	CD
molecules	O	O	NNS
O	O	O	
AP-1-	C	C	NN
and	CC	CC	CC
octamer-	C	C	*
binding	O	O	JJ
proteins	O	O	NNS
O	O	O	
Lyn	C	C	NN
and	CC	CC	CC
Jak2	C	C	NN
tyrosine	O	O	NN
kinases	O	O	NNS
O	O	O	
myeloid	C	C	JJ
and	CC	CC	CC
megakaryocyte	C	C	NN
progenitor	C	O	NN
proliferation	O	O	NN
O	O	O	
SLA-DR	C	C	NN
and	CC	CC	CC
SLA-DQ	C	C	NN
expression	O	O	NN
O	O	O	
P-glycoprotein	C	C	NN
,	CC	CC	,
steroid	C	C	NN
receptors	C	C	NNS
,	CC	CC	,
p53	C	C	NN
and	CC	CC	CC
Bcl-2	C	C	NN
expression	O	O	NN
O	O	O	
p50-	C	C	NN
and	CC	CC	CC
c-Rel-	C	C	*
selected	O	O	JJ
sequences	O	O	NNS
O	O	O	
alpha	C	C	NN
and	CC	CC	CC
beta	C	C	NN
isozymes	O	O	NNS
O	O	O	
E-selectin	C	C	NN
or	CC	CC	CC
VCAM-1	C	C	NN
mRNA	O	O	NN
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
cell	O	O	NN
differentiation	O	O	NN
O	O	O	
c-jun	C	C	NN
and	CC	CC	CC
c-fos	C	C	NN
expression	O	O	NN
O	O	O	
type	C	C	NN
I	C	C	CD
and	CC	CC	CC
type	C	C	NN
II	C	C	CD
receptors	O	O	NNS
O	O	O	
NF-kappa	C	C	NN
B	C	C	NN
and	CC	CC	CC
CArG	C	C	NN
motifs	O	O	NNS
O	O	O	
ferritin	C	C	NN
or	CC	CC	CC
transferrin	C	C	NN
receptor	O	O	NN
mRNAs	O	O	NNS
O	O	O	
5'	C	C	JJ
and	CC	CC	CC
3'	C	C	JJ
untranslated	O	O	JJ
regions	O	O	NNS
O	O	O	
persistent	C	C	JJ
or	CC	CC	CC
recurrent	C	C	JJ
inflammatory	O	O	JJ
arthritis	O	O	NN
O	O	O	
Treponema	C	C	FW
pallidum	C	C	FW
and	CC	CC	CC
Borrelia	C	C	FW
burgdorferi	C	C	FW
lipoproteins	O	O	NNS
O	O	O	
repressor	O	O	NN
proteins	O	O	NNS
BP1	C	C	NN
and	CC	CC	CC
BP2	C	C	NN
O	O	O	
fibronectin-	C	C	NN
or	CC	CC	CC
laminin-	C	C	*
coated	O	O	JJ
flasks	O	O	NNS
O	O	O	
estrogen	C	C	NN
receptor	C	C	NN
alpha	C	C	NN
(	C	C	(
ER-alpha	C	C	NN
)	C	C	)
,	CC	CC	,
ER-beta	C	C	NN
,	CC	CC	,
and	CC	CC	CC
progesterone	C	C	NN
receptor	C	C	NN
(	C	C	(
PR	C	C	NN
)	C	C	)
mRNAs	O	O	NNS
O	O	O	
NFAT	C	C	NN
and	CC	CC	CC
Oct	C	C	NN
sites	O	O	NNS
O	O	O	
molecular	C	O	JJ
mass	C	O	NN
40	C	C	CD
,	CC	CC	,
42	C	C	CD
,	CC	CC	,
70	C	C	CD
,	CC	CC	,
120	C	C	CD
,	CC	CC	,
and	CC	CC	CC
130	C	C	CD
kDa	O	O	NN
O	O	O	
NK	C	C	NN
and	CC	CC	CC
T	C	C	NN
cells	O	O	NNS
O	O	O	
insulin	O	O	*
-dependent	C	C	JJ
and	CC	CC	CC
-independent	C	C	JJ
PI	O	O	NN
3-kinase	O	O	NN
activation	O	O	NN
O	O	O	
inflammatory	C	C	JJ
or	CC	CC	CC
immune	C	C	JJ
processes	O	O	NNS
O	O	O	
HSV-2	C	O	NN
buttock	C	C	NN
and	CC	CC	CC
thigh	C	C	NN
lesions	O	O	NNS
O	O	O	
G0	C	C	NN
and	CC	CC	CC
G1	C	C	NN
phases	O	O	NNS
O	O	O	
HIV-1	C	C	NN
and	CC	CC	CC
interleukin	C	C	NN
2	C	C	CD
promoters	O	O	NNS
O	O	O	
estrogen	C	C	NN
and	CC	CC	CC
progesterone	C	C	NN
receptors	O	O	NNS
Ki-67	C	C	NN
and	CC	CC	CC
p-145	C	C	NN
antigens	O	O	NNS
blood	C	C	NN
and	CC	CC	CC
pleural	C	C	JJ
effusions	O	O	NNS
O	O	O	
protein	C	C	NN
and	CC	CC	CC
mRNA	C	C	NN
levels	O	O	NNS
O	O	O	
CD4+	C	C	JJ
and	CC	CC	CC
CD8+	C	C	JJ
T	O	O	NN
cell	O	O	NN
subpopulations	O	O	NNS
O	O	O	
HpaII	C	C	NN
and	CC	CC	CC
Hha	C	C	NN
I	C	C	CD
sites	O	O	NNS
O	O	O	
nuclear	C	O	JJ
matrix	C	C	NN
and	CC	CC	CC
nonmatrix	C	C	JJ
compartments	O	O	NNS
O	O	O	
lymphocytic	C	C	JJ
,	CC	CC	,
monocytic	C	C	JJ
,	CC	CC	,
neuronal	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
glial	C	C	JJ
cell	O	O	NN
origin	O	O	NN
O	O	O	
immune	C	C	JJ
and	CC	CC	CC
inflammatory	C	C	JJ
responses	O	O	NNS
O	O	O	
nuclear	C	C	JJ
factor-kappa	C	C	NN
B	C	C	NN
and	CC	CC	CC
activator	C	C	NN
protein-1	O	C	NN
transcription	O	O	NN
factor	O	O	NN
expression	O	O	NN
O	O	O	
type	C	C	NN
I	C	C	CD
and	CC	CC	CC
type	C	C	NN
II	C	C	CD
IFNs	O	O	NNS
O	O	O	
truncated	O	O	VBN
TSG101	C	C	NN
and	CC	CC	CC
FHIT	C	C	NN
transcripts	O	O	NNS
O	O	O	
type	C	C	NN
I	C	C	CD
and	CC	CC	CC
type	C	C	NN
II	C	C	CD
IFNs	O	O	NNS
O	O	O	
LPS-induced	O	C	JJ
IL-6	C	C	NN
and	CC	CC	CC
spontaneous	C	C	JJ
IL-1ra	C	C	NN
production	O	O	NN
O	O	O	
human	O	O	JJ
T	C	C	NN
or	CC	CC	CC
B	C	C	NN
cell	O	O	NN
O	O	O	
transcriptional	C	C	JJ
and	CC	CC	CC
posttranscriptional	C	C	JJ
levels	O	O	NNS
O	O	O	
blood	C	O	NN
plasma	C	O	NN
triidothyronine	C	C	NN
and	CC	CC	CC
thyroxine	C	C	JJ
concentration	O	O	NN
O	O	O	
M-CSF	C	C	NN
and	CC	CC	CC
c-fms	C	C	NN
expression	O	O	NN
O	O	O	
normal	C	C	JJ
and	CC	CC	CC
dex-resistant	C	C	JJ
CEM	O	O	NN
cells	O	O	NNS
O	O	O	
type	C	C	NN
I	C	C	CD
but	CC	CC	CC
not	CC	CC	RB
type	C	C	NN
II	C	C	CD
interferons	O	O	NNS
O	O	O	
nonproductive	C	C	JJ
(	C	C	(
latent	C	C	JJ
)	C	C	)
and	CC	CC	CC
productive	C	C	JJ
(	C	C	(
lytic	C	C	JJ
)	C	C	)
infections	O	O	NNS
O	O	O	
human	C	C	JJ
and	CC	CC	CC
murine	C	C	JJ
GATA-3	O	O	NN
factors	O	O	NNS
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
megakaryocytic	C	C	JJ
transcription	O	O	NN
factors	O	O	NNS
O	O	O	
amino-	C	O	NN
(	C	C	(
729-766	C	C	CD
)	C	C	)
or	CC	CC	CC
carboxy-	C	O	*
terminal	C	C	JJ
(	C	C	(
940-984	C	C	CD
)	C	C	)
region	O	O	NN
O	O	O	
PyG	C	C	NN
and	CC	CC	CC
GC	C	C	NN
boxes	O	O	NNS
O	O	O	
normal	C	C	JJ
and	CC	CC	CC
malignant	C	C	JJ
cells	O	O	NNS
O	O	O	
interferon	O	O	*
-alpha	C	C	NN
and	CC	CC	CC
-gamma	C	C	NN
O	O	O	
T-	C	C	NN
and	CC	CC	CC
0-	C	C	*
lymphocytes	O	O	NNS
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
megakaryocytic	C	C	JJ
lineages	O	O	NNS
O	O	O	
neonatal	C	C	JJ
and	CC	CC	CC
adult	C	C	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
Serum	O	C	NN
cortisol	C	C	NN
,	CC	CC	,
osteocalcin	C	C	NN
and	CC	CC	CC
urinary	C	C	JJ
cortisol	O	C	NN
levels	O	O	NNS
osteocalcin	C	C	NN
and	CC	CC	CC
urinary	C	C	JJ
cortisol	O	C	NN
O	O	O	
BcLF1	C	C	NN
and	CC	CC	CC
BFRF3	C	C	NN
promoters	O	O	NNS
O	O	O	
clinical	C	C	JJ
,	CC	CC	,
cytogenetic	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
molecular	C	C	JJ
data	O	O	NNS
O	O	O	
HTLV-I(+)	C	C	JJ
,	CC	CC	,
IL-2-independent	C	C	JJ
and	CC	CC	CC
IL-2-dependent	C	C	JJ
cell	O	O	NN
lines	O	O	NNS
O	O	O	
peptide	O	O	NN
binding	C	C	NN
and	CC	CC	CC
recognition	C	C	NN
O	O	O	
Th1-	C	C	NN
and	CC	CC	CC
Th2-	C	C	*
specific	O	O	JJ
gene	O	O	NN
expression	O	O	NN
O	O	O	
wild-type	C	C	JJ
or	CC	CC	CC
mutant	C	C	JJ
LTRs	O	O	NNS
NF-kappa	C	C	NN
B	C	C	NN
and/or	CC	CC	CC
Sp1	C	C	NN
binding	O	O	NN
sites	O	O	NNS
O	O	O	
human	C	C	JJ
and	CC	CC	CC
mouse	C	C	NN
GATA3	O	O	NN
transcription	O	O	NN
units	O	O	NNS
O	O	O	
T	C	C	NN
or	CC	CC	CC
B	C	C	NN
cell	O	O	NN
O	O	O	
immunoglobulin	C	C	NN
and	CC	CC	CC
interleukin-2	C	C	NN
genes	O	O	NNS
O	O	O	
nuclear	C	C	JJ
and	CC	CC	CC
cytoplasmic	C	C	JJ
components	O	O	NNS
O	O	O	
quiescent	C	C	JJ
and	CC	CC	CC
stimulated	C	C	VBN
cells	O	O	NNS
O	O	O	
lymphoid	C	C	JJ
and	CC	CC	CC
myeloid	C	C	JJ
cells	O	O	NNS
O	O	O	
U1B	C	C	NN
and	CC	CC	CC
U2	C	C	NN
formation	O	O	NN
O	O	O	
tumor	O	O	NN
necrosis	O	O	NN
factor-alpha	O	O	*
-dependent	C	C	JJ
and	CC	CC	CC
-independent	C	C	JJ
mechanisms	O	O	NNS
O	O	O	
cell-type-specific	C	C	JJ
and	CC	CC	CC
ubiquitous	C	C	JJ
transcriptional	O	O	JJ
regulators	O	O	NNS
O	O	O	
intracellular	O	O	JJ
sodium	C	C	NN
and	CC	CC	CC
potassium	C	C	NN
concentrations	O	O	NNS
O	O	O	
T	C	C	NN
lymphoblastoid	C	C	NN
(	C	C	(
Jurkat	C	C	NN
)	C	C	)
and	CC	CC	CC
monocytic	C	C	JJ
(	C	C	(
U937	C	C	NN
)	C	C	)
cell	O	O	NN
lines	O	O	NNS
O	O	O	
human	O	O	JJ
inflammatory	C	C	JJ
and	CC	CC	CC
immunological	C	C	JJ
diseases	O	O	NNS
O	O	O	
alpha	C	C	NN
and	CC	CC	CC
beta	C	C	NN
subunits	O	O	NNS
O	O	O	
Human	O	O	JJ
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
lymphocytes	O	O	NNS
early	C	C	JJ
and	CC	CC	CC
transient	C	C	JJ
hyperpolarization	O	O	NN
O	O	O	
resting	C	C	VBG
and	CC	CC	CC
stimulated	C	C	VBN
granulocytes	O	O	NNS
O	O	O	
Jun	C	C	NN
and	CC	CC	CC
Fos	C	C	NN
families	O	O	NNS
O	O	O	
4-	C	C	CD
or	CC	CC	CC
10-	C	C	*
bp	O	O	JJ
insertion	O	O	NN
O	O	O	
unstimulated	C	C	JJ
and	CC	CC	CC
PMA-	C	C	NN
or	CC	CC	CC
TNF-	C	C	*
stimulated	O	O	JJ
cells	O	O	NNS
O	O	O	
IgA+	C	C	JJ
and	CC	CC	CC
IgG+	C	C	JJ
plasma	O	O	NN
cells	O	O	NNS
O	O	O	
calcineurin-	O	O	*
dependent	C	C	JJ
and	CC	CC	CC
independent	C	C	JJ
pathways	O	O	NNS
O	O	O	
Murine	C	C	JJ
and	CC	CC	CC
human	C	C	JJ
T-lymphocyte	O	O	NN
GATA-3	O	O	NN
factors	O	O	NNS
O	O	O	
immunoblot	C	C	NN
and	CC	CC	CC
immunofluorescence	C	C	NN
assays	O	O	NNS
O	O	O	
male	C	C	NN
and	CC	CC	CC
female	C	C	JJ
subjects	O	O	NNS
O	O	O	
phase	O	O	NN
1	C	C	CD
and	CC	CC	CC
2	C	C	CD
neutrophil	O	O	NN
adhesion	O	O	NN
responses	O	O	NNS
O	O	O	
pre-B-	C	C	JJ
and	CC	CC	CC
mature	C	C	JJ
B-	C	C	*
cell	O	O	NN
stages	O	O	NNS
O	O	O	
bacterial	C	C	JJ
or	CC	CC	CC
viral	C	C	JJ
superantigen	O	O	NN
O	O	O	
constitutive	O	O	JJ
SLA-DR	C	C	NN
and	CC	CC	CC
SLA-DQ	C	C	NN
antigen	O	O	NN
expression	O	O	NN
O	O	O	
IL-12	C	C	NN
and	CC	CC	CC
B7.1	C	C	NN
cDNAs	O	O	NNS
O	O	O	
IL-2	O	O	NN
mRNA	C	C	NN
and	CC	CC	CC
protein	C	C	NN
levels	O	O	NNS
O	O	O	
hepatocyte	O	O	NN
nuclear	O	O	JJ
factor	O	O	*
-3alpha	C	C	NN
,	CC	CC	,
-3beta	C	C	NN
,	CC	CC	,
-3gamma	C	C	NN
,	CC	CC	,
-4gamma	C	C	NN
,	CC	CC	,
and	CC	CC	CC
-6	C	C	CD
O	O	O	
human	C	C	JJ
and	CC	CC	CC
mouse	C	C	NN
fibroblasts	O	O	NNS
G0	C	C	NN
and	CC	CC	CC
G1	C	C	NN
phases	O	O	NNS
E2F	O	O	*
1	C	C	NN
and	CC	CC	CC
-3	C	C	CD
O	O	O	
HTLV-I	O	O	NN
basal	O	C	JJ
transcription	C	C	NN
and	CC	CC	CC
expression	C	C	NN
O	O	O	
cytosolic	C	C	JJ
and	CC	CC	CC
nuclear	C	C	JJ
compartments	O	O	NNS
O	O	O	
JunB	C	C	NN
,	CC	CC	,
FosB	C	C	NN
,	CC	CC	,
and	CC	CC	CC
c-Fos	C	C	NN
transcription	O	O	NN
O	O	O	
Sp1-	C	C	NN
and	CC	CC	CC
Ets-	C	C	*
related	O	O	JJ
transcription	O	O	NN
factors	O	O	NNS
O	O	O	
p50/p65-	C	C	NN
and	CC	CC	CC
c-Rel-	C	C	*
responsive	O	O	JJ
promoters	O	O	NNS
O	O	O	
nuclear	O	O	JJ
protein-	O	O	*
dependent	C	C	JJ
and	CC	CC	CC
independent	C	C	JJ
complexes	O	O	NNS
O	O	O	
IL-2	C	C	NN
and	CC	CC	CC
the	CC	CC	DT
IL-2-R	C	C	NN
alpha	C	C	NN
genes	O	O	NNS
Ag	C	C	NN
or	CC	CC	CC
mitogen	C	C	NN
activation	O	O	NN
O	O	O	
primary	C	C	JJ
and	CC	CC	CC
secondary	C	C	JJ
hyperparathyroidism	O	O	NN
O	O	O	
medium	C	C	NN
and	CC	CC	CC
large	C	C	*
-sized	O	O	JJ
arteries	O	O	NNS
O	O	O	
promyelocyte	C	C	NN
and	CC	CC	CC
late-myeloblast-like	C	C	JJ
cell	O	O	NN
lines	O	O	NNS
O	O	O	
mononuclear	C	C	JJ
(	C	C	(
MNC	C	C	NN
)	C	C	)
and	CC	CC	CC
polymorphonuclear	C	C	JJ
leucocytes	O	O	NNS
O	O	O	
etoposide-	C	C	NN
and	CC	CC	CC
glucocorticoid-	C	C	*
induced	O	O	JJ
cytotoxicity	O	O	NN
O	O	O	
Residues	O	O	NNS
432	C	C	CD
,	CC	CC	,
435	C	C	CD
,	CC	CC	,
437	C	C	CD
,	CC	CC	,
438	C	C	CD
,	CC	CC	,
and	CC	CC	CC
440	C	C	CD
position	C	O	NN
P1	C	C	NN
,	CC	CC	,
P4	C	C	NN
,	CC	CC	,
P6	C	C	NN
,	CC	CC	,
P7	C	C	NN
,	CC	CC	,
and	CC	CC	CC
P9	C	C	NN
residues	O	O	NNS
431	C	C	CD
,	CC	CC	,
433	C	C	CD
,	CC	CC	,
434	C	C	CD
,	CC	CC	,
and	CC	CC	CC
436	C	C	CD
positions	O	O	NNS
P	O	C	NN
1	C	C	CD
,	CC	CC	,
P2	C	C	NN
,	CC	CC	,
P3	C	C	NN
,	CC	CC	,
and	CC	CC	CC
P5	C	C	NN
O	O	O	
NF-kappaB/NFAT	C	C	NN
and	CC	CC	CC
Ets	C	C	NN
binding	O	O	NN
sites	O	O	NNS
human	O	O	JJ
immunodeficiency	O	O	NN
viruses	O	O	NNS
types	O	O	NNS
1	C	C	CD
and	CC	CC	CC
2	C	C	CD
O	O	O	
erythroid	C	C	JJ
or	CC	CC	CC
granulocyte-macrophage	C	C	JJ
pathway	O	O	NN
O	O	O	
acute	C	C	JJ
and	CC	CC	CC
persistent	C	C	JJ
adenovirus	O	O	NN
infections	O	O	NNS
O	O	O	
Egr-1	C	C	NN
and	CC	CC	CC
kappaB3	C	C	NN
sites	O	O	NNS
O	O	O	
p16	C	C	NN
,	CC	CC	,
p15	C	C	NN
and	CC	CC	CC
CDK4	C	C	NN
genes	O	O	NNS
O	O	O	
recombinant	C	O	JJ
and	CC	CC	CC
nuclear	C	O	JJ
NF-kappaB	O	C	NN
proteins	O	O	NNS
O	O	O	
IFN	C	O	NN
(	C	CC	(
beta	C	C	NN
)	C	CC	)
and	CC	CC	CC
gamma	C	C	NN
O	O	O	
human	C	C	JJ
and	CC	CC	CC
murine	C	C	JJ
TNF	O	O	NN
genes	O	O	NNS
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
megakaryocytic	C	C	JJ
terminal	O	O	JJ
maturation	O	O	NN
O	O	O	
immunofluorescence	C	C	NN
and	CC	CC	CC
immunoblot	C	C	NN
assays	O	O	NNS
O	O	O	
LPS-	C	C	NN
or	CC	CC	CC
zymosan-	C	C	*
mediated	O	O	JJ
transcriptional	O	O	JJ
induction	O	O	NN
O	O	O	
TNF-alpha	C	C	NN
and	CC	CC	CC
IL-1	C	C	NN
signaling	O	O	NN
pathways	O	O	NNS
O	O	O	
IL-1	O	O	NN
receptor	O	O	NN
type	C	C	NN
I	C	C	CD
and	CC	CC	CC
type	C	C	NN
II	C	C	CD
gene	O	O	NN
expression	O	O	NN
O	O	O	
IL-2	C	C	NN
NF-AT	C	C	NN
and	CC	CC	CC
NFIL-2A	C	C	NN
sites	O	O	NNS
O	O	O	
T	C	C	NN
cell	C	C	NN
receptor-	C	C	NN
and	CC	CC	CC
phytohemagglutinin-	C	C	*
mediated	O	O	JJ
activation	O	O	NN
O	O	O	
low	O	O	JJ
THE/THF	C	C	NN
and	CC	CC	CC
alpha	C	C	NN
THF/THF	O	C	NN
ratios	O	O	NNS
O	O	O	
unicellular	C	C	JJ
and	CC	CC	CC
paired	C	C	JJ
daughter	O	O	NN
cell	O	O	NN
culture	O	O	NN
multipotent	C	C	*
/	CC	C	JJ
erythroid	CC	C	*
/monocytic	C	C	JJ
HPC	O	O	NN
growth	O	O	NN
O	O	O	
premenopausal	C	C	JJ
and	CC	CC	CC
postmenopausal	C	C	JJ
patients	O	O	NNS
O	O	O	
patient	O	O	NN
's	O	O	POS
elbow	C	C	NN
and	CC	CC	CC
genital	C	C	JJ
regions	O	O	NNS
O	O	O	
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
serum	C	C	NN
or	CC	CC	CC
tumor	C	C	NN
necrosis	O	CC	NN
factor	O	CC	NN
alpha	O	CC	NN
O	O	O	
mRNA	C	C	NN
and	CC	CC	CC
protein	C	C	NN
level	O	O	NN
O	O	O	
actin	C	C	NN
and	CC	CC	CC
fibronectin	C	C	NN
receptor	C	C	NN
mRNA	O	O	NN
O	O	O	
PKC-	O	O	*
dependent	C	C	JJ
and	CC	CC	CC
-independent	C	C	JJ
activation	O	O	NN
O	O	O	
Cellular	C	C	JJ
and	CC	CC	CC
molecular	C	C	JJ
mechanisms	O	O	NNS
O	O	O	
nervous	C	C	JJ
and	CC	CC	CC
immune	C	C	JJ
systems	O	O	NNS
O	O	O	
TGF-alpha	C	C	NN
and	CC	CC	CC
TGF-beta1	C	C	NN
expression	O	O	NN
O	O	O	
major	O	O	JJ
histocompatibility	O	O	NN
complex	O	O	NN
classes	O	O	NNS
I	C	C	CD
and	CC	CC	CC
II	C	C	CD
O	O	O	
STAT1	C	C	NN
,	CC	CC	,
STAT3	C	C	NN
and	CC	CC	CC
STAT5	C	C	NN
mRNAs	O	O	NNS
O	O	O	
c-fos	C	C	NN
,	CC	CC	,
c-jun	C	C	NN
,	CC	CC	,
and	CC	CC	CC
EGR2	C	C	NN
mRNA	O	O	NN
O	O	O	
core	O	O	NN
binding	O	O	NN
factor-	O	O	*
alpha	C	C	NN
(	C	C	(
AML1	C	C	NN
)	C	C	)
and	CC	CC	CC
beta	C	C	NN
O	O	O	
Vitamin	C	C	NN
D3-	C	C	NN
and	CC	CC	CC
retinoic	C	C	JJ
acid-	C	C	*
induced	O	O	JJ
monocytic	O	O	JJ
differentiation	O	O	NN
O	O	O	
NF-kappaB	C	C	NN
and	CC	CC	CC
Sp1	C	C	NN
sites	O	O	NNS
O	O	O	
human	O	C	JJ
osteocalcin	C	C	NN
and	CC	CC	CC
the	CC	CC	DT
mouse	C	C	NN
osteopontin	O	C	NN
gene	O	O	NN
promoters	O	O	NNS
O	O	O	
wild-type	C	C	JJ
or	CC	CC	CC
mutant	C	C	JJ
kappaB	O	O	NN
sites	O	O	NNS
O	O	O	
immune	C	C	JJ
or	CC	CC	CC
inflammatory	C	C	JJ
response	O	O	NN
O	O	O	
physico-chemical	C	C	JJ
and	CC	CC	CC
functional	C	C	JJ
parameters	O	O	NNS
BP-	O	O	*
14	C	C	NN
,	CC	CC	,
18	C	C	CD
,	CC	CC	,
19	C	C	CD
kDs	O	O	NNS
splenic	C	C	JJ
and	CC	CC	CC
brain	C	C	NN
cells	O	O	NNS
O	O	O	
cAMP-	C	C	NN
and	CC	CC	CC
cGMP-	C	C	*
dependent	O	O	JJ
protein	O	O	NN
kinases	O	O	NNS
O	O	O	
Jak1	C	C	NN
,	CC	CC	,
Jak2	C	C	NN
,	CC	CC	,
Jak3	C	C	NN
,	CC	CC	,
and	CC	CC	CC
Fes	C	C	NN
tyrosine	O	O	NN
kinases	O	O	NNS
O	O	O	
metallothionein	O	O	NN
enhancer	C	C	NN
and	CC	CC	CC
promoter	C	C	NN
regions	O	O	NNS
O	O	O	
TNF-	C	C	NN
and	CC	CC	CC
cytokine-	C	C	*
receptor	O	O	JJ
O	O	O	
91	C	C	CD
and	CC	CC	CC
84	C	C	CD
kDa	O	O	NN
proteins	O	O	NNS
O	O	O	
follicular	C	C	JJ
,	CC	CC	,
mixed	C	C	JJ
small	C	C	JJ
and	CC	CC	CC
large	C	C	JJ
cell	O	O	NN
lymphomas	O	O	NNS
O	O	O	
eosinophil	C	C	NN
and	CC	CC	CC
neutrophil	C	C	NN
differentiation	O	O	NN
O	O	O	
lymphomagenic	O	C	JJ
Akv	C	C	NN
and	CC	CC	CC
SL3-3	C	C	NN
murine	O	C	JJ
leukemia	O	C	NN
retroviruses	O	O	NNS
O	O	O	
5S	C	C	NN
rRNA	C	C	NN
and	CC	CC	CC
tRNA	C	C	NN
gene	O	O	NN
transcription	O	O	NN
O	O	O	
murine	C	C	JJ
and	CC	CC	CC
human	C	C	JJ
p40	O	O	NN
genes	O	O	NNS
O	O	O	
pre-B	C	C	NN
and	CC	CC	CC
immature	C	C	JJ
B	C	C	NN
cells	O	O	NNS
O	O	O	
PBGD	C	C	NN
and	CC	CC	CC
GATA-1	C	C	NN
mRNAs	O	O	NNS
O	O	O	
T-cell-	C	C	NN
and	CC	CC	CC
B-cell-	C	C	*
specific	O	O	JJ
transcription	O	O	NN
factors	O	O	NNS
O	O	O	
interleukin-13	C	C	NN
and	CC	CC	CC
interleukin-4	C	C	NN
genes	O	O	NNS
O	O	O	
helices	O	O	NNS
I	C	C	CD
and	CC	CC	CC
II	C	C	CD
O	O	O	
monocytic	C	C	JJ
or	CC	CC	CC
neutrophil	C	C	NN
lineages	O	O	NNS
O	O	O	
NF-kappaB	O	O	*
-dependent	C	C	JJ
and	CC	CC	CC
-independent	C	C	JJ
signaling	O	O	NN
pathways	O	O	NNS
O	O	O	
Positive	C	C	JJ
and	CC	CC	CC
negative	C	C	JJ
regulation	O	O	NN
O	O	O	
LPS-	C	C	NN
and	CC	CC	CC
IL-1beta-	C	C	*
induced	O	O	JJ
IL-6	O	O	NN
production	O	O	NN
O	O	O	
acute	C	C	JJ
and	CC	CC	CC
chronic	C	C	JJ
inflammation	O	O	NN
O	O	O	
383-bp	C	C	JJ
(	C	C	(
delta383	C	C	NN
)	C	C	)
and	CC	CC	CC
99-bp	C	C	JJ
(	C	C	(
delta99	C	C	NN
)	C	C	)
sequences	O	O	NNS
O	O	O	
eutopic	C	C	JJ
and	CC	CC	CC
ectopic	C	C	JJ
implantation	O	O	NN
sites	O	O	NNS
O	O	O	
glucocorticoid	C	C	NN
and	CC	CC	CC
beta-adrenergic	C	C	JJ
receptors	O	O	NNS
O	O	O	
SRE-	C	C	NN
and	CC	CC	CC
NF-Y-	C	C	*
binding	O	O	JJ
sites	O	O	NNS
O	O	O	
human	O	O	JJ
GM-CSF	O	O	NN
receptor	O	O	NN
alpha	C	C	NN
and	CC	CC	CC
beta	C	C	NN
subunits	O	O	NNS
GM-CSFR	O	C	*
alpha	C	O	NN
and	CC	CC	CC
beta	C	C	NN
O	O	O	
B-	C	C	NN
,	CC	CC	,
T-	C	C	NN
,	CC	CC	,
and	CC	CC	CC
NK-	C	C	*
cell	O	O	NN
lineages	O	O	NNS
O	O	O	
CD8+	C	C	JJ
and	CC	CC	CC
CD4+	C	C	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
dying	C	C	VBG
or	CC	CC	CC
infected	C	C	JJ
cells	O	O	NNS
O	O	O	
NFATp-	C	C	NN
and	CC	CC	CC
NFATc-	C	C	*
specific	O	O	JJ
antibodies	O	O	NNS
O	O	O	
human	O	O	JJ
T-cell	O	O	NN
leukemia	O	O	NN
virus	O	O	NN
type	C	C	NN
I	C	C	CD
and	CC	CC	CC
type	C	C	NN
II	C	C	CD
Tax	O	O	NN
proteins	O	O	NNS
O	O	O	
human	O	O	JJ
glial	O	C	JJ
cells	C	C	NNS
and	CC	CC	CC
lymphocytes	C	C	NNS
O	O	O	
human	C	C	JJ
and	CC	CC	CC
mouse	C	C	NN
TCF-1	O	O	NN
protein	O	O	NN
O	O	O	
anti-inflammatory	C	C	JJ
and	CC	CC	CC
proinflammatory	C	C	JJ
functions	O	O	NNS
O	O	O	
cell-cell	C	C	JJ
and	CC	CC	CC
cell-matrix	C	C	JJ
interactions	O	O	NNS
O	O	O	
TF	C	C	NN
and	CC	CC	CC
other	C	C	JJ
inflammatory	C	C	JJ
genes	O	O	NNS
O	O	O	
BCL-2+	C	C	JJ
,	CC	CC	,
CD56+	C	C	JJ
,	CC	CC	,
CD3+	C	C	JJ
,	CC	CC	,
CD8+	C	C	JJ
and	CC	CC	CC
CD68+	C	C	JJ
cells	O	O	NNS
O	O	O	
Nasal	O	C	JJ
NK-	C	C	NN
and	CC	CC	CC
T-cell	C	C	NN
lymphomas	O	O	NNS
O	O	O	
rapamycin-resistant	C	C	JJ
and	CC	CC	CC
rapamycin-sensitive	C	C	JJ
components	O	O	NNS
O	O	O	
erythroid	C	C	JJ
,	CC	CC	,
megakaryocyte	C	C	NN
,	CC	CC	,
mast	C	C	NN
and	CC	CC	CC
early	C	C	JJ
myeloid	O	C	JJ
cell	O	O	NN
lines	O	O	NNS
O	O	O	
primary	O	O	JJ
human	O	O	JJ
NK	C	C	NN
and	CC	CC	CC
T	C	C	NN
cells	O	O	NNS
O	O	O	
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
cells	O	O	NNS
O	O	O	
major	C	C	JJ
and	CC	CC	CC
one	C	CC	CD
minor	O	C	JJ
transcription	O	O	NN
start	O	O	NN
site	O	O	NN
O	O	O	
site	O	O	NN
alpha	C	C	NN
and	CC	CC	CC
beta	C	C	NN
O	O	O	
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
IL-2-	C	C	NN
and	CC	CC	CC
IL-12-	C	C	*
stimulated	O	O	JJ
cells	O	O	NNS
O	O	O	
constitutive	C	C	JJ
and	CC	CC	CC
inducible	C	C	JJ
expression	O	O	NN
O	O	O	
lymphocytic	C	C	JJ
,	CC	CC	,
hemopoietic	C	C	JJ
systems	O	O	NNS
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
lymphocyte	O	O	NN
activation	O	O	NN
O	O	O	
megakaryocytic	C	C	JJ
and	CC	CC	CC
erythroid	C	C	JJ
maturation	O	O	NN
O	O	O	
tetanus	C	O	NN
toxoid	C	O	NN
antigen-specific	C	O	JJ
T	O	O	NN
cell	O	O	NN
proliferation	C	C	NN
and	CC	CC	CC
expansion	C	C	NN
O	O	O	
TNF-	C	C	NN
and	CC	CC	CC
anti-Fas-	C	C	*
induced	O	O	JJ
activation	O	O	NN
O	O	O	
5'	C	C	JJ
or	CC	CC	CC
3'	C	C	JJ
NF-kappaB	O	O	NN
sites	O	O	NNS
O	O	O	
autocrine	C	C	JJ
and	CC	CC	CC
paracrine	C	C	JJ
fashion	O	O	NN
O	O	O	
bone	O	C	NN
morphogenetic	O	C	JJ
protein-2-	C	C	NN
and	CC	CC	CC
activin	C	C	NN
A-	C	C	*
mediated	O	O	JJ
signaling	O	O	NN
O	O	O	
estradiol	C	C	NN
and	CC	CC	CC
progesterone	C	C	NN
receptor	O	O	NN
levels	O	O	NNS
O	O	O	
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
Stat1	C	O	NN
and	CC	CC	CC
Stat3	C	O	NN
mRNA	C	C	NN
and	CC	CC	CC
protein	C	C	NN
levels	O	O	NNS
O	O	O	
dominant	O	O	JJ
negative	O	O	JJ
Rac	C	C	NN
and	CC	CC	CC
Cdc42	C	C	NN
proteins	O	O	NNS
O	O	O	
AP2	C	C	NN
and	CC	CC	CC
Sp1	C	C	NN
binding	O	O	NN
sites	O	O	NNS
5'-untranslated	C	C	JJ
and	CC	CC	CC
proximal	C	C	JJ
coding	O	C	VBG
regions	O	O	NNS
O	O	O	
gamma-	C	C	NN
and	CC	CC	CC
beta-	C	C	*
globin	O	O	NN
gene	O	O	NN
promoters	O	O	NNS
fetal	C	C	JJ
or	CC	CC	CC
the	CC	CC	DT
adult	C	C	JJ
globin	O	O	NN
gene	O	O	NN
O	O	O	
intracellular	O	O	JJ
Na+	C	C	NN
,	CC	CC	,
K+	C	C	NN
and	CC	CC	CC
Ca2+	C	C	NN
concentrations	O	O	NNS
O	O	O	
endocrine	C	C	NN
,	CC	CC	,
fibroblast	C	C	NN
,	CC	CC	,
and	CC	CC	CC
lymphoid	C	C	JJ
lineages	O	O	NNS
O	O	O	
p50	C	C	NN
and	CC	CC	CC
p65	C	C	NN
NF-kappa	C	O	NN
B	C	O	NN
subunits	O	O	NNS
O	O	O	
clonogenetic	O	O	JJ
fetal	O	O	JJ
calf	O	O	NN
serum	O	O	*
-supplemented	C	C	JJ
(	C	C	(
FCS+	C	C	JJ
)	C	C	)
or	CC	CC	CC
-nonsupplemented	C	C	JJ
(	C	C	(
FCS-	C	C	JJ
)	C	C	)
culture	O	O	NN
O	O	O	
follicular	C	C	JJ
and	CC	CC	CC
luteal	C	C	JJ
phases	O	O	NNS
O	O	O	
immunosuppressive	C	C	JJ
and	CC	CC	CC
immunosuppression-inducing	C	C	JJ
capacities	O	CC	NNS
O	O	O	
Tax-expressing	C	C	JJ
and	CC	CC	CC
HTLV-I-transformed	C	C	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
megakaryocytic	C	C	JJ
cells	O	O	NNS
O	O	O	
CD4	protein_molecule	C	*
+	protein_molecule	C	JJ
,	protein_molecule	CC	,
CD8	protein_molecule	C	*
+	protein_molecule	C	JJ
and	protein_molecule	CC	CC
CD56	protein_molecule	C	*
+	O	C	JJ
cell	O	O	NN
populations	O	O	NNS
O	O	O	
MOLT-4	C	C	NN
and	CC	CC	CC
CEM	C	C	NN
cells	O	O	NNS
O	O	O	
PMA	C	C	*
-	CC	CC	NN
but	CC	CC	CC
not	CC	CC	RB
TG	C	C	*
-induced	O	O	JJ
IL-2R	O	O	NN
alpha	C	O	NN
TG	C	C	*
-	CC	CC	NN
but	CC	CC	CC
not	CC	CC	RB
PMA	C	C	*
-induced	O	O	JJ
IL-2R	O	O	NN
alpha	O	O	NN
O	O	O	
AP-2	C	C	NN
and	CC	CC	CC
Sp1	C	C	NN
binding	O	O	NN
motifs	O	O	NNS
O	O	O	
IL-1beta-	C	C	NN
,	CC	CC	,
IL-6-	C	C	NN
and	CC	CC	CC
TNF-alpha-	C	C	*
mRNA	O	O	NN
O	O	O	
Cellular	C	O	JJ
immune	C	C	JJ
and	CC	CC	CC
cytokine	C	C	NN
pathways	O	O	NNS
O	O	O	
N-	C	C	NN
and	CC	CC	CC
C-	C	C	*
terminal	O	O	JJ
residues	O	O	NNS
O	O	O	
c-Jun-	C	C	NN
and	CC	CC	CC
GST-pi-	C	C	*
positive	O	O	JJ
plasma	O	O	NN
cells	O	O	NNS
O	O	O	
NF-kappaB	C	C	NN
and	CC	CC	CC
SRE/CArG	C	C	NN
motifs	O	O	NNS
O	O	O	
West	C	C	JJ
African	C	C	JJ
and	CC	CC	CC
East	C	C	JJ
African	O	C	JJ
populations	O	O	NNS
O	O	O	
positive	C	C	JJ
or	CC	CC	CC
negative	C	C	JJ
regulator	O	O	NN
O	O	O	
type	C	O	NN
A	C	C	NN
and	CC	CC	CC
B	C	C	NN
transcripts	O	O	NNS
O	O	O	
element-specific	C	C	JJ
and	CC	CC	CC
common	C	C	JJ
complexes	O	O	NNS
O	O	O	
alpha	O	C	NN
1	C	C	CD
,	CC	CC	,
alpha	C	C	NN
2	C	C	CD
and	CC	CC	CC
gamma	C	C	NN
globin	C	O	NN
genes	O	O	NNS
O	O	O	
viral	C	C	JJ
,	CC	CC	,
self	C	C	NN
,	CC	CC	,
and	CC	CC	CC
bacterial	C	C	JJ
peptides	O	O	NNS
O	O	O	
TATA	C	C	NN
or	CC	CC	CC
a	C	CC	DT
CAAT	C	C	NN
box	O	O	NN
O	O	O	
pro-B	C	C	JJ
,	CC	CC	,
pre-B	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
mature	C	C	JJ
B	O	C	NN
cells	O	O	NNS
O	O	O	
proximal	C	C	JJ
and	CC	CC	CC
remote	C	C	JJ
positions	O	O	NNS
O	O	O	
subgroups	O	O	NNS
A	C	C	NN
(	C	C	(
Ad12	C	C	NN
)	C	C	)
and	CC	CC	CC
B	C	C	NN
(	C	C	(
Ad3	C	C	NN
)	C	C	)
O	O	O	
possible	C	O	JJ
T-cell	C	C	NN
and	CC	CC	CC
natural	C	C	JJ
killer	C	CC	NN
(	C	C	(
T/NK	C	C	NN
)	C	C	)
populations	O	O	NNS
O	O	O	
immunoregulatory	C	C	JJ
,	CC	CC	,
cytokine	C	C	NN
and	CC	CC	CC
viral	C	C	JJ
gene	O	O	NN
expression	O	O	NN
O	O	O	
IL-4-	C	C	NN
or	CC	CC	CC
IL-5-	C	C	*
stimulated	O	O	JJ
eosinophils	O	O	NNS
O	O	O	
heavy	C	C	JJ
and	CC	CC	CC
kappa	C	C	NN
light	C	C	JJ
chain	O	O	NN
enhancers	O	O	NNS
O	O	O	
CD3-epsilon	C	C	NN
and	CC	CC	CC
T	C	C	NN
cell	C	C	NN
receptor	C	C	NN
alpha	C	C	NN
enhancers	O	O	NNS
O	O	O	
T	C	C	NN
and	CC	CC	CC
,	C	CC	,
to	C	CC	TO
a	C	CC	DT
lesser	C	CC	JJR
extent	C	CC	NN
,	CC	CC	,
B	C	C	NN
cells	O	O	NNS
O	O	O	
self	C	C	NN
and	CC	CC	CC
bacterial	C	C	JJ
peptides	O	O	NNS
O	O	O	
oxidant	C	C	JJ
and	CC	CC	CC
antioxidant	C	C	JJ
stimuli	O	O	NNS
O	O	O	
IL-2-	C	C	NN
or	CC	CC	CC
IL-7-	C	C	*
treated	O	O	JJ
cells	O	O	NNS
O	O	O	
acute	C	C	JJ
promyelocytic	C	C	JJ
and	CC	CC	CC
acute	C	C	JJ
myeloblastic	C	C	JJ
leukemia	O	O	NN
cells	O	O	NNS
O	O	O	
CD4+CD28null	C	C	NN
and	CC	CC	CC
CD8+CD28null	C	C	NN
T	O	O	NN
cells	O	O	NNS
alpha-	C	C	NN
and	CC	CC	CC
beta-	C	C	*
bound	O	O	JJ
complexes	O	O	NNS
O	O	O	
lymphoid	C	C	JJ
and	CC	CC	CC
prostatic	C	C	JJ
cells	O	O	NNS
O	O	O	
virus-infected	C	C	JJ
or	CC	CC	CC
tumor	C	C	JJ
cells	O	O	NNS
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
T-cell	C	C	NN
lines	O	O	NNS
O	O	O	
CD3	C	C	NN
and	CC	CC	CC
CD28	C	C	NN
molecules	O	O	NNS
O	O	O	
c-fos	C	C	NN
and	CC	CC	CC
c-jun	C	C	NN
transcripts	O	O	NNS
O	O	O	
human	O	O	JJ
peripheral	O	O	JJ
mononuclear	C	C	JJ
and	CC	CC	CC
polymorphonuclear	C	C	JJ
leucocytes	O	O	NNS
O	O	O	
interleukin-3-dependent	C	C	JJ
and	CC	CC	CC
p53-mediated	C	C	JJ
apoptosis	O	O	NN
O	O	O	
T	C	C	NN
helper	C	C	NN
1	C	C	CD
(	C	C	(
Th1	C	C	NN
)	C	C	)
and	CC	CC	CC
T	C	C	NN
helper	C	C	NN
2	C	C	CD
(	C	C	(
Th2	C	C	NN
)	C	C	)
cells	O	O	NNS
O	O	O	
inflammatory	C	C	JJ
and	CC	CC	CC
immune	C	C	JJ
responses	O	O	NNS
O	O	O	
Th1	C	C	NN
or	CC	CC	CC
Th2	C	C	NN
differentiation	O	O	NN
O	O	O	
lymphoid	C	C	JJ
and	CC	CC	CC
nonlymphoid	C	C	JJ
cells	O	O	NNS
HLF	C	C	NN
or	CC	CC	CC
C/EBP	C	C	NN
consensus	O	O	NN
binding	O	O	NN
sites	O	O	NNS
O	O	O	
mu	C	C	NN
and	CC	CC	CC
gamma	C	C	NN
mRNA	O	O	NN
O	O	O	
memory	C	C	NN
and	CC	CC	CC
naive	C	C	JJ
T	O	O	NN
cell	O	O	NN
subsets	O	O	NNS
O	O	O	
NF-kappa	C	C	NN
B	C	C	NN
and	CC	CC	CC
AP-1	C	C	NN
activation	O	O	NN
O	O	O	
NF	C	C	NN
kappa	C	C	NN
B	C	C	NN
and	CC	CC	CC
IL-2	C	C	NN
levels	O	O	NNS
O	O	O	
TPA-induced	C	O	JJ
c-fos	C	C	NN
and	CC	CC	CC
c-jun	C	C	NN
gene	O	O	NN
expression	O	O	NN
O	O	O	
immunosuppressive	C	C	JJ
and	CC	CC	CC
antineoplastic	C	C	JJ
agents	O	O	NNS
O	O	O	
c-jun	C	cell_type	NN
TRE	C	cell_type	NN
and	CC	cell_type	CC
c-fos	C	cell_type	NN
SRE	O	cell_type	NN
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
cell	O	O	NN
development	O	O	NN
O	O	O	
constitutive	C	C	JJ
and	CC	CC	CC
IFN	C	C	NN
inducible	O	C	JJ
expression	O	O	NN
O	O	O	
SP1	C	C	NN
,	CC	CC	,
ETS	C	C	NN
,	CC	CC	,
OCT	C	C	NN
,	CC	CC	,
and	CC	CC	CC
IKAROS/LYF-1	C	C	NN
transcription	O	O	NN
factor	O	O	NN
motifs	O	O	NNS
O	O	O	
inflammatory	C	C	JJ
and	CC	CC	CC
immune	C	C	JJ
responses	O	O	NNS
O	O	O	
c-Jun	C	C	NN
and	CC	CC	CC
GST-pi	C	C	NN
expression	O	O	NN
O	O	O	
regulatory	C	C	JJ
and	CC	CC	CC
catalytic	C	C	JJ
subunits	O	O	NNS
euthymic	C	C	JJ
,	CC	CC	,
manic	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
depressed	C	C	JJ
patients	O	O	NNS
O	O	O	
S1T	C	C	NN
and	CC	CC	CC
ATL-1K	C	C	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
phase	O	O	*
-1	C	C	JJ
and	CC	CC	CC
-2	C	C	CD
neutrophil	C	O	NN
adhesion	O	O	NN
responses	O	O	NNS
O	O	O	
HIV-1	C	C	NN
or	CC	CC	CC
HIV-2	C	C	NN
enhancers	O	O	NNS
O	O	O	
antiproliferative	C	C	JJ
and	CC	CC	CC
apoptotic	C	C	JJ
effects	O	O	NNS
O	O	O	
LEF-1	C	C	NN
and	CC	CC	CC
distal	C	C	JJ
NF-kappaB	C	C	NN
transcription	O	C	NN
factor	O	C	NN
binding	O	O	NN
sites	O	O	NNS
O	O	O	
CNS	C	C	NN
and	CC	CC	CC
immune	C	C	JJ
system	C	C	NN
origin	O	O	NN
O	O	O	
XPB	C	C	NN
and	CC	CC	CC
XPD	C	C	NN
genes	O	O	NNS
O	O	O	
p65	C	C	NN
and	CC	CC	CC
p105	C	C	NN
mRNA	O	O	NN
levels	O	O	NNS
O	O	O	
primary	O	O	JJ
human	O	O	JJ
T	C	C	NN
and	CC	CC	CC
NK	C	C	NN
cells	O	O	NNS
O	O	O	
monomorphic	C	C	JJ
or	CC	CC	CC
polymorphic	C	C	JJ
determinants	O	O	NNS
O	O	O	
Id2	C	C	NN
and	CC	CC	CC
Id3	C	C	NN
mRNA	O	O	NN
O	O	O	
p50/p65	C	C	NN
and	CC	CC	CC
p50/RelB	C	C	NN
heterodimers	O	O	NNS
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
megakaryocytic	C	C	JJ
lineage	O	O	NN
cells	O	O	NNS
O	O	O	
Immunohistochemical	C	C	JJ
and	CC	CC	CC
ultrastructural	C	C	JJ
studies	O	O	NNS
O	O	O	
cytokine	O	O	NN
redundancy	C	C	NN
and	CC	CC	CC
pleiotropy	C	C	NN
O	O	O	
p16	C	C	NN
,	CC	CC	,
p15	C	C	NN
and	CC	CC	CC
CDK4	C	C	NN
genes	O	O	NNS
O	O	O	
AP-1	C	C	NN
and	CC	CC	CC
Ikaros	C	C	NN
sites	O	O	NNS
O	O	O	
IL-2R	O	O	*
alpha	C	C	NN
and	CC	CC	CC
beta	C	C	NN
chains	O	O	NNS
O	O	O	
HLA-DRA	C	C	NN
and	CC	CC	CC
DQB	C	C	NN
reporter	O	O	NN
constructs	O	O	NNS
O	O	O	
alpha-	C	C	NN
and	CC	CC	CC
beta-	C	C	*
globin	O	O	NN
O	O	O	
CIITA	C	C	NN
and	CC	CC	CC
MHC	C	C	NN
class	C	C	NN
II	C	C	CD
gene	O	O	NN
expression	O	O	NN
macrophage	C	C	NN
and	CC	CC	CC
epithelial	C	C	JJ
cell	O	O	NN
lines	O	O	NNS
O	O	O	
T	C	C	NN
lymphocytic	C	C	JJ
and	CC	CC	CC
mononuclear	C	C	JJ
phagocytic	O	C	JJ
lineage	O	O	NN
O	O	O	
immune	C	C	JJ
and	CC	CC	CC
nervous	C	C	JJ
systems	O	O	NNS
O	O	O	
1q12	C	C	NN
and	CC	CC	CC
1p36	C	C	NN
regions	O	O	NNS
O	O	O	
B-cell	C	C	NN
and	CC	CC	CC
HeLa-cell	C	C	JJ
extracts	O	O	NNS
O	O	O	
CREB-	C	C	NN
and	CC	CC	CC
NF-kappa	C	C	NN
B-	C	C	*
like	O	O	JJ
factors	O	O	NNS
O	O	O	
B-cell-specific	C	C	JJ
and	CC	CC	CC
gamma	C	C	NN
interferon-inducible	C	C	JJ
fashion	O	O	NN
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
NF-E2	C	C	NN
and	CC	CC	CC
tandem	C	C	JJ
,	CC	C	,
inverted	C	C	JJ
GATA	C	C	NN
binding	O	O	NN
sites	O	O	NNS
O	O	O	
c-fos	C	C	NN
and	CC	CC	CC
c-jun	C	C	NN
messenger	O	O	NN
RNA	O	O	NN
O	O	O	
E1A	C	C	NN
and	CC	CC	CC
hexon	C	C	NN
primers	O	O	NNS
O	O	O	
EBV	O	O	NN
transcription	O	O	NN
factors	O	O	NNS
R	C	C	NN
and	CC	CC	CC
Z	C	C	NN
O	O	O	
STATs	O	O	*
1	C	C	NN
,	CC	CC	,
-3	C	C	CD
DNA	C	O	NN
binding	C	O	NN
and	CC	CC	CC
growth	C	O	NN
arrest	C	O	NN
STATs	O	O	*
1	C	C	NN
,	CC	CC	,
-3	C	C	CD
O	O	O	
p50-	C	C	NN
or	CC	CC	CC
p65-	C	C	*
selected	O	O	JJ
kappa	O	O	NN
B	O	O	NN
motif	O	O	NN
O	O	O	
32	C	C	CD
,	CC	CC	,
36	C	C	CD
to	C	C	TO
42	C	C	CD
and	CC	CC	CC
110	C	C	CD
kD	O	O	NN
proteins	O	O	NNS
O	O	O	
NF-AT	C	C	NN
,	CC	CC	,
AP-1	C	C	NN
and	CC	CC	CC
CLE0	C	C	NN
sequences	O	O	NNS
O	O	O	
tarsal	C	C	JJ
and	CC	CC	CC
bulbar	C	C	JJ
conjunctiva	O	O	NN
O	O	O	
immune	C	C	JJ
and	CC	CC	CC
inflammatory	C	C	JJ
responses	O	O	NNS
O	O	O	
NF	C	C	NN
kappa	C	C	NN
B	C	C	NN
or	CC	CC	CC
Sp-1	C	C	NN
elements	O	O	NNS
Tat-	C	C	NN
or	CC	CC	CC
mitogen-	C	C	*
mediated	O	O	JJ
LTR	O	O	NN
transcription	O	O	NN
O	O	O	
protein	C	O	NN
tyrosine	C	C	NN
and	CC	CC	CC
serine/threonine	C	C	NN
kinases	O	O	NNS
O	O	O	
N	C	C	NN
or	CC	CC	CC
C	C	C	NN
terminus	O	O	NN
O	O	O	
cytokine	C	C	NN
and	CC	CC	CC
immune	C	C	JJ
receptors	O	O	NNS
O	O	O	
murine	O	O	JJ
Th1	C	C	NN
and	CC	CC	CC
Th2	C	C	NN
cells	O	O	NNS
O	O	O	
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
abnormal	O	O	JJ
cAMP	C	C	NN
and	CC	CC	CC
cAMP-phosphodiesterase	C	C	NN
activity	O	O	NN
O	O	O	
immature	C	C	JJ
,	CC	CC	,
or	CC	CC	CC
primitive	C	C	JJ
erythroid	O	O	JJ
tissues	O	O	NNS
O	O	O	
LPS-	C	C	NN
and	CC	CC	CC
TNF-	C	C	*
induced	O	O	JJ
signaling	O	O	NN
O	O	O	
human	C	O	JJ
epsilon-	C	C	NN
or	CC	CC	CC
beta-	C	C	*
globin	O	O	NN
genes	O	O	NNS
O	O	O	
biochemical	C	C	JJ
and	CC	CC	CC
cell	C	C	NN
biological	C	C	JJ
properties	O	O	NNS
O	O	O	
monocytic	C	C	JJ
and	CC	CC	CC
granulocytic	C	C	JJ
maturation	O	O	NN
O	O	O	
p46	C	C	NN
and	CC	CC	CC
p54	C	C	NN
isoforms	O	O	NNS
O	O	O	
viral	C	C	JJ
and	CC	CC	CC
self	C	C	NN
peptides	O	O	NNS
O	O	O	
CD45RA	C	C	NN
and	CC	CC	CC
CD45R0	C	C	NN
T	O	O	NN
helper	O	O	NN
subsets	O	O	NNS
O	O	O	
primary	C	C	JJ
and	CC	CC	CC
secondary	C	C	JJ
stimulations	O	O	NNS
O	O	O	
XP	C	C	NN
and	CC	CC	CC
CS	C	C	NN
symptoms	O	O	NNS
O	O	O	
cytoplasmic	C	C	JJ
and	CC	CC	CC
nuclear	C	C	JJ
signaling	O	O	NN
steps	O	O	NNS
O	O	O	
XP-B	C	C	NN
and	CC	CC	CC
XP-D	C	C	NN
lymphoblastoid	O	O	JJ
cells	O	O	NNS
O	O	O	
beta-globin	C	O	NN
promoter	C	C	NN
and	CC	CC	CC
gene	C	C	NN
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
beta-casein	C	C	NN
and	CC	CC	CC
IRF-1	C	C	NN
gene	O	O	NN
promoters	O	O	NNS
O	O	O	
TNF-alpha	C	C	NN
and	CC	CC	CC
IL-6	C	C	NN
mRNAs	O	O	NNS
O	O	O	
rat	C	C	NN
and	CC	CC	CC
mouse	C	C	NN
TIS11	O	O	NN
genes	O	O	NNS
O	O	O	
cellular	C	C	JJ
and	CC	CC	CC
viral	C	C	JJ
genes	O	O	NNS
O	O	O	
transcriptional	C	C	JJ
and	CC	CC	CC
posttranscriptional	C	C	JJ
regulation	O	O	NN
O	O	O	
myelomonocytic	C	C	JJ
and	CC	CC	CC
eosinophilic	C	C	JJ
cells	O	O	NNS
O	O	O	
membrane-bound	C	C	JJ
and	CC	CC	CC
cytosolic	C	C	JJ
enzyme	O	O	NN
O	O	O	
PTF	O	O	NN
gamma	C	C	NN
and	CC	CC	CC
delta	C	C	NN
subunits	O	O	NNS
O	O	O	
interleukin	C	C	NN
(	C	C	(
IL	C	C	NN
)	C	C	)
-10	C	C	CD
and	CC	CC	CC
IL-6	C	C	*
-type	O	O	JJ
cytokines	O	O	NNS
O	O	O	
T	C	C	NN
and	CC	CC	CC
NK	C	C	NN
cells	O	O	NNS
O	O	O	
Oct-1	C	C	NN
and	CC	CC	CC
Oct-2	C	C	NN
DNA	O	O	NN
binding	O	O	NN
activity	O	O	NN
O	O	O	
serine/threonine	O	O	NN
phosphatases	O	O	*
-1	C	C	NN
and	CC	CC	CC
-2A	C	C	NN
O	O	O	
lamin	C	C	NN
A	C	C	NN
,	CC	CC	,
lamin	C	C	NN
C	C	C	NN
,	CC	CC	,
and	CC	CC	CC
vimentin	C	C	NN
transcripts	O	O	NNS
O	O	O	
granulocytic	C	C	JJ
or	CC	CC	CC
monocytic	C	C	JJ
lineage	O	O	NN
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
cells	O	O	NNS
O	O	O	
vertebral	C	C	NN
and	CC	CC	CC
hip	C	C	NN
bone	O	O	NN
density	O	O	NN
O	O	O	
Epo	C	C	NN
and	CC	CC	CC
erythroid	C	C	JJ
differentiation	O	O	NN
O	O	O	
TNF-alpha	C	C	NN
,	CC	CC	,
IL-1	C	C	NN
beta	C	C	NN
and	CC	CC	CC
phorbol	C	C	NN
myristate	C	C	NN
acetate	C	C	NN
(	C	C	(
PMA	C	C	NN
)	C	C	)
treatment	O	O	NN
O	O	O	
p65	C	C	NN
and	CC	CC	CC
c-Rel	C	C	NN
complexes	O	O	NNS
O	O	O	
calcineurin	C	O	NN
A	C	C	NN
and	CC	CC	CC
B	C	C	NN
subunits	O	O	NNS
O	O	O	
p35	C	C	NN
and	CC	CC	CC
p40	C	C	NN
chains	O	O	NNS
O	O	O	
allergic	C	C	JJ
and	CC	CC	CC
atopic	C	C	JJ
immune	O	O	JJ
responses	O	O	NNS
O	O	O	
CD4(+)	C	C	JJ
and	CC	CC	CC
CD8(+)	C	C	JJ
subsets	O	O	NNS
O	O	O	
myeloid	C	C	JJ
and	CC	CC	CC
NK	C	C	NN
cell	O	O	NN
lineages	O	O	NNS
O	O	O	
AP-1	C	C	NN
and	CC	CC	CC
Sp1	C	C	NN
proteins	O	O	NNS
O	O	O	
HLA	O	O	*
-DQ	C	C	NN
alpha	C	C	NN
or	CC	CC	CC
-DQ	C	C	NN
beta	C	C	NN
transcription	O	O	NN
O	O	O	
70-	C	C	CD
and	CC	CC	CC
90-	C	C	*
kilodalton	O	O	JJ
heat	O	O	NN
shock	O	O	NN
proteins	O	O	NNS
O	O	O	
B-cell	O	O	NN
growth	C	C	NN
and	CC	CC	CC
development	C	C	NN
O	O	O	
lymphocyte	O	O	NN
Ca2+	C	C	NN
and	CC	CC	CC
Cl-	C	C	NN
channels	O	O	NNS
O	O	O	
IKK	O	O	*
alpha	C	C	NN
and	CC	CC	CC
-beta	C	C	NN
O	O	O	
Th1	C	C	NN
and	CC	CC	CC
Th2	C	C	NN
immune	O	O	JJ
responses	O	O	NNS
infectious	C	C	JJ
,	CC	CC	,
autoimmune	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
allergic	C	C	JJ
diseases	O	O	NNS
O	O	O	
resting	C	C	VBG
and	CC	CC	CC
stimulated	C	C	VBN
T	O	O	NN
cells	O	O	NNS
O	O	O	
STAT1	C	C	NN
,	CC	CC	,
STAT3	C	C	NN
and	CC	CC	CC
STAT5	C	C	NN
RNA	O	O	NN
O	O	O	
anti-CD3-	C	C	JJ
and	CC	CC	CC
anti-CD28-	C	C	JJ
treated	C	O	JJ
Rel-/-	C	O	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
NFAT	C	C	NN
or	CC	CC	CC
AP-1	C	C	NN
sites	O	O	NNS
O	O	O	
jun	C	C	NN
and	CC	CC	CC
fos	C	C	NN
early	O	O	JJ
response	O	O	NN
genes	O	O	NNS
O	O	O	
kappa	C	C	NN
and	CC	CC	CC
lambda	C	C	NN
light-chain	O	O	JJ
genes	O	O	NNS
O	O	O	
IL-1	C	C	NN
,	CC	CC	,
IL-2	C	C	NN
,	CC	CC	,
or	CC	CC	CC
IL-4	C	C	NN
activity	O	O	NN
O	O	O	
Ets	C	C	NN
and	CC	CC	CC
NF-kappaB/NFAT	C	C	NN
families	O	O	NNS
O	O	O	
erythroid	C	C	JJ
lineage-	C	C	NN
and	CC	CC	CC
developmental	C	C	JJ
stage-	C	C	*
specific	O	O	JJ
regulation	O	O	NN
O	O	O	
c-jun	C	C	NN
,	CC	CC	,
jun	C	C	NN
B	C	C	NN
and	CC	CC	CC
jun	C	C	NN
D	C	C	NN
mRNA	O	O	NN
O	O	O	
immunosuppressive	C	C	JJ
and	CC	CC	CC
antiinflammatory	C	C	JJ
properties	O	O	NNS
O	O	O	
c-jun	C	C	NN
and	CC	CC	CC
jun	C	C	NN
B	C	C	NN
mRNA	O	O	NN
expression	O	O	NN
O	O	O	
sensitive	C	C	JJ
and	CC	CC	CC
resistant	C	C	JJ
patients	O	O	NNS
O	O	O	
alpha	C	C	NN
and	CC	CC	CC
delta	C	C	NN
gene	O	O	NN
segments	O	O	NNS
O	O	O	
nasal	C	C	NN
and	CC	CC	CC
bronchial	C	C	JJ
epithelium	O	O	NN
O	O	O	
protein	C	O	NN
phosphatase	C	O	NN
type	C	C	NN
1	C	C	CD
(	C	C	(
PP-1	C	C	NN
)	C	C	)
and	CC	CC	CC
type	C	C	NN
2A	C	C	NN
O	O	O	
exons	O	O	NNS
2	C	C	CD
,	CC	CC	,
5	C	C	CD
and	CC	CC	CC
7	C	C	CD
O	O	O	
NF-kappa	C	C	NN
B	C	C	NN
and	CC	CC	CC
Sp1	C	C	NN
binding	O	O	NN
sites	O	O	NNS
NF-kappa	C	C	NN
B	C	C	NN
and	CC	CC	CC
Sp1	C	C	NN
elements	O	O	NNS
O	O	O	
Transcriptional	C	C	JJ
and	CC	CC	CC
post-transcriptional	C	C	JJ
regulation	O	O	NN
O	O	O	
muA	C	C	NN
and	CC	CC	CC
muB	C	C	NN
elements	O	O	NNS
O	O	O	
NK	C	C	NN
and	CC	CC	CC
T	C	C	NN
cell	O	O	NN
activation	O	O	NN
O	O	O	
DNA-	O	O	*
binding	C	C	JJ
and	CC	CC	CC
dimerization	C	C	NN
domains	O	O	NNS
O	O	O	
IL4	C	C	NN
and	CC	CC	CC
IL13	C	C	NN
receptors	O	O	NNS
STAT6	C	C	NN
,	CC	CC	,
STAT3	C	C	NN
and	CC	CC	CC
STAT5	C	C	NN
proteins	O	O	NNS
O	O	O	
type	O	O	NN
1	C	C	CD
and	CC	CC	CC
2	C	C	CD
T	O	O	NN
helper	O	O	NN
cell	O	O	NN
cytokine	O	O	NN
production	O	O	NN
O	O	O	
all-trans	C	C	JJ
and	CC	CC	CC
9-cis	C	C	JJ
RA	C	O	NN
acute	C	C	JJ
and	CC	CC	CC
chronic	C	C	JJ
infection	O	O	NN
O	O	O	
AP-1-	C	C	NN
and	CC	CC	CC
NF-kappaB	C	C	NN
factor-	C	C	*
binding	O	O	JJ
elements	O	O	NNS
O	O	O	
ER-negative	C	C	JJ
and	CC	CC	CC
ER-positive	C	C	JJ
human	O	O	JJ
breast	O	O	NN
cancer	O	O	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
vimentin	O	O	NN
mRNA	C	C	NN
and	CC	CC	CC
protein	C	C	NN
levels	O	O	NNS
O	O	O	
lymphokine	C	C	NN
and	CC	CC	CC
lymphokine	C	C	NN
receptor	O	C	NN
genes	O	O	NNS
O	O	O	
IL	O	O	*
-2	C	C	NN
,	CC	CC	,
-7	C	C	CD
,	CC	CC	,
and	CC	CC	CC
-15	C	C	CD
O	O	O	
MHC	O	O	NN
I	C	C	CD
and	CC	CC	CC
II	C	C	CD
O	O	O	
erythroid	C	C	JJ
and/or	CC	CC	CC
megakaryocytic	C	C	JJ
lineages	O	O	NNS
O	O	O	
transcriptional	C	C	JJ
and	CC	CC	CC
post-transcriptional	C	C	JJ
mechanisms	O	O	NNS
O	O	O	
calcineurin	C	C	NN
and	CC	CC	CC
protein	C	C	NN
kinase	C	C	NN
C	C	C	*
-mediated	O	O	JJ
pathways	O	O	NNS
O	O	O	
type	C	O	NN
1	C	C	CD
and	CC	CC	CC
2A	C	C	NN
protein	O	O	NN
phosphatases	O	O	NNS
O	O	O	
myeloid	C	C	JJ
(	C	C	(
CD33	C	C	NN
,	CC	C	,
CD13	C	C	NN
,	CC	C	,
CD15	C	C	NN
)	C	C	)
and	CC	CC	CC
NK	C	C	NN
cell-associated	C	C	JJ
(	C	C	(
CD56	C	C	NN
)	C	C	)
antigens	O	O	NNS
O	O	O	
granulocyte	C	C	NN
or	CC	CC	CC
monocyte	C	C	NN
differentiation	O	O	NN
O	O	O	
various	O	O	JJ
synthetic	C	C	JJ
or	CC	CC	CC
natural	C	C	JJ
agonists	O	O	NNS
O	O	O	
B-lymphocyte	C	C	NN
and	CC	CC	CC
T-lymphocyte	C	C	NN
differentiation	O	O	NN
O	O	O	
Tyrosines	O	O	NNS
113	C	C	CD
,	CC	CC	,
128	C	C	CD
,	CC	CC	,
and	CC	CC	CC
145	C	C	CD
O	O	O	
lymphoid	C	C	JJ
and	CC	CC	CC
myeloid	C	C	JJ
lineages	O	O	NNS
O	O	O	
normal	C	C	JJ
or	CC	CC	CC
rheumatoid	C	C	JJ
peripheral	O	O	JJ
blood	O	O	NN
O	O	O	
fos	C	C	NN
and	CC	CC	CC
jun	C	C	NN
proteins	O	O	NNS
O	O	O	
SRE-	C	C	NN
and	CC	CC	CC
NF-Y-	C	C	*
binding	O	O	JJ
site	O	O	NN
O	O	O	
megakaryocytic	C	C	JJ
and	CC	CC	CC
erythroid	C	C	JJ
lineages	O	O	NNS
O	O	O	
NF-AT	C	C	NN
and	CC	CC	CC
AP-1	C	C	NN
sites	O	O	NNS
O	O	O	
mRNA	C	C	NN
and	CC	CC	CC
protein	C	C	NN
levels	O	O	NNS
O	O	O	
cyclin-dependent-kinase-	O	O	*
4	C	C	NN
and	CC	CC	CC
6	C	C	CD
O	O	O	
B.pertussis	C	C	FW
,	CC	CC	,
V.cholera.	C	C	FW
or	CC	CC	CC
C.botulinum	C	C	FW
toxin	O	O	NN
O	O	O	
regulatory	C	C	JJ
and	CC	CC	CC
catalytic	C	C	JJ
domains	O	O	NNS
O	O	O	
N	C	C	NN
and	CC	CC	CC
the	CC	CC	DT
C	C	C	NN
termini	O	O	NNS
O	O	O	
tumor	C	O	NN
necrosis	C	CC	NN
factor	C	CC	NN
receptor-associated	C	CC	JJ
factor	C	CC	NN
(	C	O	(
TRAF	C	O	NN
)	C	O	)
1	C	C	CD
,	CC	CC	,
2	C	C	CD
,	CC	CC	,
or	CC	CC	CC
3	C	C	CD
O	O	O	
E1A	O	C	NN
N-terminal	C	C	JJ
and	CC	CC	CC
Stat1	C	C	NN
C-terminal	C	C	JJ
residues	O	O	NNS
O	O	O	
inflammatory	C	C	JJ
and	CC	CC	CC
immune	C	C	JJ
mediated	O	C	JJ
reactions	O	O	NNS
O	O	O	
monocyte	C	C	NN
and	CC	CC	CC
T-	C	C	*
cell	O	O	NN
types	O	O	NNS
O	O	O	
megakaryocyte	C	C	NN
or	CC	CC	CC
lymphoid	C	C	JJ
markers	O	O	NNS
O	O	O	
upstream	C	C	JJ
and	CC	CC	CC
downstream	C	C	JJ
sequences	O	O	NNS
O	O	O	
most	O	C	RBS
primitive	C	C	JJ
and	CC	CC	CC
committed	C	C	VBN
progenitors	O	C	NNS
cells	O	O	NNS
O	O	O	
IL-2	C	C	NN
and	CC	CC	CC
IL-2R	C	C	NN
genes	O	O	NNS
O	O	O	
Interleukin	O	O	NN
2	C	C	CD
and	CC	CC	CC
15	C	C	CD
O	O	O	
c-Rel	C	C	NN
and	CC	CC	CC
p65	C	C	NN
subunits	O	O	NNS
O	O	O	
normal	C	C	JJ
myeloid	C	C	JJ
and	CC	CC	CC
erythroid	C	C	JJ
progenitor	O	C	NN
cell	O	O	NN
growth	O	O	NN
O	O	O	
cyclin-dependent	O	O	JJ
kinases	O	O	NNS
4	C	C	CD
and	CC	CC	CC
6	C	C	CD
O	O	O	
anti-inflammatory	C	C	JJ
and	CC	CC	CC
immunosuppressive	C	C	JJ
effects	O	O	NNS
O	O	O	
IL-5	C	C	NN
and	CC	CC	CC
IL-4	C	C	NN
genes	O	O	NNS
O	O	O	
immature	C	C	JJ
and	CC	CC	CC
mature	C	C	JJ
normal	C	O	JJ
myeloid	C	O	JJ
cells	O	O	NNS
O	O	O	
c-fos	C	C	NN
,	CC	CC	,
c-jun	C	C	NN
,	CC	CC	,
EGR2	C	C	NN
,	CC	CC	,
and	CC	CC	CC
PDGF(B)	C	C	NN
mRNA	O	O	NN
O	O	O	
murine	C	C	JJ
and	CC	CC	CC
human	C	C	JJ
cDNAs	O	O	NNS
O	O	O	
CD3	C	C	NN
and	CC	CC	CC
CD2	C	C	NN
receptor	O	O	NN
stimulation	O	O	NN
O	O	O	
Agamma-	C	C	NN
and	CC	CC	CC
the	C	CC	DT
beta-	C	C	*
globin	O	O	NN
genes	O	O	NNS
O	O	O	
Fe2+	O	C	*
/Cu2+	C	C	JJ
ions	O	O	NNS
O	O	O	
concanavalin	C	C	NN
A	C	C	NN
(	C	C	(
Con	C	C	NN
A	C	C	NN
)	C	C	)
-	C	C	:
and	CC	CC	CC
phytohemagglutinin	C	C	NN
(	C	C	(
PHA	C	C	NN
)	C	C	)
-	C	C	*
induced	O	O	JJ
T-cell	O	O	NN
proliferation	O	O	NN
O	O	O	
p65	C	C	NN
or	CC	CC	CC
c-Rel	C	C	NN
subunits	O	O	NNS
O	O	O	
polyclonal	C	C	JJ
and	CC	CC	CC
clonal	C	C	JJ
CD3-CD16+	C	O	JJ
natural	C	O	JJ
killer	C	CC	NN
(	C	CC	(
NK	C	CC	NN
)	C	CC	)
cell	O	CC	NN
lines	O	O	NNS
O	O	O	
glucocorticoid-	C	C	NN
and	CC	CC	CC
Fas-	C	C	*
mediated	O	O	JJ
cytotoxicity	O	O	NN
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
megakaryocytic	C	C	JJ
characteristics	O	O	NNS
O	O	O	
p65	C	C	NN
and	CC	CC	CC
c-Rel	C	C	NN
protein	O	O	NN
expression	O	O	NN
O	O	O	
transcriptional	C	C	JJ
and	CC	CC	CC
post-transcriptional	C	C	JJ
mechanisms	O	O	NNS
O	O	O	
p50	C	C	NN
and	CC	CC	CC
p65	C	C	NN
proteins	O	O	NNS
O	O	O	
hematopoietic	C	C	JJ
and	CC	CC	CC
non-hematopoietic	C	C	JJ
cells	O	O	NNS
O	O	O	
erythroid	C	C	JJ
lineage-	C	C	NN
and	CC	CC	CC
developmental	C	C	JJ
stage-	C	C	*
specific	O	O	JJ
manner	O	O	NN
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
megakaryocytic	C	C	JJ
differentiation	O	O	NN
O	O	O	
all-trans	C	C	JJ
and	CC	CC	CC
9-cis	C	C	JJ
RA	O	O	NN
O	O	O	
IL-6-	C	C	NN
and	CC	CC	CC
IFN-gamma-	C	C	*
induced	O	O	JJ
reporter	O	O	NN
gene	O	O	NN
activity	O	O	NN
O	O	O	
IL-2	C	O	NN
receptor	C	O	NN
(	C	O	(
IL-2R	C	O	NN
)	C	O	)
beta	C	C	NN
and	CC	CC	CC
gamma	C	C	NN
chains	O	O	NNS
O	O	O	
fatty	O	C	JJ
acid	C	C	NN
and	CC	CC	CC
lipid	C	C	NN
metabolism	O	O	NN
O	O	O	
STAT5-	C	C	NN
and	CC	CC	CC
STAT1-	C	C	*
related	O	O	JJ
factors	O	O	NNS
STAT1-	C	C	NN
,	CC	CC	,
STAT3-	C	C	NN
,	CC	CC	,
and	CC	CC	CC
STAT5-	C	C	*
related	O	O	JJ
proteins	O	O	NNS
O	O	O	
Murine	C	C	JJ
and	CC	CC	CC
human	C	C	JJ
TCF-1	O	O	NN
O	O	O	
XP-B	C	C	NN
or	CC	CC	CC
XP-D	C	C	NN
patients	O	O	NNS
O	O	O	
serum	O	O	NN
amylase	C	C	NN
and	CC	CC	CC
lipase	C	C	NN
O	O	O	
1st	C	C	JJ
and	CC	CC	CC
the	CC	CC	DT
2nd	C	C	JJ
exon	O	O	NN
O	O	O	
B-cell	C	C	NN
and	CC	CC	CC
T-cell	C	C	NN
differentiation	O	O	NN
O	O	O	
latently	C	C	RB
and	CC	CC	CC
acutely	C	C	RB
infected	O	O	JJ
cells	O	O	NNS
O	O	O	
B-lymphocyte	O	O	NN
activation	C	C	NN
and	CC	CC	CC
growth	C	C	NN
O	O	O	
c-fos	C	C	NN
and	CC	CC	CC
c-jun	C	C	NN
mRNA	O	O	NN
expression	O	O	NN
O	O	O	
128	C	C	CD
and	CC	CC	CC
246	C	C	CD
aa	O	O	NN
O	O	O	
FOS	C	C	NNS
and	CC	CC	CC
FOSB	C	C	NN
mRNAs	O	O	NNS
O	O	O	
nt	C	O	NN
1333	C	C	CD
,	CC	CC	,
1367	C	C	CD
,	CC	CC	,
or	CC	CC	CC
1419	C	C	CD
O	O	O	
normal	C	C	JJ
and	CC	CC	CC
leukemic	C	C	JJ
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
cell	C	O	NN
precursors	C	O	NNS
and	CC	CC	CC
T	C	C	NN
lymphocytes	O	O	NNS
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
cell	O	O	NN
precursors	O	O	NNS
O	O	O	
T-cell	C	C	NN
and	CC	CC	CC
dendritic	C	C	JJ
cell	O	C	NN
development	O	O	NN
O	O	O	
STATs	O	O	*
1	C	C	NN
,	CC	CC	,
3	C	C	CD
,	CC	CC	,
and	CC	CC	CC
6	C	C	CD
O	O	O	
CD4-	C	C	JJ
CD8-	C	C	JJ
,	CC	CC	,
CD4+	C	C	JJ
CD8+	C	C	JJ
,	CC	CC	,
CD4+	C	C	JJ
CD8-	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
CD4-	C	C	JJ
CD8+	O	C	JJ
cell	O	O	NN
populations	O	O	NNS
O	O	O	
thymus	C	C	NN
or	CC	CC	CC
T	C	C	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
cells	O	O	NNS
O	O	O	
IL-2-	C	C	NN
and	CC	CC	CC
IFNgamma-	C	C	*
dependent	O	O	JJ
transcription	O	O	NN
O	O	O	
HTLV-1-infected	C	C	JJ
and	CC	CC	CC
Tax-expressing	C	C	JJ
T-cell	O	O	NN
lines	O	O	NNS
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
nonerythroid	C	C	JJ
cells	O	O	NNS
O	O	O	
DNA-	C	C	NN
and	CC	CC	CC
the	CC	CC	DT
steroid	C	C	*
-binding	O	O	JJ
region	O	O	NN
O	O	O	
p50	C	C	NN
and	CC	CC	CC
RelA	C	C	NN
(	C	C	(
p65	C	C	NN
)	C	C	)
proteins	O	O	NNS
neonatal	C	C	JJ
and	CC	CC	CC
adult	C	C	JJ
cells	O	O	NNS
O	O	O	
E2A	C	C	NN
and	CC	CC	CC
PBX1	C	C	NN
genes	O	O	NNS
O	O	O	
T	C	C	NN
cell	C	C	NN
and	CC	CC	CC
B	C	C	NN
cell	O	C	NN
specification	O	O	NN
O	O	O	
t	C	C	NN
(	C	C	(
8	C	C	CD
;	C	C	:
21	C	C	CD
)	C	C	)
and	CC	CC	CC
t	C	C	NN
(	C	C	(
3	C	C	CD
;	C	C	:
21	C	C	CD
)	C	C	)
myeloid	O	O	JJ
leukemias	O	O	NNS
O	O	O	
TPA-treated	O	O	JJ
U-937	C	C	NN
,	CC	CC	,
and	CC	CC	CC
not	CC	CC	RB
TUR	C	C	NN
,	CC	CC	,
cells	O	O	NNS
O	O	O	
calcium-	C	C	NN
and	CC	CC	CC
calmodulin-	C	C	*
dependent	O	O	JJ
phosphatase	O	O	NN
O	O	O	
tetanus	C	C	NN
toxoid	C	C	NN
(	C	C	(
TT	C	C	NN
)	C	C	)
-	C	C	:
and	CC	CC	CC
myelin	C	C	JJ
basic	C	C	JJ
protein	C	C	NN
(	C	C	(
MBP	C	C	NN
)	C	C	)
-	C	C	*
specific	O	O	JJ
human	O	O	JJ
T	O	O	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
gamma-globin	C	C	NN
and	CC	CC	CC
erythroid-specific	C	C	JJ
5-aminolevulinate	O	C	JJ
synthetase	O	C	NN
transcripts	O	O	NNS
O	O	O	
hyper-	C	C	JJ
and	CC	CC	CC
hypo	C	C	*
thyroidism	O	O	NN
O	O	O	
preactivated	O	O	JJ
primary	O	O	JJ
NK	C	C	NN
and	CC	CC	CC
NK3.3	C	C	NN
cells	O	O	NNS
O	O	O	
T-	C	C	NN
and	CC	CC	CC
B-	C	C	*
cell	O	O	NN
lines	O	O	NNS
O	O	O	
TCR-alpha	C	C	NN
and	CC	CC	CC
CD3-epsilon	C	C	NN
enhancers	O	O	NNS
O	O	O	
murine	C	C	JJ
and	CC	CC	CC
human	C	C	JJ
factors	O	O	NNS
O	O	O	
tissue-specific	O	O	JJ
late	O	O	JJ
histone	O	O	NN
H2A-2	C	C	NN
and	CC	CC	CC
H2B-2	C	C	NN
genes	O	O	NNS
O	O	O	
intestinal	C	O	JJ
calcium	C	C	NN
and	CC	CC	CC
phosphate	C	C	NN
absorption	O	O	NN
O	O	O	
solution	C	C	NN
and	CC	CC	CC
crystal	C	C	JJ
structures	O	O	NNS
O	O	O	
natural	C	C	JJ
and	CC	CC	CC
synthetic	C	C	JJ
PPARgamma	O	O	NN
agonists	O	O	NNS
O	O	O	
autocrine	C	C	JJ
or	CC	CC	CC
paracrine	C	C	JJ
action	O	O	NN
O	O	O	
homodimer	C	C	NN
and	CC	CC	CC
heterodimer	C	C	NN
formation	O	O	NN
O	O	O	
HLA-DR-	C	C	JJ
,	CC	CC	,
CD33+	C	C	JJ
,	CC	CC	,
CD56+	C	C	JJ
,	CC	CC	,
CD16-	C	C	JJ
myeloid/natural	O	O	JJ
killer	O	O	NN
cell	O	O	NN
acute	O	O	JJ
leukemia	O	O	NN
O	O	O	
serines	O	C	NNS
32	C	C	CD
and	CC	CC	CC
36	C	C	CD
O	O	O	
human	C	O	JJ
herpesvirus	C	CC	NN
6	C	CC	CD
(	C	O	(
HHV-6	C	O	NN
)	C	O	)
strains	C	O	VBZ
GS	C	C	NN
and	CC	CC	CC
Z-29	C	C	NN
O	O	O	
IFN	O	O	*
-alpha	C	C	NN
and	CC	CC	CC
-beta	C	C	NN
O	O	O	
GATA	C	C	NN
and	CC	CC	CC
CACCC	C	C	NN
sites	O	O	NNS
H5	O	O	NN
promoter	C	C	NN
and	CC	CC	CC
enhancer	C	C	NN
O	O	O	
owl	C	C	NN
monkey	C	C	NN
and	CC	CC	CC
cotton-top	C	C	JJ
tamarin	C	C	NN
receptors	O	O	NNS
O	O	O	
transcriptional	C	C	JJ
and	CC	CC	CC
post-transcriptional	C	C	JJ
mechanisms	O	O	NNS
O	O	O	
mammalian	O	O	JJ
MCM5	C	C	NN
and	CC	CC	CC
MCM6	C	C	NN
genes	O	O	NNS
O	O	O	
untransformed	O	O	JJ
progestin	C	C	NN
,	CC	CC	,
estrogen	C	C	NN
,	CC	CC	,
androgen	C	C	NN
,	CC	CC	,
and	CC	CC	CC
glucocorticoid	C	C	NN
receptor	O	O	NN
complexes	O	O	NNS
rabbit	C	O	NN
uterine	C	C	NN
and	CC	CC	CC
liver	C	C	NN
cytosols	O	O	NNS
O	O	O	
immune	C	C	JJ
and	CC	CC	CC
inflammatory	C	C	JJ
responses	O	O	NNS
O	O	O	
TNF-alpha-	C	C	NN
and	CC	CC	CC
NF-kappaB-	C	C	*
dependent	O	O	JJ
mechanism	O	O	NN
O	O	O	
persistent	C	C	JJ
or	CC	CC	CC
recurrent	C	C	JJ
inflammatory	O	O	JJ
arthritis	O	O	NN
O	O	O	
transformed	C	C	VBN
and	CC	CC	CC
normal	C	C	JJ
lymphocytes	O	O	NNS
O	O	O	
PRL-	O	O	*
secreting	C	C	JJ
and	CC	CC	CC
nonsecreting	C	C	JJ
lymphoid	O	O	JJ
cells	O	O	NNS
O	O	O	
primary	O	O	JJ
human	O	O	JJ
T	C	C	NN
and	CC	CC	CC
NK	C	C	NN
cells	O	O	NNS
O	O	O	
cytotoxic	C	C	JJ
and	CC	CC	CC
NF-kappa	C	C	NN
B	C	C	NN
activation	O	O	NN
O	O	O	
first	C	C	JJ
or	CC	CC	CC
the	CC	CC	DT
third	C	C	JJ
intron	O	O	NN
O	O	O	
endocrine	C	C	JJ
and	CC	CC	CC
exocrine	C	C	JJ
precursor	O	O	NN
cells	O	O	NNS
O	O	O	
MBP-	C	C	NN
or	CC	CC	CC
GST-	C	C	*
HBD	O	O	NN
O	O	O	
young	C	C	JJ
and	CC	CC	CC
elderly	C	C	JJ
donors	O	O	NNS
O	O	O	
Lck/Fyn-	C	C	NN
or	CC	CC	CC
zap-70-	C	C	*
dependent	O	O	JJ
signaling	O	O	NN
pathways	O	O	NNS
O	O	O	
Jun	C	C	NN
and	CC	CC	CC
Fos	C	C	NN
proteins	O	O	NNS
O	O	O	
1.3	C	C	CD
,	CC	CC	,
0.6	C	C	CD
,	CC	CC	,
and	CC	CC	CC
0.2	C	C	CD
kb	O	O	NN
5'-flanking	O	O	JJ
DNA	O	O	NN
O	O	O	
interleukin-4	C	C	NN
and	CC	CC	CC
interleukin-5	C	C	NN
genes	O	O	NNS
O	O	O	
MRL-lpr/lpr	C	C	NN
and	CC	CC	CC
C3H-gld/gld	C	C	JJ
CD4(-)	C	C	JJ
CD8(-)	C	C	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
persistent	C	C	JJ
or	CC	CC	CC
recurrent	C	C	JJ
inflammatory	O	O	JJ
arthritis	O	O	NN
O	O	O	
atopic	C	C	JJ
and	CC	CC	CC
nonatopic	C	C	JJ
individuals	O	O	NNS
O	O	O	
Th0	C	C	NN
,	CC	CC	,
Th1	C	C	NN
,	CC	CC	,
and	CC	CC	CC
Th2	C	C	NN
clones	O	O	NNS
O	O	O	
c-jun	C	C	NN
and	CC	CC	CC
c-fos	C	C	NN
gene	O	O	NN
products	O	O	NNS
O	O	O	
S	C	C	NN
and	CC	CC	CC
J	C	C	NN
elements	O	O	NNS
O	O	O	
tyrosine	C	C	NN
and	CC	CC	CC
serine	C	C	NN
phosphorylation	O	O	NN
O	O	O	
activated	O	O	VBN
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
serum-supplemented	C	C	JJ
and	CC	CC	CC
serum-free	C	C	JJ
cultures	O	O	NNS
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
cells	O	O	NNS
transcription	C	C	NN
and	CC	CC	CC
differentiation	C	C	NN
factors	O	O	NNS
O	O	O	
binding	C	C	NN
and	CC	CC	CC
signal	C	C	NN
transducing	O	C	NN
component	O	O	NN
human	O	O	JJ
Th1	C	C	NN
but	CC	CC	CC
not	CC	CC	RB
Th2	C	C	NN
clones	O	O	NNS
Th1	C	C	NN
but	CC	CC	CC
not	CC	CC	RB
the	CC	CC	DT
Th2	C	C	NN
pathway	O	O	NN
O	O	O	
phytohemagglutinin-	C	C	NN
and	CC	CC	CC
phorbol	C	C	NN
ester-	C	C	*
activated	O	O	JJ
Jurkat	O	O	NN
cells	O	O	NNS
O	O	O	
EBV-positive	C	C	JJ
and	CC	CC	CC
EBV-negative	C	C	JJ
primary	O	O	JJ
effusion	O	O	NN
lymphoma	O	O	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
Jurkat	C	C	NN
and	CC	CC	CC
NC2.10	C	C	NN
induction	C	O	NN
85	C	C	CD
,	CC	CC	,
75	C	C	CD
,	CC	CC	,
and	CC	CC	CC
54	C	C	CD
kDa	O	O	NN
O	O	O	
basal	C	C	JJ
and	CC	CC	CC
Tax-mediated	C	C	JJ
transcription	O	O	NN
O	O	O	
basal	C	C	JJ
and	CC	CC	CC
T3	C	C	*
-values	O	O	NNS
O	O	O	
purified	C	O	VBN
human	O	O	JJ
monocytes	C	C	NNS
and	CC	CC	CC
macrophages	C	C	NNS
O	O	O	
murine	C	C	JJ
and	CC	CC	CC
human	C	C	JJ
B	O	O	NN
lymphocyte	O	O	NN
immunoglobulin	O	O	NN
production	O	O	NN
O	O	O	
adolescent	C	C	JJ
and	CC	CC	CC
young	C	C	JJ
adult	O	C	JJ
patients	O	O	NNS
O	O	O	
CD8+	C	C	JJ
and	CC	CC	CC
CD4+	C	C	JJ
cells	O	O	NNS
O	O	O	
NF-kappaB	O	O	*
-dependent	C	C	JJ
and	CC	CC	CC
-independent	C	C	JJ
signaling	O	O	NN
pathways	O	O	NNS
O	O	O	
endothelial	C	C	JJ
and/or	CC	CC	CC
leukocyte	C	C	NN
adhesion	O	O	NN
molecules	O	O	NNS
beta1	C	C	NN
and	CC	CC	CC
beta2	C	C	NN
integrins	O	O	NNS
O	O	O	
EBV-negative	O	C	JJ
Burkitt	O	C	NN
lymphoma	C	C	NN
or	CC	CC	CC
human	C	C	JJ
embryonic	C	C	JJ
kidney	C	C	NN
293	C	C	CD
cells	O	O	NNS
O	O	O	
antigen	C	C	NN
and	CC	CC	CC
cytokine	C	C	NN
receptors	O	O	NNS
O	O	O	
T-	C	C	NN
and	CC	CC	CC
B-	C	C	*
lymphocytes	O	O	NNS
O	O	O	
IL-13	C	C	NN
and	CC	CC	CC
IL-4	C	C	NN
genes	O	O	NNS
O	O	O	
kappa	C	C	NN
and	CC	CC	CC
lambda	C	C	NN
L	C	O	NN
chain	C	O	NN
mRNA	O	O	NN
levels	O	O	NNS
O	O	O	
physiological	C	C	JJ
and	CC	CC	CC
pathological	C	C	JJ
conditions	O	O	NNS
O	O	O	
HCMV	C	C	NN
and	CC	CC	CC
chimpanzee	C	C	NN
CMV	C	C	NN
MIE	O	C	NN
enhancers	O	O	NNS
multimerized	C	O	JJ
wild-type	C	C	JJ
and	CC	CC	CC
mutant	C	C	JJ
elements	O	O	NNS
O	O	O	
mammalian	C	C	JJ
and	CC	CC	CC
Drosophila	C	C	NN
homeodomains	O	O	NNS
O	O	O	
nuclear	C	C	JJ
and	CC	CC	CC
cytoplasmic	C	C	JJ
extracts	O	O	NNS
O	O	O	
murine	C	C	JJ
and	CC	CC	CC
human	C	C	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
T	C	C	NN
and	CC	CC	CC
NK	C	C	NN
cells	O	O	NNS
O	O	O	
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
fetal	C	other_name	JJ
and	CC	other_name	CC
adult	C	other_name	JJ
hematopoietic	O	other_name	JJ
O	O	O	
EBV	O	C	NN
nuclear	O	C	JJ
proteins	O	C	NNS
3	C	C	CD
and	CC	CC	CC
6	C	C	CD
O	O	O	
NF-AT1	C	C	NN
,	CC	CC	,
AP-1	C	C	NN
,	CC	CC	,
and	CC	CC	CC
NF-kB	C	C	NN
sites	O	O	NNS
O	O	O	
B	O	O	NN
cell	O	O	NN
proliferation	C	C	NN
and	CC	CC	CC
differentiation	C	C	NN
O	O	O	
T	C	C	NN
and	CC	CC	CC
monocytic	C	C	JJ
lineages	O	O	NNS
O	O	O	
PyG	C	C	NN
and	CC	CC	CC
AT	C	C	NN
boxes	O	O	NNS
O	O	O	
Positive	C	C	JJ
and	CC	CC	CC
negative	C	C	JJ
regulation	O	O	NN
O	O	O	
Interferon	O	O	*
-alpha	C	C	NN
and	CC	CC	CC
-beta	C	C	NN
O	O	O	
TNF-	C	C	NN
and/or	CC	CC	CC
anti-Fas-	C	C	*
induced	O	O	JJ
cell	O	O	NN
death	O	O	NN
O	O	O	
IL-2	C	C	*
-	CC	CC	NN
but	CC	CC	CC
not	CC	CC	RB
IL-12	C	C	*
-stimulated	O	O	JJ
NK	O	O	NN
cells	O	O	NNS
O	O	O	
c-fos	C	C	NN
,	CC	CC	,
c-myc	C	C	NN
,	CC	CC	,
p53	C	C	NN
and	CC	CC	CC
the	CC	C	DT
hybrid	C	C	NN
bcr/abl	C	C	NN
mRNA	O	O	NN
levels	O	O	NNS
O	O	O	
humoral-	C	C	JJ
and	CC	CC	CC
cellular-	C	C	*
mediated	O	O	JJ
immune	O	O	JJ
responses	O	O	NNS
O	O	O	
Ig	O	O	NN
enhancer	C	C	NN
and	CC	CC	CC
promoter	C	C	NN
O	O	O	
IL-2-	C	C	NN
and	CC	CC	CC
IL-7-	C	C	*
induced	O	O	JJ
activation	O	O	NN
O	O	O	
androgen-	C	C	NN
and	CC	CC	CC
antiandrogen-	C	C	*
bound	O	O	JJ
receptor	O	O	NN
complexes	O	O	NNS
O	O	O	
CREB	C	C	NN
and	CC	CC	CC
ATF1	C	C	NN
proteins	O	O	NNS
O	O	O	
W-X-Y	C	C	NN
but	CC	CC	CC
not	CC	CC	RB
the	CC	CC	DT
X-Y	C	C	NN
elements	O	O	NNS
O	O	O	
octamer	C	C	NN
and	CC	CC	CC
heptamer	C	C	NN
sites	O	O	NNS
O	O	O	
Stat1	C	C	NN
and	CC	CC	CC
Stat3	C	C	NN
transcriptional	O	O	JJ
activity	O	O	NN
O	O	O	
G1-	C	C	NN
and	CC	CC	CC
G2/M-	C	C	*
phase	O	O	NN
nuclear	O	O	JJ
p62c-fos	C	C	NN
and	CC	CC	CC
p39c-jun	C	C	NN
O	O	O	
simian	C	C	JJ
virus	C	C	NN
40	C	C	CD
or	CC	CC	CC
Moloney	C	C	NN
murine	C	C	JJ
leukemia	C	C	NN
virus	C	C	NN
promoters	O	O	NNS
O	O	O	
sIgM-	C	C	NN
and	CC	CC	CC
sIgD-	C	C	*
crosslinking	O	O	NN
O	O	O	
interferon	O	C	NN
alpha-	C	C	NN
and	CC	CC	CC
interferon	C	C	NN
gamma-	C	C	*
induced	O	O	JJ
genes	O	O	NNS
O	O	O	
PKC/Ras-	C	C	NN
and	CC	CC	CC
CaM/CN-	C	C	*
mediated	O	O	JJ
pathways	O	O	NNS
O	O	O	
eosinophilic	C	C	JJ
and	CC	CC	CC
neutrophilic	C	C	JJ
differentiation	O	O	NN
O	O	O	
Cdk2	C	C	NN
and	CC	CC	CC
Id-bHLH	C	C	JJ
functions	O	O	NNS
O	O	O	
normal	C	C	JJ
and	CC	CC	CC
malignant	C	C	JJ
cells	O	O	NNS
O	O	O	
phosphatases	O	O	NNS
1	C	C	CD
and	CC	CC	CC
2A	C	C	NN
O	O	O	
big	C	C	JJ
T	C	C	NN
and	CC	CC	CC
small	C	C	JJ
t	O	C	NN
allele	O	O	NN
O	O	O	
PML	C	C	NN
and	CC	CC	CC
Rb	C	C	NN
proteins	O	O	NNS
O	O	O	
proto-oncogenes	O	O	NNS
c-jun	C	C	NN
and	CC	CC	CC
c-fos	C	C	NN
O	O	O	
basal	C	C	JJ
and	CC	CC	CC
PMA	C	C	*
-induced	O	C	JJ
promoter	O	O	NN
activity	O	O	NN
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
nonerythroid	C	C	JJ
cells	O	O	NNS
O	O	O	
EBV-positive	C	C	JJ
and	CC	CC	CC
EBV-negative	C	C	JJ
Burkitt	O	O	NN
's	O	O	POS
lymphoma	O	O	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
immunoglobulin	C	O	NN
heavy-	C	C	JJ
and	CC	CC	CC
light-	C	C	*
chain	O	O	JJ
genes	O	O	NNS
O	O	O	
c-jun	C	C	NN
,	CC	CC	,
jun-B	C	C	NN
,	CC	CC	,
or	CC	CC	CC
jun-D	C	C	NN
expression	O	O	NN
vectors	O	O	NNS
O	O	O	
humoral	C	C	JJ
and	CC	CC	CC
CD8	C	C	NN
responses	O	O	NNS
O	O	O	
Stage	C	O	NN
I	C	C	CD
and	CC	CC	CC
II	C	C	CD
breast	O	O	NN
cancer	O	O	NN
patients	O	O	NNS
O	O	O	
human	C	C	JJ
and	CC	CC	CC
simian	C	C	JJ
Epstein-Barr	O	O	JJ
virus	O	CC	NN
oncogene	O	O	NN
LMP1	O	CC	NN
O	O	O	
coronary	C	C	JJ
and	CC	CC	CC
carotid	C	C	JJ
arteries	O	CC	NNS
O	O	O	
HLA	O	O	*
-DR	C	C	NN
and	CC	CC	CC
-DP	C	C	NN
O	O	O	
immature	C	C	JJ
and	CC	CC	CC
mature	C	C	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
immune	C	C	JJ
and	CC	CC	CC
clinical	C	C	JJ
parameters	O	O	NNS
O	O	O	
interleukin	C	C	NN
(	C	C	(
IL	C	C	NN
)	C	C	)
-2	C	C	CD
and	CC	CC	CC
IL-4	C	C	NN
promoter	O	O	NN
activation	O	O	NN
O	O	O	
memory	C	C	NN
and	CC	CC	CC
naive	C	C	JJ
T	O	O	NN
cells	O	O	NNS
subsets	O	O	NNS
O	O	O	
ezrin	C	C	*
/	CC	CC	*
moesin	C	C	*
/	CC	CC	*
radixin	C	C	NN
proteins	O	O	NNS
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
cells	O	O	NNS
O	O	O	
nonhematopoietic	C	C	JJ
and	CC	CC	CC
hematopoietic	C	C	JJ
cell	O	O	NN
lines	O	O	NNS
O	O	O	
IKK	O	O	*
-alpha	C	C	NN
and	CC	CC	CC
-beta	C	C	NN
activity	O	O	NN
O	O	O	
Spi-1	C	C	NN
and	CC	CC	CC
Fli-1	C	C	NN
genes	O	O	NNS
O	O	O	
Sp1	C	C	NN
and	CC	CC	CC
CREB	C	C	NN
binding	O	O	NN
site	O	O	NN
oligonucleotides	O	O	NNS
O	O	O	
protein	O	O	NN
phosphatase	O	O	NN
1	C	C	CD
and	CC	CC	CC
2A	C	C	NN
inhibitors	O	O	NNS
O	O	O	
STATs	O	O	NNS
3	C	C	CD
and	CC	CC	CC
5	C	C	CD
O	O	O	
RA	O	O	NN
receptor	O	O	NN
alpha	C	C	NN
,	CC	CC	,
beta	C	C	NN
,	CC	CC	,
and	CC	CC	CC
gamma	C	C	NN
O	O	O	
binding	C	C	NN
,	CC	CC	,
reconstitution	C	C	NN
and	CC	CC	CC
cotransfection	C	C	NN
experiments	O	O	NNS
O	O	O	
c-rel	C	C	NN
and	CC	CC	CC
v-rel	C	C	NN
(	C	O	(
proto	C	O	NN
)	C	O	)
oncogenes	O	O	NNS
O	O	O	
T	O	O	NN
lymphocyte	O	O	NN
differentiation	C	C	NN
and	CC	CC	CC
activation	C	C	NN
O	O	O	
IFN-gamma	C	C	NN
and	CC	CC	CC
GM-CSF	C	C	NN
cytoplasmic	C	O	JJ
mRNA	O	O	NN
O	O	O	
primary	C	C	JJ
and	CC	CC	CC
long-term	C	C	JJ
human	O	O	JJ
lymphoid	O	O	JJ
cells	O	O	NNS
O	O	O	
mRNA	C	C	NN
or	CC	CC	CC
protein	C	C	NN
level	O	O	NN
O	O	O	
genetic	C	C	JJ
or	CC	CC	CC
neoplastic	C	C	JJ
familial	O	O	JJ
disorders	O	O	NNS
O	O	O	
U-937	C	C	NN
,	CC	CC	,
K-562	C	C	NN
,	CC	CC	,
and	CC	CC	CC
HeLa	C	C	NN
cell	O	O	NN
extracts	O	O	NNS
O	O	O	
lymphoblastoid	C	O	JJ
T-cell-line-expressing	C	O	JJ
wild-type	C	C	JJ
and	CC	CC	CC
mutated	C	C	VBN
CD4	O	O	NN
receptors	O	CC	NNS
O	O	O	
positions	O	O	NNS
-153	C	C	CD
,	CC	CC	,
-178	C	C	CD
,	CC	CC	,
-286	C	C	CD
,	CC	CC	,
-875	C	C	CD
,	CC	CC	,
and	CC	CC	CC
-1011	C	C	CD
O	O	O	
inflammatory	C	C	JJ
and	CC	CC	CC
immune	C	C	JJ
processes	O	O	NNS
O	O	O	
X1	C	O	NN
and	CC	CC	CC
X2	C	O	NN
box	O	C	NN
protein-DNA	O	O	JJ
interactions	O	O	NNS
O	O	O	
lpr/lpr	C	C	NN
and	CC	CC	CC
gld/gld	C	C	NN
CD4(-)	C	C	JJ
CD8(-)	C	C	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
Cardiac	C	C	JJ
and	CC	CC	CC
adrenergic	C	C	JJ
diseases	O	O	NNS
O	O	O	
PKC-dependent	C	C	JJ
and	CC	CC	CC
PKC-independent	C	C	JJ
pathways	O	O	NNS
O	O	O	
multipotent	C	C	JJ
progenitor	C	C	NN
(	C	C	(
EML	C	C	NN
)	C	C	)
or	CC	CC	CC
committed	C	C	VBN
promyelocyte	C	C	JJ
(	C	C	(
MPRO	C	C	NN
)	C	C	)
stages	O	O	NNS
O	O	O	
T	O	O	NN
cell	O	O	NN
activation	C	C	NN
and	CC	CC	CC
growth	C	C	NN
O	O	O	
AP-1-	C	C	NN
and	CC	CC	CC
NF-AT/AP-1-	C	C	*
binding	O	O	JJ
sites	O	O	NNS
O	O	O	
TNF-alpha-	C	C	NN
and	CC	CC	CC
PMA-	C	C	*
stimulated	O	O	JJ
U1	O	O	NN
cells	O	O	NNS
O	O	O	
B-	C	C	NN
and	CC	CC	CC
T-	C	C	*
lymphocyte	O	O	NN
development	O	O	NN
O	O	O	
beta-	C	C	NN
and	CC	CC	CC
gamma-	C	C	*
globin	O	O	NN
O	O	O	
G1	C	C	NN
and	CC	CC	CC
S	C	C	NN
phases	O	O	NNS
O	O	O	
IL-4	O	O	NN
receptor	O	O	NN
subunits	O	O	NNS
alpha	C	C	NN
and	CC	CC	CC
gamma	C	C	NN
O	O	O	
XPB	C	C	NN
or	CC	CC	CC
XPD	C	C	NN
gene	O	O	NN
O	O	O	
IFNgamma-	C	C	NN
and	CC	CC	CC
IFNalpha-	C	C	*
induced	O	O	JJ
gene	O	O	NN
expression	O	O	NN
O	O	O	
human	O	O	JJ
glioblastoma	C	C	NN
and	CC	CC	CC
neuroblastoma	C	C	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
site	C	O	NN
alpha-	C	C	NN
and	CC	CC	CC
beta-	C	C	*
binding	O	O	JJ
activities	O	O	NNS
O	O	O	
allergic	C	C	JJ
and	CC	CC	CC
parasitic	C	C	JJ
disorders	O	O	NNS
O	O	O	
CALM	C	C	NN
and	CC	CC	CC
MLL	C	C	NN
rearrangements	O	O	NNS
O	O	O	
serum-free	C	C	JJ
or	CC	CC	CC
serum	C	C	NN
containing	O	C	NN
media	O	O	NNS
O	O	O	
Flow	O	C	NN
cytometric	C	C	JJ
and	CC	CC	CC
morphological	C	C	JJ
analyses	O	O	NNS
O	O	O	
c-fos	C	C	NN
and	CC	CC	CC
c-jun	C	C	NN
mRNA	O	O	NN
expression	O	O	NN
activated	O	C	VBN
cord	C	C	NN
and	CC	CC	CC
adult	C	C	JJ
lymphocytes	O	O	NNS
O	O	O	
myeloid	C	C	JJ
and	CC	CC	CC
natural	C	C	JJ
killer	C	C	NN
(	C	C	(
NK	C	C	NN
)	C	C	)
cells	O	O	NNS
O	O	O	
human	O	O	JJ
T-	C	C	NN
and	CC	CC	CC
B-	C	C	*
cell	O	O	NN
lines	O	O	NNS
O	O	O	
PC-3	C	C	NN
and	CC	CC	CC
DU-145	C	C	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
wild-type	C	C	JJ
and	CC	CC	CC
class	C	C	NN
II-deficient	C	C	JJ
B	C	O	NN
cells	O	O	NNS
O	O	O	
LMP	O	O	*
1	C	C	NN
and	CC	CC	CC
2	C	C	CD
O	O	O	
caspase	O	O	*
-1	C	C	NN
and	CC	CC	CC
-3	C	C	CD
O	O	O	
pre	C	O	JJ
and	CC	CC	CC
post	C	O	*
menopausal	O	C	JJ
women	O	O	NNS
O	O	O	
transcriptional	C	C	JJ
and	CC	CC	CC
posttranslational	C	C	JJ
levels	O	O	NNS
O	O	O	
positions	O	O	NNS
-585	C	C	CD
and	CC	CC	CC
-650	C	C	CD
O	O	O	
Raf-1	C	C	NN
and	CC	CC	CC
MEK1	C	C	NN
expression	O	O	NN
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
human	C	C	JJ
and	CC	CC	CC
mouse	C	C	NN
primary	O	O	JJ
T	O	O	NN
lymphocytes	O	O	NNS
O	O	O	
primary	O	O	JJ
human	O	O	JJ
NK	C	C	NN
and	CC	CC	CC
T	C	C	NN
cells	O	O	NNS
O	O	O	
antigenic	C	C	JJ
or	CC	CC	CC
mitogenic	C	C	JJ
stimulation	O	O	NN
O	O	O	
primary	C	C	JJ
and	CC	CC	CC
secondary	C	C	JJ
immune	O	O	JJ
responses	O	O	NNS
O	O	O	
X	C	C	NN
and	CC	CC	CC
Y	C	C	NN
boxes	O	O	NNS
O	O	O	
CD40L	C	C	NN
and	CC	CC	CC
IL-4	C	C	NN
responsive	O	O	JJ
elements	O	O	NNS
O	O	O	
U937	C	C	NN
and	CC	CC	CC
THP-1	C	C	NN
cells	O	O	NNS
O	O	O	
peripheral	O	O	JJ
white	O	C	JJ
blood	O	C	NN
cell	C	C	NN
and	CC	CC	CC
granulocyte	C	C	NN
O	O	O	
immune	C	C	JJ
and	CC	CC	CC
endocrine	C	C	JJ
systems	O	O	NNS
O	O	O	
nuclear	C	C	JJ
factor	C	CC	NN
kappa	C	CC	NN
B	C	CC	NN
(	C	C	(
NF-kappa	C	C	NN
B	C	CC	NN
)	C	C	)
-	C	C	:
and	CC	CC	CC
Sp1	C	C	*
-binding	O	O	JJ
sites	O	O	NNS
O	O	O	
Stat1	O	O	NN
protein	C	C	NN
and	CC	CC	CC
mRNA	C	C	NN
levels	O	O	NNS
O	O	O	
human	C	C	JJ
and	CC	CC	CC
mouse	C	C	NN
CD19	C	O	NN
genes	O	O	NNS
O	O	O	
human	C	C	JJ
(	C	C	(
U937	C	C	NN
)	C	C	)
and	CC	CC	CC
murine	C	C	JJ
(	C	C	(
J774	C	C	NN
)	C	C	)
monocytic	O	O	JJ
cell	O	O	NN
lines	O	O	NNS
O	O	O	
clinical	C	C	JJ
and	CC	CC	CC
molecular	C	C	JJ
remission	O	O	NN
O	O	O	
herbimycin	C	C	NN
A	C	C	NN
and	CC	CC	CC
Rp-cAMP-	C	C	*
sensitive	O	O	JJ
pathway	O	O	NN
O	O	O	
neoplastic	C	C	JJ
and	CC	CC	CC
normal	C	C	JJ
B	O	O	NN
cells	O	O	NNS
O	O	O	
AP-1	C	C	NN
and	CC	CC	CC
NF-AT	C	C	NN
transactivating	O	O	NN
pathways	O	O	NNS
O	O	O	
recombinant	O	O	JJ
human	O	O	JJ
nm23	O	O	*
-H1	C	C	NN
,	CC	CC	,
-H2	C	C	NN
,	CC	CC	,
mouse	C	O	NN
nm23	O	O	*
-M1	C	C	NN
,	CC	CC	,
and	CC	CC	CC
-M2	C	C	NN
proteins	O	C	NNS
human	O	O	JJ
nm23	O	O	*
-H1	C	C	NN
,	CC	CC	,
-H2	C	C	NN
mouse	O	O	NN
nm23	O	O	*
-M1	C	C	NN
,	CC	CC	,
and	CC	CC	CC
-M2	C	C	NN
O	O	O	
Rheumatoid	O	O	JJ
arthritis	O	O	NN
synovial	O	C	JJ
fluid	C	C	NN
and	CC	CC	CC
blood	C	C	NN
O	O	O	
hemin-	C	C	NN
and	CC	CC	CC
erythropoietin-	C	C	*
induced	O	O	JJ
erythroid	O	O	JJ
differentiation	O	O	NN
O	O	O	
type	C	C	NN
I	C	C	CD
and	CC	CC	CC
type	C	C	NN
II	C	C	CD
interferons	O	O	NNS
O	O	O	
humoral	C	C	JJ
and	CC	CC	CC
cell	C	C	NN
mediated	C	C	JJ
immune	O	O	JJ
responses	O	O	NNS
O	O	O	
benign	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
malignant	C	C	JJ
tumors	O	O	NNS
O	O	O	
MOLT-4	C	C	NN
and	CC	CC	CC
CEM	C	C	NN
cells	O	O	NNS
O	O	O	
MHC	O	O	NN
class	C	C	NN
I	C	C	CD
and	CC	CC	CC
class	C	C	NN
II	C	C	CD
molecules	O	O	NNS
O	O	O	
viral	C	C	JJ
and	CC	CC	CC
host	C	C	NN
cellular	O	C	JJ
factors	O	O	NNS
O	O	O	
myeloperoxidase	C	C	NN
and	CC	CC	CC
CD34	C	C	NN
genes	O	O	NNS
O	O	O	
U937	C	C	NN
and	CC	CC	CC
Jurkat	C	C	NN
T	O	C	NN
lymphoid	O	C	JJ
cells	O	O	NNS
O	O	O	
IL-4	C	DNA_domain_or_region	NN
and	CC	DNA_domain_or_region	CC
IL-5	C	DNA_domain_or_region	NN
genes	O	DNA_domain_or_region	NNS
O	O	O	
acute	C	C	JJ
and	CC	CC	CC
chronic	C	C	JJ
inflammation	O	C	NN
O	O	O	
sIgM-	C	C	NN
and	CC	CC	CC
sIgD-	C	C	*
crosslinking	O	O	NN
Egr-1	C	C	NN
and	CC	CC	CC
c-fos	C	C	NN
mRNA	O	O	NN
O	O	O	
IL-2-induced	O	O	JJ
NK	O	O	NN
cytolytic	C	C	JJ
and	CC	CC	CC
proliferative	C	C	JJ
activities	O	O	NNS
O	O	O	
major	O	O	JJ
histocompatibility	O	O	NN
complex	O	O	NN
class	O	O	NN
I	C	C	CD
or	CC	CC	CC
II	C	C	CD
MHC	O	O	NN
I	C	C	CD
or	CC	CC	CC
II	C	C	CD
O	O	O	
OKA	C	C	NN
but	CC	CC	CC
not	CC	CC	RB
TNF	C	C	NN
stimulation	O	O	NN
O	O	O	
interleukin-8	O	C	NN
AP-1	C	C	NN
and	CC	CC	CC
kappa	C	C	NN
B-like	O	C	JJ
sites	O	O	NNS
O	O	O	
NF-IL6	C	C	NN
and	CC	CC	CC
NF-kappa	C	C	NN
B	C	C	NN
sites	O	O	NNS
bacterial	C	C	JJ
or	CC	CC	CC
mycobacterial	C	C	JJ
response	O	O	NN
elements	O	O	NNS
O	O	O	
monocytic	C	C	JJ
or	CC	CC	CC
neutrophilic	C	C	JJ
lineages	O	O	NNS
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
megakaryocytic	C	C	JJ
lineages	O	O	NNS
O	O	O	
Oct-	C	C	NN
and	CC	CC	CC
NFATp/c-	C	C	*
binding	O	O	JJ
sites	O	O	NNS
O	O	O	
Stat	O	O	*
5a	C	C	NN
and	CC	CC	CC
b	C	C	NN
proteins	O	O	NNS
O	O	O	
FasL-	C	C	NN
and	CC	CC	CC
a	CC	C	DT
consensus	C	C	NN
NF-kappaB-	C	C	*
reporter	O	O	NN
construct	O	O	NN
O	O	O	
antiatherogenic	C	C	JJ
and	CC	CC	CC
antiinflammatory	C	C	JJ
properties	O	O	NNS
O	O	O	
voltage-gated	C	C	JJ
and	CC	CC	CC
calcium-activated	C	C	JJ
K+	O	O	NN
channels	O	O	NNS
O	O	O	
Ets	C	C	NN
and	CC	CC	CC
NF-kappaB/NFAT	C	C	NN
proteins	O	O	NNS
O	O	O	
heavy	C	C	JJ
and	CC	CC	CC
light	C	C	JJ
chain	O	O	NN
genes	O	O	NNS
gamma	C	C	NN
and	CC	CC	CC
lambda	C	C	NN
genes	O	O	NNS
O	O	O	
hematopoietic	O	O	JJ
transcription	O	O	NN
factors	O	O	NNS
PU.1	C	C	NN
and	CC	CC	CC
GATA-1	C	C	NN
O	O	O	
estrogen-dependent	C	C	JJ
and	CC	CC	CC
tissue-specific	C	C	JJ
regulation	O	O	NN
O	O	O	
EBNA	O	O	*
1	C	C	NN
,	CC	CC	,
2	C	C	CD
,	CC	CC	,
3A	C	C	NN
,	CC	CC	,
3B	C	C	NN
,	CC	CC	,
3C	C	C	NN
,	CC	CC	,
-LP	C	C	NN
O	O	O	
AML1-	C	C	NN
or	CC	CC	CC
LBF4-	C	C	*
binding	O	O	JJ
sites	O	O	NNS
O	O	O	
interleukin	C	O	NN
(	C	O	(
IL	C	O	NN
)	C	O	)
-8	C	C	CD
and	CC	CC	CC
-6	C	C	CD
O	O	O	
c-fos	C	C	NN
,	CC	CC	,
c-jun	C	C	NN
,	CC	CC	,
and	CC	CC	CC
NF	C	C	NN
kappa	C	C	NN
B	C	C	NN
mRNA	O	O	NN
O	O	O	
Th1	C	C	NN
or	CC	CC	CC
Th2	C	C	NN
differentiation	O	O	NN
O	O	O	
cathepsin	O	O	NN
B	C	C	NN
,	CC	CC	,
L	C	C	NN
,	CC	CC	,
and	CC	CC	CC
D	C	C	NN
O	O	O	
CREB/ATF	C	C	NN
and	CC	CC	CC
SRF	C	C	NN
pathways	O	O	NNS
O	O	O	
lymphocyte	C	C	NN
and	CC	CC	CC
macrophage	C	C	NN
receptor	O	O	NN
isoforms	O	O	NNS
O	O	O	
tumor	C	C	NN
necrosis	C	C	NN
factor	C	C	NN
alpha-induced	C	C	JJ
and	CC	CC	CC
protein	C	C	NN
kinase	C	C	NN
C	C	C	NN
(	C	C	(
PKC	C	C	NN
)	C	C	)
-dependent	O	C	JJ
activation	O	O	NN
O	O	O	
HS	O	O	NN
I	C	C	CD
,	CC	CC	,
IV	C	C	CD
,	CC	CC	,
and	CC	CC	CC
V	C	C	CD
promoters	O	O	NNS
1a	C	C	NN
and	CC	CC	CC
1b	C	C	NN
O	O	O	
ACLA-treated	C	C	JJ
but	CC	CC	CC
not	CC	CC	RB
in	CC	CC	IN
DOX-treated	C	C	JJ
cells	O	O	NNS
O	O	O	
Ets	C	C	NN
and	CC	CC	CC
SP1	C	C	NN
motifs	O	O	NNS
O	O	O	
GATA-1	C	C	NN
and	CC	CC	CC
Sp1	C	C	NN
binding	O	O	NN
sites	O	O	NNS
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
cell	O	O	NN
activation	O	O	NN
nonstimulated	O	O	JJ
Ramos	C	C	NN
and	CC	CC	CC
Jurkat	C	C	NN
cells	O	O	NNS
O	O	O	
Th1	C	C	NN
and	CC	CC	CC
Th2	C	C	NN
cells	O	O	NNS
O	O	O	
c-fos	C	C	NN
and/or	CC	CC	CC
c-jun	C	C	NN
mRNA	O	O	NN
O	O	O	
murine	C	C	JJ
and	CC	CC	CC
human	C	C	JJ
p40	O	O	NN
promoter	O	O	NN
regions	O	O	NNS
O	O	O	
B	C	C	NN
and	CC	CC	CC
not	CC	CC	RB
T	C	C	NN
cells	O	O	NNS
O	O	O	
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
cells	O	O	NNS
O	O	O	
SRF	C	C	NN
and	CC	CC	CC
ETS	C	C	NN
motifs	O	O	NNS
O	O	O	
LT-beta	C	C	NN
and	CC	CC	CC
TNF-alpha	C	C	NN
receptors	O	O	NNS
O	O	O	
Stat1-dependent	C	C	JJ
,	CC	CC	,
Stat4-dependent	C	C	JJ
and	CC	CC	CC
Stat4-independent	C	C	JJ
phases	O	O	NNS
O	O	O	
c-fos	C	C	NN
and	CC	CC	CC
c-jun	C	C	NN
expression	O	O	NN
O	O	O	
human	C	O	JJ
T	C	C	NN
and	CC	CC	CC
natural	C	C	JJ
killer	C	C	NN
cells	O	O	NNS
O	O	O	
ER+	C	C	JJ
and	CC	CC	CC
ER-	C	C	*
cells	O	O	NNS
O	O	O	
c-fos	C	C	NN
,	CC	CC	,
c-jun	C	C	NN
and	CC	CC	CC
jun	C	C	NN
B	C	C	NN
proto-oncogenes	O	O	NNS
O	O	O	
46,XX	C	C	NN
or	CC	CC	CC
46,XY	C	C	NN
karyotypes	O	O	NNS
O	O	O	
PRDII	C	C	NN
and	CC	CC	CC
tetrahexamer	C	C	NN
binding	O	O	NN
proteins	O	O	NNS
O	O	O	
T	C	C	NN
lymphocytic	C	C	JJ
and	CC	CC	CC
monocytic	C	C	JJ
cells	O	O	NNS
O	O	O	
growth	O	C	NN
hormone	C	C	NN
and	CC	CC	CC
prolactin	C	C	NN
genes	O	O	NNS
O	O	O	
Human	C	C	JJ
and	CC	CC	CC
mouse	C	C	NN
Rhom-2	O	O	NN
O	O	O	
CAT	C	C	NN
and	CC	CC	CC
IL-6	C	C	NN
luciferase	O	C	NN
assays	O	O	NNS
O	O	O	
CD3	C	C	NN
and	CC	CC	CC
CD28	C	C	NN
receptors	O	O	NNS
O	O	O	
IL-2	C	C	NN
and	CC	CC	CC
IL-2-R	C	C	NN
alpha	C	C	NN
genes	O	O	NNS
IL-2	C	C	NN
and	CC	CC	CC
IL-2-R	C	C	NN
alpha	C	C	NN
genes	O	O	NNS
O	O	O	
ERK1/2	C	C	NN
and	CC	CC	CC
p38	C	C	NN
cascades	O	O	NNS
O	O	O	
humoral	C	C	JJ
or	CC	CC	CC
cellular	C	C	JJ
immunity	O	O	NN
O	O	O	
AML	C	C	NN
and	CC	CC	CC
Ets	C	C	NN
proteins	O	O	NNS
basal	C	C	JJ
and	CC	CC	CC
TGF-beta-inducible	C	C	JJ
promoter	O	O	NN
activity	O	O	NN
O	O	O	
resting	C	C	VBG
,	CC	CC	,
activated	C	C	VBN
,	CC	CC	,
and	CC	CC	CC
anergized	C	C	VBN
cells	O	O	NNS
O	O	O	
viral	C	C	JJ
and	CC	CC	CC
cellular	C	C	JJ
genes	O	O	NNS
O	O	O	
cathepsin	O	O	NN
B	C	C	NN
,	CC	CC	,
L	C	C	NN
,	CC	CC	,
and	CC	CC	CC
D	C	C	NN
O	O	O	
U3	C	C	NN
and	CC	CC	CC
R	C	C	NN
regions	O	O	NNS
O	O	O	
mRNA	C	C	NN
and	CC	CC	CC
protein	C	C	NN
levels	O	O	NNS
O	O	O	
X1-	C	C	NN
or	CC	CC	CC
X2-	C	C	*
boxes	O	O	NNS
O	O	O	
noncanonical	O	O	JJ
Egr	C	C	NN
and	CC	CC	CC
Sp1	C	C	NN
binding	O	O	NN
sites	O	O	NNS
O	O	O	
topoisomerases	O	O	NNS
I	C	C	CD
and	CC	CC	CC
II	C	C	CD
O	O	O	
gene	C	C	NN
targeting	C	C	NN
and	CC	CC	CC
transgenic	C	C	JJ
experiments	O	O	NNS
O	O	O	
transmembrane	C	C	NN
and	CC	CC	CC
intracellular	C	C	JJ
domains	O	O	NNS
O	O	O	
C	C	C	NN
epsilon-	C	C	NN
,	CC	CC	,
Fc	C	C	NN
gamma	C	C	NN
RI-	C	C	NN
,	CC	CC	,
and	CC	CC	CC
SIE	C	C	NN
GAS	O	O	NN
motif	O	O	NN
O	O	O	
rat	C	C	NN
and	CC	CC	CC
human	C	C	JJ
fra-1	O	O	NN
O	O	O	
T-	C	C	NN
and	CC	CC	CC
B-	C	C	*
lymphocyte	O	O	NN
O	O	O	
erythrocytic	C	C	JJ
(	C	C	(
globins	C	C	NNS
)	C	C	)
and	CC	CC	CC
megakaryocytic	C	C	JJ
markers	O	O	NNS
O	O	O	
multiple	C	O	JJ
positive	C	C	JJ
and	CC	CC	CC
negative	C	C	JJ
transcriptional	C	O	JJ
regulatory	O	O	JJ
elements	O	O	NNS
O	O	O	
N-terminal	C	C	JJ
and	CC	CC	CC
androgen-binding	C	C	JJ
domains	O	O	NNS
O	O	O	
TCR	O	O	NN
alpha	C	C	NN
beta	C	C	NN
or	CC	CC	CC
-gamma	C	C	NN
delta	C	C	NN
chains	O	O	NNS
O	O	O	
granulocyte	C	C	NN
and	CC	CC	CC
T-cell	C	C	NN
DNA	O	O	NN
O	O	O	
apoptotic	C	C	JJ
or	CC	CC	CC
necrotic	C	C	JJ
cell	O	O	NN
death	O	O	NN
O	O	O	
T-	O	O	*
acute	C	C	JJ
and	CC	CC	CC
-	C	CC	*
chronic	O	C	JJ
leukemias	O	O	NNS
O	O	O	
Jak1	C	C	NN
,	CC	CC	,
Jak3	C	C	NN
,	CC	CC	,
Stat1	C	C	NN
,	CC	CC	,
Stat3	C	C	NN
,	CC	CC	,
and	CC	CC	CC
Stat5	C	C	NN
expression	O	O	NN
O	O	O	
natural	C	C	JJ
or	CC	CC	CC
synthetic	C	C	JJ
ligands	O	O	NNS
O	O	O	
Truncated	O	O	VBN
c-Jun	C	C	NN
and	CC	CC	CC
c-Fos	C	C	NN
mutant	O	O	JJ
proteins	O	O	NNS
dimerization	C	C	NN
and	CC	CC	CC
DNA	C	C	NN
binding	O	C	NN
domains	O	O	NNS
O	O	O	
cytoplasmic	C	C	JJ
and	CC	CC	CC
transmembrane	C	C	JJ
domains	O	O	NNS
O	O	O	
normal	C	C	JJ
and	CC	CC	CC
leukemic	C	C	JJ
cells	O	O	NNS
O	O	O	
p53	C	C	NN
,	CC	CC	,
Bax	C	C	NN
,	CC	CC	,
or	CC	CC	CC
Bak	C	C	NN
gene	O	O	NN
expression	O	O	NN
O	O	O	
Nb2	C	C	NN
and	CC	CC	CC
C196	C	C	NN
T	O	O	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
CD4+	C	C	JJ
and	CC	CC	CC
CD8+	C	C	JJ
T	O	O	NN
lymphocytes	O	O	NNS
O	O	O	
Jak1	C	C	NN
,	CC	CC	,
Jak3	C	C	NN
,	CC	CC	,
Stat1	C	C	NN
,	CC	CC	,
Stat3	C	C	NN
,	CC	CC	,
and	CC	CC	CC
Stat5	C	C	NN
expression	O	O	NN
O	O	O	
rat	C	C	NN
and	CC	CC	CC
mouse	C	C	NN
tissues	O	O	NNS
O	O	O	
Megakaryocytic	C	C	JJ
and	CC	CC	CC
erythrocytic	C	C	JJ
lineages	O	O	NNS
O	O	O	
wild-type	C	C	JJ
or	CC	CC	CC
mutant	C	C	JJ
human	O	C	JJ
CD40	O	O	NN
O	O	O	
CD3	C	C	NN
or	CC	CC	CC
CD45	C	C	NN
expression	O	O	NN
O	O	O	
tal-1	C	C	NN
and	CC	CC	CC
GATA-1	C	C	NN
genes	O	O	NNS
O	O	O	
tumor	C	O	NN
necrosis	CC	O	NN
factor	CC	O	NN
receptor-associated	CC	O	JJ
factors	CC	O	NNS
(	O	O	(
TRAFs	O	O	NNS
)	O	O	)
1	C	C	CD
,	CC	CC	,
2	C	C	CD
,	CC	CC	,
3	C	C	CD
,	CC	CC	,
5	C	C	CD
,	CC	CC	,
and	CC	CC	CC
6	C	C	CD
O	O	O	
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
cell	O	O	NN
co-cultures	O	O	NNS
O	O	O	
IL-1	C	C	NN
beta	C	C	NN
and	CC	CC	CC
I	C	C	NN
kappa	C	C	NN
B	C	C	NN
alpha/MAD-3	C	C	NN
mRNA	O	C	NN
levels	O	O	NNS
O	O	O	
Human	O	O	JJ
MCM5	C	C	NN
and	CC	CC	CC
MCM6	C	C	NN
promoters	O	O	NNS
O	O	O	
Protein	O	O	NN
phosphatases	O	O	NNS
1	C	C	CD
and	CC	CC	CC
2A	C	C	NN
O	O	O	
human	O	O	JJ
CD4+	C	C	JJ
but	CC	CC	CC
not	CC	CC	RB
CD8+	C	C	JJ
T	O	O	NN
cells	O	O	NNS
O	O	O	
human	O	O	JJ
chromosomes	O	O	NNS
11p15	C	C	NN
and	CC	CC	CC
11p13	C	C	NN
O	O	O	
HL-60-	C	C	NN
and	CC	CC	CC
THP-1-	C	C	*
derived	O	O	JJ
macrophages	O	O	NNS
O	O	O	
human	C	O	JJ
T-cell	C	O	NN
leukemia	C	O	NN
virus	C	O	NN
type	C	C	NN
I	C	C	CD
(	C	C	(
HTLV-I	C	C	NN
)	C	C	)
(	C	C	(
ATL-1k	C	C	NN
,	CC	C	,
MT-2	C	C	NN
,	CC	C	,
S-LB1	C	C	NN
)	C	C	)
and	CC	CC	CC
type	C	C	NN
II	C	C	CD
(	C	C	(
Mo	C	C	NN
)	C	C	)
O	O	O	
TNFalpha-	C	C	NN
and	CC	CC	CC
IL-10-	C	C	*
pretreated	O	O	JJ
U937	O	O	NN
cells	O	O	NNS
O	O	O	
c-myc	C	C	NN
and	CC	CC	CC
bcl-2	C	C	NN
mRNA	O	O	NN
induction	O	O	NN
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
cells	O	O	NNS
O	O	O	
G1	C	C	NN
and	CC	CC	CC
G2	C	C	NN
stages	O	O	NNS
O	O	O	
biochemical	C	C	JJ
and	CC	CC	CC
mutagenesis	C	C	NN
analyses	O	O	NNS
O	O	O	
coding	C	C	NN
and	CC	CC	CC
intronic	C	C	JJ
sequences	O	O	NNS
O	O	O	
PML	O	O	NN
transcript	C	C	NN
and	CC	CC	CC
protein	C	C	NN
expression	O	O	NN
O	O	O	
B	C	C	NN
cell	C	C	NN
antigen-receptor	C	C	NN
(	C	C	(
BCR	C	C	NN
)	C	C	)
-	C	C	:
and	CC	CC	CC
TCR-	C	C	*
mediated	O	O	JJ
signaling	O	O	NN
thresholds	O	O	NNS
O	O	O	
extracellular	C	C	JJ
and	CC	CC	CC
intracellular	C	C	JJ
pH	O	O	NN
O	O	O	
HLA-DMA	C	C	NN
and	CC	CC	CC
HLA-DMB	C	C	NN
gene	O	O	NN
expression	O	O	NN
O	O	O	
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
cell	O	O	NN
function	O	O	NN
O	O	O	
IL-2-	C	C	NN
,	CC	CC	,
IL-12-	C	C	NN
,	CC	CC	,
and	CC	CC	CC
IFN-alpha-	C	C	*
mediated	O	O	JJ
signaling	O	O	NN
pathways	O	O	NNS
O	O	O	
Ets	C	C	NNS
and	CC	CC	CC
AP-1	C	C	NN
sites	O	O	NNS
O	O	O	
purine-box/ARRE/NF-AT	C	C	NN
and	CC	CC	CC
NF-kappaB	C	C	NN
target	O	O	NN
DNA	O	O	NN
sequences	O	O	NNS
O	O	O	
HIV-1	C	C	NN
and	CC	CC	CC
HIV-2	C	C	NN
enhancers	O	O	NNS
HIV-1	C	C	NN
and	CC	CC	CC
HIV-2	C	C	NN
enhancers	O	O	NNS
O	O	O	
IFN-gamma	C	C	NN
and	CC	CC	CC
GM-CSF	C	C	NN
gene	O	O	NN
expression	O	O	NN
O	O	O	
lipopolysaccharide	C	C	NN
(	C	C	(
LPS	C	C	NN
)	C	C	)
-	C	C	:
and	CC	CC	CC
lipoprotein-lipopeptide-	C	C	*
induced	O	O	JJ
immune	O	O	JJ
cell	O	O	NN
signaling	O	O	NN
events	O	O	NNS
O	O	O	
IL-1-	C	C	NN
and	CC	CC	CC
IL-18-	C	C	*
mediated	O	O	JJ
function	O	O	NN
O	O	O	
serum	O	O	NN
thyroxine	C	C	NN
(	C	C	(
T4	C	C	NN
)	C	C	)
and	CC	CC	CC
thyrotropin	C	C	NN
(	C	C	(
TSH	C	C	NN
)	C	C	)
levels	O	O	NNS
O	O	O	
cytoplasmic	C	C	JJ
and/or	CC	CC	CC
nuclear	C	C	JJ
receptor	O	O	NN
O	O	O	
Notch	C	C	NN
and	CC	CC	CC
NF-kappaB	C	C	NN
signaling	O	O	NN
pathways	O	O	NNS
O	O	O	
(8;21)(q22;q22)	C	C	NN
and	CC	CC	CC
(3;21)(q26;q22)	C	C	NN
translocations	O	O	NNS
O	O	O	
Drosophila	C	C	NN
and	CC	CC	CC
human	C	C	JJ
TAF	O	O	NN
subunits	O	O	NNS
O	O	O	
LPS-free	C	C	JJ
and	CC	CC	CC
serum-free	C	C	JJ
conditions	O	O	NNS
O	O	O	
pre-B	C	C	JJ
cell	C	C	NN
and	CC	CC	CC
plasma	C	C	NN
cell	O	C	NN
lines	O	O	NNS
O	O	O	
monocytic	C	C	JJ
and	CC	CC	CC
neutrophilic	C	C	JJ
cells	O	O	NNS
O	O	O	
NFATp/c	C	C	NN
and	CC	CC	CC
an	C	C	DT
activating	C	C	VBG
protein	C	C	NN
1	C	C	CD
(	C	C	(
AP-1	C	C	NN
)	C	C	)
binding	O	O	NN
site	O	O	NN
O	O	O	
NGAL	O	O	NN
mRNA	C	C	NN
and	CC	CC	CC
protein	C	C	NN
levels	O	O	NNS
O	O	O	
NFATp	C	C	NN
and	CC	CC	CC
NFATc	C	C	NN
family	O	O	NN
members	O	O	NNS
O	O	O	
ductal	C	C	JJ
,	CC	CC	,
exocrine	C	C	JJ
and	CC	CC	CC
endocrine	C	C	JJ
compartments	O	O	NNS
O	O	O	
exons	O	O	NNS
1	C	C	CD
and	CC	CC	CC
2	C	C	CD
O	O	O	
CD14	C	C	NN
and	CC	CC	CC
CD23	C	C	NN
expression	O	O	NN
O	O	O	
GABP	O	O	NN
alpha	C	C	NN
and	CC	CC	CC
-beta	C	C	NN
O	O	O	
alpha-	C	C	NN
and	CC	CC	CC
beta-	C	C	*
herpesvirus	O	O	NN
systems	O	O	NNS
immediate	C	C	JJ
early	C	C	JJ
and	CC	CC	CC
early	C	C	JJ
proteins	O	O	NNS
O	O	O	
hypo	C	C	*
-	C	CC	JJ
,	CC	CC	,
eu	C	C	*
-	CC	CC	JJ
and	CC	CC	CC
hyper	C	C	*
thyroid	O	O	JJ
patients	O	O	NNS
O	O	O	
tissue-	C	C	NN
and	CC	CC	CC
gene-	C	C	*
specific	O	O	JJ
functions	O	O	NNS
O	O	O	
collagens	O	O	NNS
type	C	O	NN
I	C	C	CD
and	CC	CC	CC
IV	C	C	CD
O	O	O	
Egr	O	O	*
-1	C	C	NN
,	CC	CC	,
-2	C	C	CD
,	CC	CC	,
and	CC	CC	CC
-3	C	C	CD
O	O	O	
A	C	C	NN
or	CC	CC	CC
B	C	C	NN
Epstein-Barr	O	O	JJ
virus	O	O	NN
infection	O	O	NN
O	O	O	
protein	O	O	NN
phosphatase	O	O	NN
1	C	C	CD
and	CC	CC	CC
2A	C	C	NN
inhibitors	O	O	NNS
O	O	O	
IFN-beta	C	C	NN
and	CC	CC	CC
IFN-alpha	C	C	NN
RNA	O	O	NN
O	O	O	
p50/p65	C	C	NN
and	CC	CC	CC
p50/c-Rel	C	C	NN
complexes	O	O	NNS
O	O	O	
adenovirus	C	C	NN
E1A	CC	C	NN
and	CC	CC	CC
hexon	C	C	NN
genes	O	O	NNS
O	O	O	
lymphoid-restricted	C	C	JJ
and	CC	CC	CC
structurally	C	C	RB
related	O	C	JJ
gene	O	O	NN
O	O	O	
TNF	C	C	*
-	CC	CC	NN
or	CC	CC	CC
PMA-	C	C	*
induced	O	O	JJ
NF-kappa	O	O	NN
B	O	CC	NN
activity	O	O	NN
O	O	O	
human	C	C	JJ
and	CC	CC	CC
murine	C	C	JJ
T-ALL	O	O	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
T	O	O	NN
rosetting	O	O	NN
CD4+	C	C	JJ
and	CC	CC	CC
CD8+	C	C	JJ
T	O	O	NN
lymphocytes	O	O	NNS
O	O	O	
B-	C	C	NN
and	CC	CC	CC
T-	C	C	*
cell	O	O	NN
development	O	O	NN
O	O	O	
Ets	C	C	NN
and	CC	CC	CC
NF-kappaB/NFAT	C	C	NN
proteins	O	O	NNS
O	O	O	
human	O	O	JJ
Jurkat	O	C	NN
T	C	C	NN
or	CC	CC	CC
293	C	C	CD
cells	O	O	NNS
O	O	O	
human	C	C	JJ
and	CC	CC	CC
rat	C	C	NN
T	O	O	NN
lymphocytes	O	O	NNS
O	O	O	
NF-kappa	O	O	NN
B	O	O	*
-dependent	C	C	JJ
and	CC	CC	CC
-independent	C	C	JJ
pathways	O	O	NNS
O	O	O	
IFNalpha-	C	C	NN
and	CC	CC	CC
IFNgamma-	C	C	*
induced	O	O	JJ
DNA	O	O	NN
binding	O	O	NN
complexes	O	O	NNS
O	O	O	
Fas/APO-1/CD95-	C	C	NN
and	CC	CC	CC
TCR-	C	C	*
mediated	O	O	JJ
apoptosis	O	O	NN
O	O	O	
interferon	O	O	NN
gamma	C	C	NN
,	CC	CC	,
but	CC	CC	CC
not	CC	CC	RB
alpha	C	C	NN
or	CC	CC	CC
beta	C	C	NN
O	O	O	
Oct	C	C	NN
and	CC	CC	CC
NFAT	C	C	NN
family	O	O	NN
proteins	O	O	NNS
O	O	O	
XP-B	C	C	NN
and	CC	CC	CC
XP-D	C	C	NN
lymphoblastoid	O	O	JJ
cells	O	O	NNS
O	O	O	
E2F-1	C	C	NN
and	CC	CC	CC
DP-1	C	C	NN
mRNAs	O	O	NNS
O	O	O	
N-	C	C	NN
and	CC	CC	CC
C-	C	C	*
terminal	O	O	JJ
SH2	O	O	NN
domains	O	O	NNS
O	O	O	
AP-1	C	C	NN
and	CC	CC	CC
CREB/ATF	C	C	NN
proteins	O	O	NNS
O	O	O	
murine	O	O	JJ
T	C	C	NN
and	CC	CC	CC
mast	C	C	NN
cells	O	O	NNS
O	O	O	
corticosteroid-sensitive	C	C	JJ
(	C	C	(
CS	C	C	JJ
)	C	C	)
and	CC	CC	CC
corticosteroid-resistant	C	C	JJ
(	C	C	(
CR	C	C	JJ
)	C	C	)
asthmatic	O	O	JJ
subjects	O	O	NNS
O	O	O	
normal	O	C	JJ
bone	O	C	NN
marrow	O	C	NN
myeloid	C	C	JJ
and	CC	CC	CC
erythroid	C	C	JJ
progenitor	C	C	NN
cells	O	O	NNS
O	O	O	
NF	C	C	NN
kappa	C	C	NN
B	C	C	NN
and	CC	CC	CC
the	CC	C	DT
NF-activated	C	C	JJ
T	O	C	NN
cell	O	C	NN
binding	O	O	NN
sites	O	O	NNS
O	O	O	
Morphologic	C	C	JJ
and	CC	CC	CC
cytofluorometry	C	C	NN
analysis	O	O	NN
O	O	O	
immune	O	O	JJ
system	O	O	NN
regulatory	C	C	JJ
and	CC	CC	CC
effector	C	C	NN
cells	O	O	NNS
O	O	O	
c-	C	C	NN
and	CC	CC	CC
v-	C	C	*
rel	O	O	NN
O	O	O	
STATs	O	O	*
1	C	C	NN
and	CC	CC	CC
-3	C	C	CD
O	O	O	
immediate-early	C	C	JJ
and	CC	CC	CC
early	C	C	JJ
classes	O	O	NNS
of	O	O	IN
viral	O	O	JJ
genes	O	O	NNS
O	O	O	
PU.1	C	C	NN
,	CC	CC	,
Ikaros	C	C	NN
and	CC	CC	CC
GATA-3	C	C	NN
genes	O	O	NNS
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
lymphoid	O	O	JJ
lineages	O	O	NNS
O	O	O	
neutrophil	C	C	NN
and	CC	CC	CC
monocyte	C	C	NN
differentiation	O	O	NN
O	O	O	
CD14	C	C	NN
and	CC	CC	CC
CD23	C	C	NN
gene	O	O	NN
expression	O	O	NN
O	O	O	
mixed	C	C	*
/	CC	CC	*
erythroid	C	C	*
/	CC	CC	*
monocytic	C	C	JJ
to	O	O	TO
granulocytic	O	O	JJ
colony	O	O	NN
formation	O	O	NN
O	O	O	
gluco-	C	C	JJ
and	CC	CC	CC
mineralo	C	C	*
corticoid	O	O	NN
receptors	O	O	NNS
O	O	O	
Nuclear	O	O	JJ
Rel-A	C	C	NN
and	CC	CC	CC
c-Rel	C	C	NN
protein	O	O	NN
complexes	O	O	NNS
O	O	O	
B	C	C	NN
and	CC	CC	CC
T	C	C	NN
cells	O	O	NNS
O	O	O	
murine	C	C	JJ
and	CC	CC	CC
human	C	C	JJ
tumor	O	O	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
human	O	O	JJ
B	C	C	NN
cell	C	C	NN
and	CC	CC	CC
monocyte	C	C	NN
functions	O	O	NNS
O	O	O	
lymphocyte	O	O	NN
development	C	C	NN
and	CC	CC	CC
homeostasis	C	C	NN
O	O	O	
autoradiographic	C	C	JJ
and	CC	CC	CC
immunohistochemical	C	C	JJ
techniques	O	O	NNS
O	O	O	
deltaspi-B	C	C	NN
and	CC	CC	CC
spi-B	C	C	NN
mRNAs	O	O	NNS
O	O	O	
HL-60	C	C	NN
and	CC	CC	CC
NB4	C	C	NN
cells	O	O	NNS
O	O	O	
USF-	C	C	NN
and	CC	CC	CC
Sp1-	C	C	*
regulated	O	O	JJ
promoters	O	O	NNS
O	O	O	
Sp1-	C	C	NN
and	CC	CC	CC
PU.1-	C	C	*
family	O	O	NN
members	O	O	NNS
O	O	O	
cytoplasmic	C	C	JJ
and	CC	CC	CC
nuclear	C	C	JJ
membranes	O	O	NNS
O	O	O	
CD3	C	C	NN
and	CC	CC	CC
CD2	C	C	NN
receptors	O	O	NNS
O	O	O	
CREB/ATF	C	C	NN
and	CC	CC	CC
Sp1	C	C	NN
factors	O	O	NNS
O	O	O	
CRE	C	C	NN
and	CC	CC	CC
kappaB3	C	C	NN
sites	O	O	NNS
O	O	O	
consensus	C	C	NN
and	CC	CC	CC
non-consensus	C	C	JJ
GAS	O	O	NN
motifs	O	O	NNS
O	O	O	
thyroid	O	O	NN
hormone	O	CC	NN
receptors	O	CC	NNS
(	O	O	(
TR	O	O	NN
)	O	O	)
alpha	C	C	NN
and	CC	CC	CC
beta	C	C	NN
O	O	O	
CD2	C	C	NN
and	CC	CC	CC
CD28	C	C	NN
adhesion	O	O	NN
molecules	O	O	NNS
O	O	O	
Th1	C	C	NN
and	CC	CC	CC
Th2	C	C	NN
clones	O	O	NNS
Th1	C	C	NN
and	CC	CC	CC
Th2	C	C	NN
clones	O	O	NNS
O	O	O	
glucocorticoid	C	C	NN
and	CC	CC	CC
mineralocorticoid	C	C	NN
binding	O	O	NN
sites	O	O	NNS
O	O	O	
tyrosine	C	C	NN
and	CC	CC	CC
serine	C	C	NN
phosphorylation	O	O	NN
O	O	O	
mineralocorticoid	C	C	NN
(	C	C	(
MR	C	C	NN
)	C	C	)
and	CC	CC	CC
glucocorticoid	C	C	NN
receptor	C	C	NN
(	C	C	(
GR	C	C	NN
)	C	C	)
levels	O	O	NNS
O	O	O	
lymphocytic	O	C	JJ
leukemia	C	C	NN
and	CC	CC	CC
lymphoma	C	C	NN
cells	O	O	NNS
O	O	O	
human	O	O	JJ
HSs	O	O	NNS
2	C	C	CD
and	CC	CC	CC
3	C	C	CD
NF-E2	C	C	NN
and	CC	CC	CC
GATA	C	C	NN
sites	O	O	NNS
O	O	O	
T	C	C	NN
and	CC	CC	CC
NK	C	C	NN
cells	O	O	NNS
O	O	O	
EBF	C	C	NN
and	CC	CC	CC
E47	C	C	NN
binding	O	O	NN
sites	O	O	NNS
O	O	O	
hyper-	C	C	JJ
and	CC	CC	CC
hypo	C	C	*
thyroid	O	O	JJ
patients	O	O	NNS
O	O	O	
NF-kappa	C	C	NN
B	C	C	NN
(	C	C	(
p50/p65	C	C	NN
)	C	C	)
-	C	C	:
or	CC	CC	CC
AP-1	C	C	NN
(	C	C	(
c-Jun/c-Fos	C	C	NN
)	C	C	)
-	C	C	:
expression	O	O	NN
vectors	O	O	NNS
O	O	O	
Id2	C	C	NN
and	CC	CC	CC
Id3	C	C	NN
mRNA	O	O	NN
O	O	O	
E1A-	C	C	NN
or	CC	CC	CC
E1B-	C	C	*
specific	O	O	JJ
CTLs	O	O	NNS
O	O	O	
human	C	C	JJ
,	CC	CC	,
mouse	C	C	NN
,	CC	CC	,
and	CC	CC	CC
Drosophila	C	C	FW
sequences	O	O	NNS
O	O	O	
IL-2R	O	O	NN
alpha-	C	C	NN
,	CC	CC	,
beta-	C	C	NN
,	CC	CC	,
and	CC	CC	CC
gamma-	C	C	*
chain	O	O	NN
expression	O	O	NN
O	O	O	
NFkappaB	C	C	NN
,	CC	CC	,
AP1	C	C	NN
and	CC	CC	CC
ETS	C	C	*
-like	O	O	JJ
binding	O	O	VBG
motifs	O	O	NNS
O	O	O	
AML	C	C	NN
and	CC	CC	CC
Ets	C	C	NN
proteins	O	O	NNS
O	O	O	
AP-1	C	C	NN
(	C	C	(
-186	C	C	CD
to	C	C	TO
-176	C	C	CD
)	C	C	)
and	CC	CC	CC
the	CC	C	DT
kappa	C	C	NN
B	C	C	NN
sites	O	O	NNS
O	O	O	
beta-	C	C	NN
versus	CC	CC	CC
alpha-	C	C	*
globin	O	O	NN
chains	O	O	NNS
O	O	O	
humoral	C	C	JJ
or	CC	CC	CC
cell-mediated	C	C	JJ
immunity	O	O	NN
O	O	O	
NF-kappa	C	C	NN
B-	C	C	NN
,	CC	CC	,
AP-1-	C	C	NN
and	CC	CC	CC
NF-AT-	C	C	*
binding	O	O	JJ
sequences	O	O	NNS
PKC-	C	C	NN
and	CC	CC	CC
Ca2+-	C	C	*
signaling	O	O	JJ
pathways	O	O	NNS
O	O	O	
cellular	C	C	JJ
and	CC	CC	CC
viral	C	C	JJ
anti-apoptotic	O	O	JJ
proteins	O	O	NNS
O	O	O	
glucocorticoid	O	C	NN
receptor	C	C	NN
(	C	C	(
GR	C	C	NN
)	C	C	)
and	CC	CC	CC
methallothionein	C	C	NN
(	C	C	(
MTIIa	C	C	NN
)	C	C	)
mRNA	O	O	NN
expression	O	O	NN
levels	O	O	NNS
O	O	O	
type	C	C	NN
I	C	C	CD
and	CC	CC	CC
type	C	C	NN
II	C	C	CD
IL-1	O	O	NN
receptors	O	O	NNS
O	O	O	
c-fos	C	C	NN
and	CC	CC	CC
c-jun	C	C	NN
mRNA	O	O	NN
expression	O	O	NN
O	O	O	
55-	C	C	CD
and	CC	CC	CC
85-	C	C	*
kDa	O	O	JJ
proteins	O	O	NNS
O	O	O	
Hepa-1	O	C	NN
wild-type	C	C	JJ
and	CC	CC	CC
Ah	C	C	NN
receptor	C	C	NN
deficient	O	C	JJ
c12	O	C	NN
cell	O	O	NN
lines	O	O	NNS
O	O	O	
resting	C	C	VBG
and	CC	CC	CC
activated	C	C	VBN
T	O	O	NN
cells	O	O	NNS
O	O	O	
PKC-	C	C	NN
and	CC	CC	CC
Ca(2+)-	C	C	*
dependent	O	O	JJ
signal	O	O	NN
transduction	O	O	NN
pathways	O	O	NNS
O	O	O	
cell-cell	C	C	JJ
and	CC	CC	CC
cell-extracellular	C	C	JJ
matrix	O	C	NN
interactions	O	O	NNS
O	O	O	
EBV	O	O	NN
nuclear	O	O	JJ
proteins	O	O	NNS
2	C	C	CD
,	CC	CC	,
3	C	C	CD
,	CC	CC	,
4	C	C	CD
,	CC	CC	,
and	CC	CC	CC
6	C	C	CD
genes	O	O	NNS
O	O	O	
Th1	C	C	NN
and	CC	CC	CC
Th2	C	C	NN
effector	O	O	NN
functions	O	O	NNS
O	O	O	
amino-	C	C	NN
or	CC	CC	CC
carboxyl-	C	C	*
terminal	O	O	JJ
domains	O	O	NNS
O	O	O	
Polyclonal	C	C	JJ
and	CC	CC	CC
clonal	C	C	JJ
CTL	O	O	NN
O	O	O	
basal	C	C	JJ
and	CC	CC	CC
IL-4	C	C	*
/	CC	C	*
IL-13	C	C	*
-induced	O	C	JJ
IL-1R	O	O	NN
gene	O	CC	NN
expression	O	O	NN
O	O	O	
20-methyl-	C	C	NN
and	CC	CC	CC
20-methyl-23-	C	C	*
eneanalogues	O	O	NN
O	O	O	
XP-B	C	C	NN
and	CC	CC	CC
XP-D	C	C	NN
cells	O	O	NNS
O	O	O	
DR	O	protein_molecule	NN
beta	C	protein_molecule	NN
,	CC	protein_molecule	,
DP	C	protein_molecule	NN
alpha	C	protein_molecule	NN
and	CC	protein_molecule	CC
-beta	C	protein_molecule	NN
,	CC	protein_molecule	,
and	CC	protein_molecule	CC
DQ	C	protein_molecule	NN
alpha	C	protein_molecule	NN
genes	O	protein_molecule	NNS
DP	C	O	NN
alpha	C	C	NN
and	CC	CC	CC
-beta	C	C	NN
O	O	O	
pim-1	C	cell_type	NN
,	CC	cell_type	,
and	CC	cell_type	CC
IRF-1	C	cell_type	NN
O	O	O	
p40	C	C	NN
and	CC	CC	CC
p35	C	C	NN
mRNA	O	O	NN
p40	C	C	NN
and	CC	CC	CC
p70	C	C	NN
production	O	O	NN
O	O	O	
HEL	C	C	NN
,	CC	CC	,
KU812	C	C	NN
and	CC	CC	CC
K562	C	C	NN
cells	O	O	NNS
monocytic	C	C	JJ
or	CC	CC	CC
granulocytic	C	C	JJ
differentiation	O	O	NN
HL-60	C	C	NN
,	CC	CC	,
U937	C	C	NN
and	CC	CC	CC
HEL/S	C	C	NN
cells	O	O	NNS
O	O	O	
Thr	O	O	*
102	C	C	NN
and	CC	CC	CC
-	C	CC	*
104	O	C	CD
O	O	O	
cultured	O	O	VBN
human	C	C	JJ
and	CC	CC	CC
murine	C	C	JJ
cell	O	O	NN
lines	O	O	NNS
O	O	O	
basal	C	C	JJ
and	CC	CC	CC
phorbol	C	C	NN
12-myristate	C	CC	NN
13-acetate	C	CC	*
-inducible	O	C	JJ
transcription	O	O	NN
O	O	O	
control	C	C	NN
,	CC	CC	,
E2-treated	C	C	JJ
,	CC	CC	,
and	CC	CC	CC
TAM-treated	C	C	JJ
ER+	C	C	JJ
and	CC	CC	CC
ER-	C	C	*
cells	O	O	NNS
ER+	C	C	JJ
and	CC	CC	CC
ER-	C	C	*
cells	O	O	NNS
O	O	O	
70-	C	C	CD
and	CC	CC	CC
90-	C	C	*
kDa	O	O	JJ
heat	O	O	NN
shock	O	O	NN
proteins	O	O	NNS
O	O	O	
cyclophilin	O	C	NN
A	O	CC	*
/CsA	C	C	NN
or	CC	CC	CC
FKBP12	C	C	*
/FK506	O	C	NN
complexes	O	O	NNS
O	O	O	
decreased	C	C	VBN
plasma	C	C	NN
cyst	C	C	NN
(	C	C	(
e	C	C	NN
)	C	C	)
ine	C	C	NN
and	CC	CC	CC
intracellular	C	C	JJ
GSH	O	C	NN
levels	O	O	NNS
O	O	O	
TCR	O	O	*
alpha	C	C	NN
beta	C	C	NN
and	CC	CC	CC
gamma	C	C	NN
delta	C	C	NN
cells	O	O	NNS
O	O	O	
AP-1	C	C	NN
and	CC	CC	CC
Elf-1	C	C	NN
sites	O	O	NNS
O	O	O	
wild-type	C	C	JJ
and	CC	CC	CC
mutated	C	C	VBN
receptors	O	O	NNS
O	O	O	
PEBP2	C	C	NN
alpha	C	C	NN
A	C	C	NN
and	CC	CC	CC
PEBP2	C	C	NN
alpha	C	C	NN
B	C	C	NN
genes	O	O	NNS
O	O	O	
T	C	C	NN
and	CC	CC	CC
B	C	C	NN
lymphocytes	O	O	NNS
O	O	O	
mononuclear	C	C	JJ
(	C	C	(
MNL	C	C	NN
)	C	C	)
and	CC	CC	CC
polymorphonuclear	C	C	NN
(	C	C	(
PML	C	C	NN
)	C	C	)
leucocytes	O	O	NNS
O	O	O	
CD45-	C	C	NN
or	CC	CC	CC
CD3-	C	C	*
negative	O	O	JJ
variants	O	O	NNS
O	O	O	
8;21	C	C	NN
and	CC	CC	CC
3;21	C	C	NN
chromosome	O	O	NN
translocations	O	O	NNS
O	O	O	
G1	C	C	NN
and	CC	CC	CC
S	C	C	NN
phase	O	O	NN
expression	O	O	NN
O	O	O	
Th1-	C	C	NN
and	CC	CC	CC
Th2-	C	C	*
type	O	O	JJ
cytokines	O	O	NNS
O	O	O	
erythroid	C	C	JJ
and	CC	CC	CC
non-erythroid	C	C	JJ
nuclear	O	O	JJ
proteins	O	O	NNS
O	O	O	
human	O	C	JJ
T	C	C	NN
and	CC	CC	CC
monocytic	C	C	JJ
cell	O	O	NN
lines	O	O	NNS
O	O	O	
p65	C	C	*
-	CC	CC	NN
and	CC	CC	CC
p50	C	C	*
-selected	O	O	JJ
motifs	O	O	NNS
O	O	O	
positions	O	O	NNS
-30	C	C	CD
,	CC	CC	,
-44	C	C	CD
,	CC	CC	,
-213	C	C	CD
,	CC	CC	,
and	CC	CC	CC
-579	C	C	CD
O	O	O	
CD14	O	O	NN
cell	O	C	NN
surface	C	C	NN
or	CC	CC	CC
mRNA	C	C	NN
expression	O	O	NN
O	O	O	
p21	C	C	NN
(	C	C	(
WAF1/CIP1	C	C	NN
)	C	C	)
and	CC	CC	CC
p27	C	C	NN
(	C	C	(
KIP1	C	C	NN
)	C	C	)
mRNA	O	O	NN
O	O	O	
OM10.1	C	C	NN
and	CC	CC	CC
Ach2	C	C	NN
cells	O	O	NNS
O	O	O	
type	C	C	NN
A	C	C	NN
or	CC	CC	CC
type	C	C	NN
B	C	C	NN
EBV	O	O	NN
infection	O	O	NN
O	O	O	
unstimulated	C	C	JJ
and	CC	CC	CC
LPS-stimulated	C	C	JJ
cells	O	O	NNS
O	O	O	
H9	C	C	NN
and	CC	CC	CC
CEM	C	C	NN
cells	O	O	NNS
O	O	O	
TNF-alpha-	C	C	NN
and	CC	CC	CC
calyculin	C	C	NN
A-induced	C	C	JJ
I	C	C	NN
kappa	C	C	NN
B	C	C	NN
alpha	C	C	NN
degradation	O	O	NN
O	O	O	
Mono	C	C	NN
A	C	C	NN
and	CC	CC	CC
Mono	C	C	NN
B	C	C	NN
protein	O	O	NN
complexes	O	O	NNS
O	O	O	
human	O	C	JJ
adenovirus	O	C	NN
type	C	C	NN
5	C	C	CD
early	O	C	JJ
regions	O	C	NNS
E1A	C	C	NN
and	CC	CC	CC
E1B	C	C	NN
O	O	O	
Monocyte	O	O	NN
migration	C	C	NN
and	CC	CC	CC
activation	C	C	NN
O	O	O	
c-fos	C	C	NN
and	CC	CC	CC
the	CC	CC	DT
c-jun	C	C	NN
mRNA	O	O	NN
expression	O	O	NN
O	O	O	
TPA-	C	C	NN
or	CC	CC	CC
okadaic	C	C	JJ
acid-	C	C	*
induced	O	O	JJ
monocytic	O	O	JJ
differentiation	O	O	NN
O	O	O	
Ets	C	C	NN
and	CC	CC	CC
NF-kappaB/NFAT	C	C	NN
proteins	O	O	NNS
O	O	O	
tumor	C	O	NN
necrosis	C	O	NN
factor	C	O	NN
(	C	C	(
TNF	C	O	NN
)	C	C	)
receptors	O	O	NNS
I	C	C	CD
(	C	C	(
p55	C	C	NN
)	C	C	)
and	CC	CC	CC
II	C	C	CD
(	C	C	(
p75	C	C	NN
)	C	C	)
O	O	O	
-70	C	C	CD
to	C	C	TO
-65	C	C	CD
and	CC	CC	CC
-121	C	C	CD
to	C	C	TO
-103	C	C	CD
regions	O	O	NNS
O	O	O	
OM10.1	C	C	NN
and	CC	CC	CC
Ach2	C	C	NN
cells	O	O	NNS
O	O	O	
IL-1	C	C	NN
beta	C	C	NN
and	CC	CC	CC
TNF	C	C	NN
alpha	C	C	NN
mRNA	O	O	NN
O	O	O	
TCR	O	O	*
alpha	C	C	NN
beta	C	C	NN
and	CC	CC	CC
gamma	C	C	NN
delta	C	C	NN
cells	O	O	NNS
O	O	O	
mitogen-	C	C	NN
and	CC	CC	CC
stress-	C	C	*
activated	O	O	JJ
protein	O	O	NN
kinases	O	O	NNS
O	O	O	
ERK-dependent	C	C	JJ
and	CC	CC	CC
ERK-independent	C	C	JJ
pathways	O	O	NNS
O	O	O	
core-	C	C	NN
and	CC	CC	CC
O-side	C	C	JJ
chain-	C	C	*
specific	O	O	JJ
mAbs	O	O	NNS
O	O	O	
lymphoid	C	C	JJ
and	CC	CC	CC
myeloid	C	C	JJ
cell	O	O	NN
types	O	O	NNS
O	O	O	
cis-	C	C	JJ
and	CC	CC	CC
trans-	C	C	*
acting	O	O	JJ
elements	O	O	NNS
O	O	O	
cellular	C	C	JJ
and	CC	CC	CC
viral	C	C	JJ
genes	O	O	NNS
O	O	O	
ferrous	C	C	JJ
or	CC	CC	CC
ferric	C	C	JJ
chloride	O	O	NN
O	O	O	
jun	C	C	NN
and	CC	CC	CC
fos	C	C	NN
gene	O	O	NN
families	O	O	NNS
O	O	O	
erythrocytic	C	C	JJ
and	CC	CC	CC
megakaryocytic	C	C	JJ
markers	O	O	NNS
O	O	O	
mature	C	C	JJ
and	CC	CC	CC
immature	C	C	JJ
T-cell	O	O	NN
lines	O	O	NNS
O	O	O	
Lineage-	C	C	NN
and	CC	CC	CC
stage-	C	C	*
specific	O	O	JJ
expression	O	O	NN
primitive	C	C	JJ
and	CC	CC	CC
definitive	C	C	JJ
hematopoiesis	O	O	NN
O	O	O	
PKC	O	O	NN
isoenzymes	O	O	NNS
alpha	C	C	NN
and	CC	CC	CC
beta	C	C	NN
O	O	O	
immunoglobulin	C	C	NN
and	CC	CC	CC
class	C	C	NN
II	C	C	CD
major	C	C	JJ
histocompatibility	C	C	NN
(	C	C	(
MHC	C	C	NN
)	C	C	)
genes	O	O	NNS
O	O	O	
